Sarcopenia - dismech

🔗

Mappings

ICD-10-CM

ICD10CM:M62.84 Sarcopenia

ICD-10-CM M62.84 is the billable diagnosis code created for sarcopenia in 2016; the obsoleted MONDO:0006516 also carried it as an exact match xref.

📘

Definitions

2

EWGSOP2 sarcopenia case definition

The dominant European clinical algorithm. Case-find (SARC-F or clinical suspicion), then assess muscle strength — low strength alone establishes "probable sarcopenia" and is sufficient to start treatment. Confirm with low muscle quantity or quality (DXA, BIA, CT, or MRI). Grade severity by physical performance (gait speed, SPPB, TUG, 400 m walk); poor performance defines severe sarcopenia.

DIAGNOSTIC_CRITERIA

Show evidence (1 reference)

PMID:30312372 SUPPORT Human Clinical

"focuses on low muscle strength as a key characteristic of sarcopenia, uses detection of low muscle quantity and quality to confirm the sarcopenia diagnosis, and identifies poor physical performance as indicative of severe sarcopenia"

The consensus statement of the three-tier algorithm described here.

AWGS 2019 sarcopenia case definition

The Asian consensus, with population-specific cut-offs and separate community and hospital algorithms. Notably introduces "possible sarcopenia" — low strength or low physical performance alone — explicitly to enable lifestyle intervention in primary care before a confirmatory mass measurement is available.

DIAGNOSTIC_CRITERIA

Show evidence (1 reference)

PMID:32033882 SUPPORT Human Clinical

"AWGS 2019 also introduces "possible sarcopenia," defined by either low muscle strength or low physical performance only, specifically for use in primary health care or community-based health promotion, to enable earlier lifestyle interventions."

States the "possible sarcopenia" category and its intended use.

👪

Inheritance

1

Polygenic inheritance HP:0010982

Sarcopenia risk is distributed across many common variants of small effect interacting with age, activity, nutrition, and comorbidity. There is no Mendelian mode of inheritance, and penetrance in the monogenic sense does not apply.

Polygenic inheritance

Show evidence (1 reference)

PMID:36771461 SUPPORT Human Clinical

"The substantial decline in skeletal muscle mass, strength, and gait speed is a sign of severe sarcopenia, which may partly depend on genetic risk factors."

Supports a partial, multi-locus genetic contribution rather than a Mendelian one; the same study's 73-locus result is cited under genetic.

◆

Subtypes

4

Primary (age-related) sarcopenia

Sarcopenia diagnosed when advancing age is the only apparent cause, with no identifiable contributing disease, immobilisation, or nutritional deficit.

Show evidence (1 reference)

PMID:35053049 SUPPORT Other

"Sarcopenia is diagnosed as primary when there are no other specific causes."

States the definitional criterion that separates primary from secondary sarcopenia.

Secondary sarcopenia

Sarcopenia attributable to an identifiable driver beyond ageing — disuse and immobilisation, inadequate energy or protein intake, or chronic disease such as organ failure, malignancy, or inflammatory disease. More common than the primary form.

Show evidence (2 references)

PMID:35053049 SUPPORT Other

"However, secondary sarcopenia occurs if other factors, including malignancy or organ failure, are evident in addition to aging."

Defines secondary sarcopenia by the presence of a driver additional to ageing.

PMID:35053049 SUPPORT Other

"The prevalence of secondary sarcopenia is far greater than that of primary sarcopenia and requires special attention."

Supports the claim that the secondary form is the more common one.

Sarcopenic obesity

Concurrent low muscle mass/strength and excess adiposity, in which adipose-derived inflammatory signalling and ectopic intramuscular lipid amplify anabolic resistance. Outcomes are worse than for either component alone.

Show evidence (1 reference)

PMID:27891296 SUPPORT Other

"He also established that obese persons with sarcopenia had worse outcomes than non-obese persons with sarcopenia and obese persons with intact muscle mass."

Establishes sarcopenic obesity as a distinct stratum with worse outcomes.

◈

Mechanistic Hypotheses

2

Neuromuscular Junction Excitability Failure as a Reversible Driver

nmj_excitability_failure EMERGING

Evidence balance 2 support

Holds that a substantial and pharmacologically reversible share of age-related weakness comes not from lost contractile tissue but from failure to reliably excite the tissue that remains — postsynaptic NaV1.4 depletion lowering the safety factor for neuromuscular transmission. Its distinguishing prediction is that restoring fiber excitability improves strength without changing muscle mass. Evidence is strong in aged rodents; the human data establish that transmission failure tracks weakness severity but do not yet include a therapeutic trial, so this is recorded as emerging rather than canonical.

Show evidence (2 references)

PMID:42424105 SUPPORT Model Organism

"Together, these findings demonstrate that NMJ transmission deficits are a key, reversible driver of sarcopenia and reveal a novel therapeutic target for addressing muscle weakness in aging."

The paper's own summary claim, which is the hypothesis this group states. Graded MODEL_ORGANISM because the reversibility half of the claim rests on the rodent rescue arm.

PMID:42424105 SUPPORT Model Organism

"This excitability defect, distinct from potential synaptic cholinergic transmission abnormalities, represents a novel disease mechanism of sarcopenia."

Supports the specific claim that distinguishes this hypothesis: the lesion is one of fiber excitability rather than cholinergic transmission.

Canonical Multifactorial Convergence on Muscle Protein Balance

canonical_multifactorial_convergence CANONICAL

Evidence balance 2 support

The mainstream account: denervation, mitochondrial dysfunction, inflammaging, hormonal decline, satellite-cell exhaustion, and anabolic resistance are partially independent inputs that converge on a persistently negative muscle protein balance and on regenerative failure. It explains why single-target interventions have repeatedly failed to restore function and why exercise — which acts on many arms at once — remains the most effective treatment.

Show evidence (2 references)

PMID:38225199 SUPPORT Other

"Sarcopenia is caused by complex and interdependent pathophysiological mechanisms, including aging, neuromuscular junction impairment, mitochondrial dysfunction, insulin resistance, lipotoxicity, endocrine factors, oxidative stress, and inflammation."

Enumerates the interdependent inputs this hypothesis group asserts converge.

PMID:42464764 SUPPORT Computational

"Clinically, interventions targeting single mechanisms are unlikely to fully restore muscle anabolism in older adults, particularly when multiple impairments coexist."

Supports the hypothesis's distinguishing prediction that single-target interventions under-perform; derived from simulation rather than trial data.

?

Discussions and Knowledge Gaps

5

Do older women and older men with sarcopenia differ in how much strength, muscle mass, and function they gain from resistance training, and if so, in which direction and through which mechanism?

KNOWLEDGE GAP OPEN sarcopenia_resistance_training_sex_difference

Attached to

treatments#Progressive Resistance Exercise Training pathophysiology#Blunted Load-Induced mTORC1 Signalling

The evidence points both ways. A supervised 18-week trial in adults over 65 found larger torque and muscle-quality gains in men. SPRINTT, a larger multicomponent trial in physical frailty and sarcopenia, reported lean-mass and grip benefits in women. The meta-analysis that finds similar relative hypertrophy across sexes was limited to adults aged 18-45. The only mechanistic model of anabolic resistance was built from male data. Sex is therefore an unresolved effect modifier for the cornerstone treatment, and the mechanistic layer cannot yet say whether the load-sensing deficit differs by sex.

Proposed experiments

Sex-stratified individual-participant meta-analysis of resistance training in sarcopenia

sex_stratified_rt_sarcopenia_ipd

Pool individual-participant data from resistance-training RCTs in sarcopenic older adults and test a sex-by-treatment interaction on grip strength, appendicular lean mass, and gait speed. Adjust for baseline strength, training intensity, and protein intake. Where acute biopsy substudies exist, add mTORC1 effector phosphorylation after a standard loading bout.

Would support

pathophysiology#Blunted Load-Induced mTORC1 Signalling

Supporting outcome

A sex-by-treatment interaction persists after adjustment, and the sex with the smaller clinical gain also shows the smaller acute mTORC1 response to loading.

Refuting outcome

No sex-by-treatment interaction remains once baseline strength and training dose are adjusted for, indicating that the published differences reflect cohort and dosing differences rather than biology.

Does reversing neuromuscular junction transmission failure improve strength in humans with sarcopenia, and how much of age-related weakness is attributable to this reversible excitability defect rather than to lost contractile tissue?

KNOWLEDGE GAP OPEN sarcopenia_nmj_reversibility_in_humans

Attached to

pathophysiology#Neuromuscular Junction Transmission Failure treatments#ClC-1 Chloride Channel Inhibition

The human evidence establishes that transmission failure tracks weakness severity; the rescue is rodent-only. The attributable fraction matters practically, because it sets the ceiling on what an excitability-targeting drug could achieve, and it is the one prediction that separates this model from the mass-centred account. It is also the question that would explain why myostatin-pathway drugs add mass without adding strength.

Proposed experiments

Randomised trial of ClC-1 inhibition in older adults with sarcopenia

clc1_inhibition_rct_sarcopenia

Placebo-controlled trial in older adults with confirmed sarcopenia, powered on maximal voluntary contraction, with single-fiber EMG measurement of transmission failure and DXA muscle mass as co-primary mechanistic readouts.

Would support

pathophysiology#Neuromuscular Junction Transmission Failure

Supporting outcome

Strength improves relative to placebo with no corresponding increase in appendicular lean mass, and the improvement tracks the reduction in measured transmission failure.

Refuting outcome

Transmission failure is reduced pharmacologically without any accompanying improvement in maximal voluntary contraction, indicating the deficit is not rate-limiting for force in humans.

Do rodent ageing models represent the inflammatory arm of human sarcopenia well enough to support translational inference about anti-inflammatory interventions?

HUMAN MODEL MISMATCH OPEN sarcopenia_rodent_inflammaging_fidelity

Attached to

pathophysiology#Chronic Low-Grade Inflammation animal_models#Naturally aged C57BL/6 mouse (28 months)

The cross-species transcriptomic comparison found that rodents reproduce the mitochondrial changes of human sarcopenia at gene level but the inflammatory response only at pathway level. Evidence therefore exists in the model, but its fidelity to human inflammaging is the open question — the HUMAN_MODEL_MISMATCH case rather than a plain absence of evidence. This matters because inflammaging is one of the arms most often nominated as a drug target.

Proposed experiments

Species-matched inflammatory profiling of sarcopenic human and rodent muscle

cross_species_muscle_inflammatory_profiling

Profile the inflammatory transcriptome and cytokine content of skeletal muscle from aged humans and aged rodents stratified by measured sarcopenia status rather than by chronological age, and test whether the gene-level divergence reported across species is a true biological difference or an artefact of comparing animals and people matched on age instead of on muscle phenotype. The stratification is the point: the source study's own conclusion is that muscle mass, not age, indicates muscle health.

Would support

pathophysiology#Chronic Low-Grade Inflammation

Supporting outcome

Phenotype-matched aged rodents and humans show concordant muscle inflammatory gene expression, indicating the previously reported gene-level divergence came from age-matching rather than from species biology, and that rodent inflammaging findings can be carried across.

Refuting outcome

The divergence persists after phenotype matching, establishing that rodent muscle inflammaging is not a faithful model of the human arm and that anti-inflammatory targets validated only in rodents should not be assumed to translate.

Which common genetic variants actually modify sarcopenia risk, and what is the effect size of the widely cited ACTN3 R577X association in older adults?

KNOWLEDGE GAP OPEN sarcopenia_genetic_susceptibility_unverified

Attached to

genetic#ACTN3

The genetic section rests on leads carried forward from a deep-research report without primary-source verification in this session. The ACTN3 and GWAS claims are plausible and widely repeated, which is exactly the condition under which an unverified claim propagates. Recorded as an explicit gap so that a later curation pass verifies or removes them rather than inheriting them as established.

Why do interventions that reliably add muscle mass in older adults so often fail to add strength or physical function, and which mechanism should a sarcopenia trial's primary endpoint therefore measure?

KNOWLEDGE GAP OPEN sarcopenia_mass_versus_strength_endpoints

Attached to

pathophysiology#Loss of Skeletal Muscle Mass, Strength and Quality pathophysiology#Neuromuscular Junction Transmission Failure treatments#Bimagrumab (Anti-Activin Type II Receptor Antibody) treatments#Myostatin Ligand Neutralization (Landogrozumab, Trevogrumab) treatments#Selective Androgen Receptor Modulation (Enobosarm, MK-0773)

The dissociation is now the single most consistent finding across this entry's pharmacological treatments, and it recurs across drug classes that share no mechanism. Bimagrumab raised lean body mass by 7% in older adults with sarcopenia and produced no functional difference from placebo; MK-0773 raised lean mass in sarcopenic women with no strength or function gain; landogrozumab met its lean-mass endpoint while moving only some performance measures. Reading these as three separate disappointments misses that they are one result repeated. The pattern is not absolute: the earlier 40-person bimagrumab study did find gait-speed and walking-distance gains in its slowest-walking participants, which is itself a lead - it suggests the dissociation may be a question of who is treated rather than of what the drug does. Two explanations are on the table and they imply different drug-development programmes: either added mass is added low-quality tissue, or force production in aged muscle is limited by something other than contractile mass - excitability and neuromuscular transmission being the candidate this entry already models. Which is right determines whether strength, specific force, or mass belongs in the primary endpoint, and PMID:42706321 argues the field should shift away from mass.

Proposed experiments

Partitioning drug-induced lean-mass gain into contractile quality and excitability

mass_gain_quality_partition

In a trial of an agent with an established lean-mass effect, measure appendicular lean mass, single-fiber specific force from biopsy, and neuromuscular transmission by single-fiber EMG in the same participants before and after treatment, and test which of the two intermediate measures accounts for the gap between the mass change and the maximal-voluntary-contraction change.

Would support

pathophysiology#Neuromuscular Junction Transmission Failure

Supporting outcome

Mass rises without a corresponding rise in single-fiber specific force, and the residual weakness tracks unchanged transmission failure - indicating that force is limited by excitability and that mass-adding drugs cannot close the gap on their own.

Refuting outcome

Single-fiber specific force falls as mass rises, with transmission unchanged, indicating the added tissue is of lower contractile quality and that the problem is the anabolic drug's tissue product rather than the neuromuscular arm.

⚙

Pathophysiology

17

Alpha Motor Neuron Loss and Muscle Fiber Denervation

Progressive age-related attrition of spinal alpha motor neurons withdraws innervation from the muscle fibers of the lost motor units. Denervated fibers are either rescued by collateral sprouting from a surviving neighbouring motor neuron or are lost, so motor neuron number sets an upper bound on how much contractile tissue can be maintained. Fast-twitch (type II) fibers are preferentially affected.

alpha motor neuron CL:0008038 skeletal muscle fiber CL:0008002

response to denervation GO:0014894 ↑ INCREASED

skeletal muscle tissue UBERON:0001134

Downstream

Neuromuscular Junction Transmission Failure Withdrawal and remodelling of motor nerve terminals destabilises the junction before frank fiber loss.

Failure of Compensatory Motor Unit Remodeling Declining motor neuron number is the deficit that collateral reinnervation must compensate for.

Show evidence (3 references)

PMID:29527694 SUPPORT Human Clinical

"The age-related loss of muscle mass is related to the loss of innervating motor neurons and denervation of muscle fibres."

States motor neuron loss and denervation as the substrate of age-related muscle loss.

PMID:29527694 SUPPORT Human Clinical

"The motor unit numbers were reduced in all groups of old compared with young men"

Reports the measured reduction in motor unit number with age in humans.

PMID:40678078 SUPPORT Other

"Neurodegeneration and age-related muscle fibers denervation further exacerbate muscle loss, particularly affecting fast-twitch fibers, and reduce motor unit integrity."

Supports the preferential effect on fast-twitch fibers and on motor unit integrity.

Neuromuscular Junction Transmission Failure

Transmission across the neuromuscular junction fails intermittently in weak older people and in aged rodents, in proportion to the severity of weakness. The lesion is postsynaptic and electrical rather than cholinergic: the skeletal-muscle voltage-gated sodium channel NaV1.4 is locally depleted from the post-synaptic membrane, so the endplate potential less reliably reaches threshold for a propagated action potential. Pharmacological NaV1.4 blockade in young adult rats reproduces the phenotype, and lowering the competing chloride conductance by inhibiting ClC-1 restores it — making this a reversible driver of weakness rather than a downstream marker of fiber loss.

skeletal muscle fiber CL:0008002

neuromuscular junction GO:0031594

Animal models

Aged rat neuromuscular transmission model Rat recapitulates Reproduces the human finding of NMJ transmission failure and adds the electrophysiological localisation to post-synaptic fiber excitability that human studies could not provide.

Downstream

Type II Myofiber Atrophy and Fiber-Type Shift

Loss of Skeletal Muscle Mass, Strength and Quality Intermittent transmission failure reduces force output independently of how much contractile tissue remains, which is one reason strength falls faster than mass.

Show evidence (3 references)

PMID:42424105 SUPPORT Human Clinical

"Here, we demonstrate that weak older individuals exhibit NMJ transmission failure that correlates with muscle weakness severity."

Establishes NMJ transmission failure in humans and its correlation with weakness severity.

PMID:42424105 SUPPORT Model Organism

"Preclinical experiments showed similar NMJ transmission failure in aged rodents that was associated with localized loss of muscle fiber excitability at the NMJ."

Localises the defect to muscle fiber excitability at the junction in aged rodents.

PMID:38225199 SUPPORT Other

"NMJ instability is considered to be an initiating and driving factor of the pathology of sarcopenia"

Review support for placing NMJ instability upstream rather than as a consequence.

Postsynaptic NaV1.4 Depletion

Immunohistochemistry across humans and rodents shows a localized reduction of the skeletal-muscle voltage-gated sodium channel NaV1.4 (SCN4A) at the post-synaptic membrane of the neuromuscular junction. Acute pharmacological inhibition of NaV1.4 in adult rats is sufficient to reproduce the aged transmission phenotype, establishing the channel loss as a cause of the excitability defect rather than a correlate.

voltage-gated sodium channel activity GO:0005248 ↓ DECREASED

Downstream

Neuromuscular Junction Transmission Failure

Show evidence (1 reference)

PMID:42424105 SUPPORT Human Clinical

"Across species, immunohistochemistry identified a localized reduction in the voltage-gated sodium channel specific for skeletal muscle (NaV1.4) at the post-synaptic NMJ membrane."

Reports the cross-species localisation of NaV1.4 loss to the postsynaptic membrane.

Failure of Compensatory Motor Unit Remodeling

Healthy ageing muscle offsets motor neuron loss by collateral reinnervation, enlarging the surviving motor units — measurable as larger motor unit potentials. Sarcopenic muscle does not: motor unit potentials in sarcopenic older men resemble those of young men rather than those of healthy or pre-sarcopenic older men. The distinguishing lesion in sarcopenia is therefore not denervation itself, which is near-universal with age, but the failure of the rescue mechanism.

musculature of limb UBERON:0004480

Downstream

Type II Myofiber Atrophy and Fiber-Type Shift Fibers not rescued by reinnervation atrophy and are lost.

Show evidence (2 references)

PMID:29527694 SUPPORT Human Clinical

"These findings suggest that a failure to expand the motor unit size distinguishes sarcopenic from pre-sarcopenic muscles."

States the study's central finding, which is the claim of this node.

PMID:29527694 SUPPORT Human Clinical

"Reinnervation of denervated muscle fibres probably expands the motor unit size in the non-sarcopenic and pre-sarcopenic old, but not in the sarcopenic old."

Contrasts successful with failed reinnervation across the sarcopenia spectrum.

Mitochondrial Dysfunction and Oxidative Stress

Ageing myofibers accumulate mitochondrial damage with reduced biogenesis, impaired oxidative phosphorylation, defective mitophagy, and excess reactive oxygen species. Because mitochondria are enriched on both sides of the neuromuscular junction and support its transmission, this deficit both destabilises the junction and lowers the ATP available for contraction and for protein synthesis, placing it upstream of several other arms of the chain.

skeletal muscle fiber CL:0008002

cellular respiration GO:0045333 ↓ DECREASED

mitochondrion GO:0005739

Animal models

Naturally aged C57BL/6 mouse (28 months) Mouse recapitulates Transcriptomic comparison shows the mitochondrial arm of human sarcopenia is reproduced in rodents.

Downstream

Neuromuscular Junction Transmission Failure

Chronic Low-Grade Inflammation

Muscle Satellite Cell Exhaustion

Show evidence (2 references)

PMID:42511674 SUPPORT Other

"Mitochondrial dysfunction appears to represent an early upstream event that promotes excessive reactive oxygen species production, defective mitophagy, inflammatory activation, and cellular senescence."

Supports placing mitochondrial dysfunction upstream of inflammation and senescence in this chain.

PMID:33580198 SUPPORT Model Organism

"We found that rodents recapitulate mitochondrial changes observed in human sarcopenia, while inflammatory responses are conserved at pathway but not gene level."

Cross-species transcriptomic support that mitochondrial change is a conserved feature of sarcopenic muscle.

Chronic Low-Grade Inflammation

Persistent sterile elevation of circulating IL-6 and TNF-alpha ("inflammaging") activates NF-kappaB signalling in myofibers, which drives the atrogene program and suppresses myogenic differentiation. It is a systemic input to muscle rather than a muscle-intrinsic lesion, which is why it links sarcopenia to the wider multimorbidity of ageing.

positive regulation of NF-kappaB signalling GO:0043123 ↑ INCREASED

Downstream

Ubiquitin-Proteasome Myofibrillar Proteolysis

Muscle Satellite Cell Exhaustion

Show evidence (2 references)

PMID:42511674 SUPPORT Other

"Chronic inflammation, mediated primarily through IL-6 and TNF-α, further accelerates muscle catabolism and regenerative failure, whereas senescence-associated pathways impair satellite cell function and muscle repair."

Names the mediators and the two consequences this node routes to downstream.

PMID:38046952 SUPPORT Other

"Various studies suggest that the gene expression of Atrogin-1 and MuRF1 is differentially regulated by FOXO and NF-κB pathways"

Substantiates the NF-kappaB half of this node's claim and its GO annotation: NF-kappaB is one of the two pathways regulating the atrogene program, which the mediator snippet above does not itself state.

Muscle Satellite Cell Exhaustion

Skeletal muscle satellite cells — the resident stem cells that repair and regenerate myofibers — decline in number and in proliferative and differentiative capacity with age, in a niche degraded by chronic inflammation, mitochondrial dysfunction, and accumulating senescent cells. Regenerative failure converts what would be recoverable injury into permanent fiber loss.

skeletal muscle satellite cell CL:0000594

skeletal muscle satellite cell proliferation GO:0014841 ↓ DECREASED skeletal muscle tissue regeneration GO:0043403 ↓ DECREASED

Downstream

Type II Myofiber Atrophy and Fiber-Type Shift

Myosteatosis and Intramuscular Fibro-Adipogenic Infiltration

Show evidence (1 reference)

PMID:40678078 SUPPORT Other

"With age, both the structure and function of these components deteriorate: myonuclei become disorganized, gene expression skews toward catabolic, inflammatory, and fibrotic pathways, and satellite cell numbers and activity decline."

Supports the decline in satellite cell number and activity with age.

Declining Anabolic Hormone Signalling

Circulating growth hormone, IGF-1, testosterone, and estrogen fall with age (the sex-hormone half of that claim is what the cited evidence covers directly; the GH/IGF-1 decline is stated by the same reviews but is not separately quoted here). Because IGF-1 signalling through PI3K/AKT is the principal positive regulator of muscle protein content — driving mTOR-dependent synthesis while restraining FOXO-driven atrogene transcription — its withdrawal simultaneously weakens synthesis and releases the brake on degradation.

Downstream

Anabolic Resistance

Ubiquitin-Proteasome Myofibrillar Proteolysis

Show evidence (2 references)

PMID:40724988 SUPPORT Other

"Particular attention is given to the role of declining sex hormones, such as testosterone and estrogen, as key drivers of anabolic resistance and muscle loss during aging."

Supports declining sex hormones as drivers of anabolic resistance and muscle loss.

PMID:38046952 SUPPORT Other

"The IGF-1/PI3K/AKT pathway, by inhibiting FOXO, prevents the upregulation of Atrogin-1 and suppresses muscle atrophy"

Establishes the mechanism by which loss of IGF-1 signalling releases the atrogene program, linking this node to proteolysis downstream.

Blunted Load-Induced mTORC1 Signalling

Resistance exercise is sensed mechanically by the myofiber. Load converges on mTORC1 via candidate mechanosensors: costamere and integrin deformation acting through FAK-TSC2-Rheb, a DGKzeta-phosphatidic acid axis, and filamin C-BAG3 signalling at the Z-disc. mTORC1 then drives muscle protein synthesis. In older muscle the same bout of exercise produces a smaller rise in mTOR, S6K1 and 4E-BP1 phosphorylation and in protein synthesis. The dose-response curve is flattened rather than abolished: older muscle still responds, but needs higher intensity to approach the young response. This node is the loading arm of anabolic resistance; the feeding arm is captured on the Anabolic Resistance node itself.

skeletal muscle fiber CL:0008002

cellular response to mechanical stimulus GO:0071260 ↓ DECREASED load-induced TORC1 signaling GO:0038202 ↓ DECREASED

Downstream

Anabolic Resistance A blunted protein-synthetic response to loading is one of the two stimulus arms that make up anabolic resistance.

Show evidence (5 references)

PMID:30335577 SUPPORT REVIEW SYNTHESIS Other

"A large body of work shows that a mammalian target of rapamycin complex 1 (mTORC1)-mediated increase of muscle protein synthesis is the key, but not sole, mechanism by which resistance exercise causes muscle hypertrophy."

Establishes mTORC1-driven protein synthesis as the pathway that resistance loading acts through.

PMID:30335577 SUPPORT REVIEW SYNTHESIS Other

"Mechanical signals are the prime hypertrophy stimuli candidates, and a filamin-C-BAG3-dependent regulation of mTORC1, Hippo, and autophagy signaling is a plausible albeit still incompletely characterized hypertrophy sensor."

Names mechanical load as the stimulus and filamin C-BAG3 as a candidate sensor, and records that the sensor is not settled.

PMID:27909410 SUPPORT REVIEW SYNTHESIS Other

"This may e.g. implicate mechanical activation of signaling through a diacylglycerol kinase (DGKζ)-phosphatidic acid (PA) axis or implicate integrin deformation to signal through a Focal adhesion kinase (FAK)-Tuberous Sclerosis Complex 2 (TSC2)-Ras homolog enriched in brain (Rheb) axis."

Names the two further candidate mechanotransduction routes to mTORC1 listed in the description.

+ 2 more references

Anabolic Resistance

Ageing muscle mounts a blunted muscle-protein-synthesis response to the same anabolic stimulus — dietary protein and leucine, or a bout of resistance exercise — so that a larger dose is needed to reach the same synthetic rate. Systems-level analysis indicates that no single age-related impairment accounts for it; the resistant phenotype emerges only when several dysregulated nutrient-sensing and signalling processes act together, which is why single-target interventions under-perform.

skeletal muscle fiber CL:0008002

TORC1 signaling GO:0038202 ↓ DECREASED

Computational models

Multiscale kinetic model of leucine-stimulated muscle protein metabolism KINETIC MATLAB Reproduces the reduced protein-synthetic response to feeding in older adults, and only when several impairments are combined.

Downstream

Negative Net Muscle Protein Balance

Show evidence (3 references)

PMID:42464764 SUPPORT Computational

"Sarcopenia, the age-related loss of skeletal muscle mass and function, is primarily caused by anabolic resistance, which is the blunted stimulation of muscle protein synthesis (MPS) and impaired suppression of muscle protein breakdown following anabolic stimuli such as feeding."

Defines anabolic resistance as modelled here and places it upstream of muscle loss.

PMID:42464764 SUPPORT Computational

"Instead, anabolic resistance emerged only when multiple impairments operated together."

Supports the multifactorial claim in this node's description; the finding comes from a kinetic simulation, not a human feeding study.

PMID:40678078 SUPPORT Other

"Compounding this is anabolic resistance, a hallmark of aging muscle, in which higher levels of dietary protein and amino acids are required to stimulate muscle protein synthesis effectively."

Independent review support for the raised anabolic threshold.

Myostatin and Activin Receptor Signalling

Myostatin (GDF8) and activins signal through the type II activin receptors (ActRIIA/ActRIIB) and SMAD2/3 to restrain muscle growth, opposing IGF-1/AKT/mTOR anabolic signalling and reinforcing atrogene expression. The axis is the leading pharmacological target class in sarcopenia. Antibody blockade of the receptors increased thigh muscle volume and lean body mass in a phase-1 study of 24 healthy older and obese adults, which is the available evidence that the pathway restrains mass in ageing muscle — though that study did not reach significance on appendicular lean mass specifically, and no trial has yet shown the pathway is over-active in sarcopenia rather than merely blockable.

activin receptor activity GO:0017002

Downstream

Anabolic Resistance

Ubiquitin-Proteasome Myofibrillar Proteolysis

Show evidence (2 references)

PMID:33264516 SUPPORT Human Clinical

"Bimagrumab is a human monoclonal antibody that blocks the ActRIIs, preventing the activity of myostatin and other negative skeletal muscle regulators."

Identifies the receptor and ligands of the axis modelled by this node.

PMID:33264516 SUPPORT INDIRECT Human Clinical

"A single dose of bimagrumab rapidly increased TMV and LBM and decreased body adiposity in older adults."

Therapeutic blockade increasing muscle volume and lean mass in older adults supports the pathway restraining mass; the inference runs from the drug response back to the mechanism, hence INDIRECT.

Ubiquitin-Proteasome Myofibrillar Proteolysis

FOXO3, de-repressed by weakened IGF-1/PI3K/AKT signalling and driven further by NF-kappaB, transcribes the muscle-specific E3 ubiquitin ligases atrogin-1 (FBXO32) and MuRF1 (TRIM63), which ubiquitinate myofibrillar proteins for proteasomal destruction. This is the dominant degradative route in skeletal muscle atrophy, acting alongside autophagy-lysosomal, calpain, and caspase systems.

proteasome-mediated ubiquitin-dependent protein catabolic process GO:0043161 ↑ INCREASED

Downstream

Negative Net Muscle Protein Balance

Show evidence (2 references)

PMID:38046952 SUPPORT Other

"Atrogin-1 and MuRF1 are significantly upregulated by FOXO3 in all muscle atrophy scenarios"

Names the transcription factor and the two E3 ligases central to this node.

PMID:38046952 SUPPORT Other

"the ubiquitin-proteasome pathway emerges as an especially cardinal avenue for intracellular protein degradation, wielding pronounced influence over the muscle atrophy trajectory"

Supports treating the ubiquitin-proteasome route as the dominant degradative arm.

Negative Net Muscle Protein Balance

The convergence point of the anabolic and catabolic arms: when degradation persistently exceeds synthesis, myofiber protein content falls and atrophy follows. Muscle mass is maintained only while this balance is neutral, so both a blunted synthetic response and an accelerated degradative one produce the same result.

skeletal muscle fiber CL:0008002

Downstream

Type II Myofiber Atrophy and Fiber-Type Shift

Show evidence (1 reference)

PMID:38046952 SUPPORT Other

"Under catabolic conditions, protein degradation surpasses synthesis, leading to muscle weakness and atrophy."

States the balance claim that defines this node.

Type II Myofiber Atrophy and Fiber-Type Shift

Fast-twitch type II fibers lose cross-sectional area preferentially, while fibers rescued by collateral reinnervation from slow motor neurons take on type I properties, producing fiber-type grouping and a net shift toward slow phenotype. Because type II fibers generate the highest power, this disproportionately costs explosive strength — the capacity needed to arrest a stumble — which is part of why strength declines faster than mass.

type II (fast) skeletal muscle fiber CL:0000190

skeletal muscle atrophy GO:0014732 ↑ INCREASED

skeletal muscle tissue UBERON:0001134

Downstream

Loss of Skeletal Muscle Mass, Strength and Quality

Show evidence (1 reference)

PMID:40678078 SUPPORT Other

"Neurodegeneration and age-related muscle fibers denervation further exacerbate muscle loss, particularly affecting fast-twitch fibers, and reduce motor unit integrity."

Supports the preferential loss of fast-twitch fibers via denervation.

Myosteatosis and Intramuscular Fibro-Adipogenic Infiltration

Space vacated by lost myofibers is filled by adipose and fibrous tissue, and lipid also accumulates ectopically within fibers. Intramuscular ceramide accumulation impairs insulin signalling and suppresses protein synthesis via eIF2-alpha phosphorylation, so myosteatosis is not merely a passive radiological marker of poor muscle quality but feeds back onto anabolic resistance. This arm is amplified in sarcopenic obesity.

skeletal muscle tissue UBERON:0001134

Downstream

Anabolic Resistance

Loss of Skeletal Muscle Mass, Strength and Quality

Show evidence (1 reference)

PMID:25139155 SUPPORT Model Organism

"Hence, OR were more prone to ectopic muscle lipid accumulation than YR, leading to decreased muscle protein anabolism."

Old rats accumulate ectopic muscle lipid and lose protein anabolism, supporting the feedback from myosteatosis to reduced anabolism.

Capillary Rarefaction and Impaired Muscle Perfusion

Skeletal muscle capillary density falls with age and the endothelial glycocalyx regulating exchange across the capillaries that remain is compromised, so less oxygen, substrate, insulin and amino acid reaches the myofiber for a given cardiac output. The proposed proximate cause is a signalling insufficiency rather than an endothelial one: production of the soluble VEGF decoy receptor sFlt-1 rises with age, leaving VEGFA-driven capillary sprouting unable to keep pace. This is a delivery lesion, not a contractile one, which is why it appears here upstream of anabolic resistance and of the bioenergetic deficit rather than alongside them.

capillary endothelial cell CL:0002144

angiogenesis GO:0001525 ↓ DECREASED

skeletal muscle tissue UBERON:0001134

Downstream

Anabolic Resistance

Mitochondrial Dysfunction and Oxidative Stress

Show evidence (3 references)

PMID:24577061 SUPPORT Human Clinical

"Skeletal muscle capillary density is reduced with aging and type 2 diabetes and accompanied by impairments in endothelial glycocalyx function, which is indicative of compromised vascular function."

The direct human measurement this node asserts, in healthy older men compared with young men, covering both the density loss and the glycocalyx-function component.

PMID:24577061 SUPPORT INDIRECT Human Clinical

"Adequate muscle perfusion is required for the maintenance of skeletal muscle mass."

Supports treating perfusion as load-bearing for muscle mass, which is what places this node upstream rather than making it an incidental correlate. INDIRECT because the sentence states the premise the study was designed around rather than a result it measured.

PMID:34326210 SUPPORT Model Organism

"Increasing VEGF signaling prevented age-associated capillary loss, improved organ perfusion and function, and extended life span."

The interventional counterpart in mice: restoring VEGF signalling reverses the capillary loss, which supports the sFlt-1/VEGF-insufficiency mechanism this node's description names.

Loss of Skeletal Muscle Mass, Strength and Quality

The clinical convergence node. Reduced contractile tissue, degraded muscle quality, and unreliable neuromuscular transmission together produce the measurable triad on which the diagnosis rests: low strength (the primary criterion), low muscle quantity or quality (confirmatory), and poor physical performance (which grades severity). Strength falls out of proportion to mass, which is why EWGSOP2 moved strength to the front of the definition.

skeletal muscle organ UBERON:0014892

Animal models

Naturally aged C57BL/6 mouse (28 months) Mouse recapitulates Aged mice lose muscle mass and grip strength together, reproducing the defining human combination rather than mass loss alone.

Naturally occurring sarcopenia in aged companion dogs and cats Dog partially recapitulates Reproduces age-related lean body mass loss arising without an underlying disease, in a long-lived outbred species sharing the human environment.

Show evidence (2 references)

PMID:30312372 SUPPORT Human Clinical

"Sarcopenia is a progressive and generalised skeletal muscle disorder that is associated with increased likelihood of adverse outcomes including falls, fractures, physical disability and mortality."

The consensus statement of the clinical endpoint this node represents.

PMID:30312372 SUPPORT Human Clinical

"In these revised guidelines, muscle strength comes to the forefront, as it is recognised that strength is better than mass in predicting adverse outcomes"

Supports the strength-over-mass claim made in this node's description.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

7

Musculoskeletal 3

Low Muscle Strength VERY_FREQUENT Generalized muscle weakness HP:0003324

Course: PROGRESSIVE

Show evidence (2 references)

PMID:30312372 SUPPORT Human Clinical

"focuses on low muscle strength as a key characteristic of sarcopenia, uses detection of low muscle quantity and quality to confirm the sarcopenia diagnosis, and identifies poor physical performance as indicative of severe sarcopenia"

Establishes low muscle strength as the primary diagnostic criterion.

PMID:32033882 SUPPORT Human Clinical

"low muscle strength is defined as handgrip strength <28 kg for men and <18 kg for women"

Gives the AWGS 2019 operational cut-offs for this phenotype.

Decreased Muscle Mass HP:0003199

Course: PROGRESSIVE

No frequency is recorded. Low muscle mass is confirmatory rather than primary under EWGSOP2, so by construction it is absent in "probable" sarcopenia; the cited snippet gives diagnostic cut-offs, not a frequency.

Show evidence (1 reference)

PMID:32033882 SUPPORT Human Clinical

"AWGS 2019 retains the original cutoffs for height-adjusted muscle mass: dual-energy X-ray absorptiometry, <7.0 kg/m2 in men and <5.4 kg/m2 in women"

Gives the operational cut-offs defining low muscle mass.

Type 2 Muscle Fiber Atrophy HP:0003554

Show evidence (1 reference)

PMID:40678078 SUPPORT Other

"Neurodegeneration and age-related muscle fibers denervation further exacerbate muscle loss, particularly affecting fast-twitch fibers, and reduce motor unit integrity."

Supports preferential involvement of fast-twitch (type II) fibers.

Nervous System 2

Impaired Physical Performance Gait disturbance HP:0001288

Show evidence (1 reference)

PMID:32033882 SUPPORT Human Clinical

"criteria for low physical performance are 6-m walk <1.0 m/s, Short Physical Performance Battery score ≤9, or 5-time chair stand test ≥12 seconds"

Gives the operational thresholds for the physical-performance domain.

Falls HP:0002527

Show evidence (1 reference)

PMID:30312372 SUPPORT Human Clinical

"Sarcopenia is a progressive and generalised skeletal muscle disorder that is associated with increased likelihood of adverse outcomes including falls, fractures, physical disability and mortality."

Names falls among the adverse outcomes associated with sarcopenia.

Constitutional 1

Frailty HP:0033675

Show evidence (1 reference)

PMID:27891296 SUPPORT Other

"Sarcopenia is the most important cause of frailty in older persons."

Supports the relationship between sarcopenia and frailty asserted here.

Other 1

Physical Disability and Loss of Independence

Deliberately unbound. HPO has no term for acquired physical disability or loss of independence in an older adult; the nearest candidates (HP:0012759 Neurodevelopmental abnormality, HP:0001288 Gait disturbance) name something else, and the dismech term contract prefers no term to a wrong one. Revisit if a suitable HP or functional-status term appears.

Show evidence (1 reference)

PMID:30312372 SUPPORT Human Clinical

"impairs ability to perform activities of daily living"

States the ADL impairment recorded by this phenotype.

🧬

Genetic Associations

4

ACTN3

Gene: ACTN3 hgnc:165 relationship_type: UNKNOWN variant_origin: GERMLINE

Show evidence (1 reference)

PMID:27861536 NO_EVIDENCE Human Clinical

"No definite conclusions can be inferred in relation to EL owing to its lack of association with both rs1815739 and rs1805086."

Recorded as NO_EVIDENCE, not REFUTE. This study genotypes the same ACTN3 R577X polymorphism but tests it against exceptional longevity, not against sarcopenia, so it does not bear on the claim either way. It is cited to record that the nearest cached primary source was examined and found not to be about this disease, rather than leaving the gene silently unsourced.

MSTN

Gene: MSTN hgnc:4223 relationship_type: UNKNOWN

Show evidence (1 reference)

PMID:33264516 SUPPORT INDIRECT Human Clinical

"Bimagrumab is a human monoclonal antibody that blocks the ActRIIs, preventing the activity of myostatin and other negative skeletal muscle regulators."

Identifies myostatin as a negative regulator of skeletal muscle acting via ActRIIs; the relevance to sarcopenia is via the therapeutic response, so the support is indirect.

SCN4A

Gene: SCN4A hgnc:10591 gene page relationship_type: BIOMARKER

Show evidence (1 reference)

PMID:42424105 SUPPORT Human Clinical

"Across species, immunohistochemistry identified a localized reduction in the voltage-gated sodium channel specific for skeletal muscle (NaV1.4) at the post-synaptic NMJ membrane."

Documents the loss of the SCN4A gene product at the junction in sarcopenia.

Polygenic sarcopenia risk loci (UK Biobank)

Gene: IRS1 hgnc:6125 relationship_type: SUSCEPTIBILITY variant_origin: GERMLINE

Show evidence (2 references)

PMID:36771461 SUPPORT Human Clinical

"By combining summary statistics of genome-wide association studies (GWAS) of handgrip strength, lean mass and walking pace, we have identified 78 independent SNPs (from 73 loci) associated with all three traits with consistent effect directions."

Establishes the polygenic architecture recorded by this entry: 78 SNPs across 73 loci associated with all three sarcopenia-defining traits in the same direction.

PMID:36771461 SUPPORT Human Clinical

"Of the 78 SNPs, 55 polymorphisms were also associated with body fat percentage and 25 polymorphisms with type 2 diabetes (T2D), indicating that sarcopenia, obesity and T2D share many common risk alleles."

Supports shared genetic architecture with adiposity and type 2 diabetes, which is the genetic counterpart of the sarcopenic-obesity subtype.

💊

Medical Actions

21

Progressive Resistance Exercise Training

Action: progressive resistance training Ontology label: Exercise Intervention NCIT:C62739

Platform: Behavioral / lifestyle

Moderate-to-high intensity progressive resistance training, typically three sessions weekly at 60-80% of one-repetition maximum, is the cornerstone intervention and the only one that reliably improves strength, mass, and physical performance together. Benefit is demonstrable even in frail nonagenarians. Response varies widely between individuals, but in a pooled analysis of 195 older adults every participant improved on at least one outcome, and longer programmes produced more responders. Differences by age, sex, reproductive status and baseline function are recorded under effect_modifiers. A SPRINTT sex result pointing the other way is kept in the evidence, because it rests on separate within-sex results.

Mechanism Target:

Negative Net Muscle Protein Balance — Restores muscle protein balance by stimulating synthesis.

Loss of Skeletal Muscle Mass, Strength and Quality — Directly improves the strength, mass, and performance domains.

Effect differs by subgroup:

age age 75 years or younger vs older than 75 years — larger effect on gait speed meta analysis subgroup

Subgroup analysis in a meta-analysis restricted to older adults with sarcopenia. The same analysis reported higher heterogeneity in the larger-effect subgroups, so the gradient is suggestive rather than settled.

Show evidence (1 reference)

PMID:42304276 SUPPORT Human Clinical

"Subgroup analysis of gait speed indicated that shorter intervention cycles (≤12 weeks), younger age (≤75 years), and a weekly training frequency of three sessions yielded larger effect sizes with higher heterogeneity"

Reports the age gradient for gait speed in a sarcopenic population.

age older men (about 70 years) vs young men (about 25 years) — smaller effect on acute muscle protein synthesis and mTORC1 signalling after a resistance bout cross stratum comparison

Acute tracer and biopsy studies rather than training trials. The dose-response is flattened rather than abolished, which is the basis for prescribing higher intensity to older adults. The mechanism is recorded as the Blunted Load-Induced mTORC1 Signalling node.

Show evidence (2 references)

PMID:19001042 SUPPORT Human Clinical

"In each group, there was a sigmoidal dose-response relationship between MPS at 1-2 h post-exercise and exercise intensity, which was blunted (P < 0.05) in the older men."

Blunted synthetic response to the same relative load in older men.

PMID:21798089 SUPPORT Human Clinical

"After exercise, MPS increased from baseline only in the younger group (P< 0.05), with MPS being significantly greater than that in the older group (P <0.05)."

Independent replication of the age difference in acute protein synthesis.

age older adults (65 years and over) vs young adults (18-30 years) — no difference on strength, body composition and mitochondrial adaptations to 8 weeks of training cross stratum comparison

Each age group was randomised to endurance, resistance or combined training. Most training adaptations did not differ by age, which sits alongside the blunted acute response: older muscle adapts, at a higher stimulus cost per bout.

Show evidence (1 reference)

PMID:25599385 SUPPORT Human Clinical

"Importantly, most of the adaptations to training occurred independent of age."

Reports age-independence of most training adaptations.

sex women over 65 vs men over 65 — smaller effect on knee extensor maximal torque and muscle quality cross stratum comparison, interaction tested

18 weeks of supervised resistance training with no untrained control arm. Muscle cross-sectional area did not differ by sex, so the gap is in strength per unit muscle rather than in hypertrophy. SPRINTT reported the opposite pattern for a multicomponent programme; that result is in the treatment evidence, not here, because it rests on separate within-sex results without an interaction test.

Show evidence (2 references)

PMID:27354538 SUPPORT Human Clinical

"Maximal torque increased by 15.8 ± 10.6% in women and 41.7 ± 25.5% in men, whereas muscle quality increased by 8.8 ± 17.5% in women and by 33.7 ± 25.6% in men."

Quantifies the smaller torque and muscle-quality gains in women.

PMID:27354538 SUPPORT Human Clinical

"There were no interaction effects with sex for muscle ACSA or muscle fat, but an interaction effect was observed for muscle quality"

Records the formal sex interaction tests and the absence of a sex difference in muscle size.

reproductive status postmenopausal women vs premenopausal women — no difference on muscular strength and functional mass meta analysis subgroup, interaction tested

Meta-analysis of 126 studies in healthy women; age, training duration and frequency also did not moderate the response.

Show evidence (1 reference)

PMID:41963141 SUPPORT Human Clinical

"Resistance training significantly improved muscular strength in both premenopausal (standardized mean difference = 1.50 [95% confidence interval: 1.28-1.73]) and postmenopausal women (standardized mean difference = 1.46 [95% confidence interval: 1.26-1.67]), with no subgroup difference (p = 0.520)."

Formal subgroup comparison by menopausal status, null.

baseline severity SPPB score 8-9 vs SPPB score 3-7 — no effect on incident mobility disability post hoc subgroup, interaction tested

In SPRINTT, the programme reduced mobility disability only in participants with lower baseline function. The separate SPPB 8-9 analysis was run because a qualitative interaction with SPPB category was found. SPRINTT's intervention was multicomponent (moderate-intensity physical activity plus nutritional counselling), so this records effect modification for that programme; whether progressive resistance training alone behaves the same way is not established.

Show evidence (2 references)

PMID:35545258 SUPPORT Human Clinical

"In participants with SPPB scores of 8 or 9, mobility disability occurred in 46/155 (29.7%) in the multicomponent intervention and 38/159 (23.9%) controls (hazard ratio 1.25, 95% confidence interval 0.79 to 1.95; P=0.34)."

No benefit in the higher-function stratum.

PMID:35545258 SUPPORT Human Clinical

"As a qualitative interaction between SPPB category and intervention arm was found when the cumulative event curves for participants with SPPB scores of 3-7 and a score of 8 or 9 were compared, we analysed those with an SPPB score of 8 or 9 separately."

Records the interaction between baseline function and treatment arm.

Show evidence (8 references)

PMID:42304276 SUPPORT Human Clinical

"The pooled mean differences (MD) were 2.95 kg for handgrip strength, 0.15 m/s for gait speed, 0.25 kg/m² for ASMI, and -1.79 s for the five-times sit-to-stand test (all P<0.0001)."

Quantifies the pooled effect of resistance exercise across all four outcome domains.

PMID:41566419 SUPPORT Human Clinical

"Clinicians and exercise practitioners should tailor intensity (60-80% 1RM), frequency, and progression to optimize adherence, effectiveness, and long-term functional outcomes in sarcopenia management."

Source for the 60-80% 1RM intensity range, from 25 RCTs in sarcopenic older adults.

PMID:2342214 SUPPORT Human Clinical

"We conclude that high-resistance weight training leads to significant gains in muscle strength, size, and functional mobility among frail residents of nursing homes up to 96 years of age."

Shows the intervention remains effective in the oldest and frailest stratum.

+ 5 more references

Dietary Protein and Leucine Supplementation

Action: dietary intervention Ontology label: Dietary Intervention NCIT:C15447

Platform: Behavioral / lifestyle

Increased daily protein intake (roughly 1.0-1.2 g/kg/day, higher with inflammatory disease) using high-quality leucine-rich protein, aimed at overcoming the raised anabolic threshold of ageing muscle. Most effective combined with resistance training rather than alone.

Mechanism Target:

Anabolic Resistance — Supplies substrate above the raised anabolic threshold.

Show evidence (1 reference)

PMID:40678078 SUPPORT INDIRECT Other

"Compounding this is anabolic resistance, a hallmark of aging muscle, in which higher levels of dietary protein and amino acids are required to stimulate muscle protein synthesis effectively."

Gives the rationale for raising protein intake; it states the requirement rather than reporting a supplementation trial outcome, hence INDIRECT.

Vitamin D Repletion

Action: Pharmacotherapy NCIT:C15986

Agent: cholecalciferol (vitamin D3) CHEBI:28940

Platform: Small molecule

Correction of vitamin D deficiency, recommended where a deficit is documented rather than as universal supplementation. Vitamin D status is one of the traits positively associated with the protective allele set in sarcopenia GWAS, and repletion is a standard adjunct alongside resistance training and protein intake.

Show evidence (1 reference)

PMID:36771461 SUPPORT INDIRECT Human Clinical

"whereas protective alleles were positively associated with bone mineral density, serum testosterone, IGF1, and 25-hydroxyvitamin D levels, height, intelligence, cognitive performance, educational attainment, income, physical activity, ground coffee drinking"

Genetically protective alleles track higher 25-hydroxyvitamin D, which supports vitamin D status as relevant to sarcopenia risk. INDIRECT: this is a genetic association, not a supplementation trial.

Bimagrumab (Anti-Activin Type II Receptor Antibody)

Action: Pharmacotherapy NCIT:C15986

Agent: bimagrumab NCIT:C116852

Platform: Monoclonal antibody

Investigational human monoclonal antibody blocking the type II activin receptors, preventing myostatin and related ligands from restraining muscle growth. In a phase-1 study of 24 healthy older and obese volunteers it increased thigh muscle volume and lean body mass while reducing fat mass, although appendicular lean mass did not reach significance. Critically, the same study detected no accompanying change in muscle strength — the mass-versus-function dissociation that has recurred across the myostatin-pathway programme and is the main reason no drug is yet approved for sarcopenia.

Mechanism Target:

Myostatin and Activin Receptor Signalling — Blocks the receptor through which myostatin and activins restrain muscle growth.

Show evidence (7 references)

PMID:33264516 SUPPORT Human Clinical

"A single dose of bimagrumab rapidly increased TMV and LBM and decreased body adiposity in older adults."

Supports the muscle mass and body composition effect in the target population.

PMID:33264516 REFUTE Human Clinical

"No change in muscle strength was detected in either bimagrumab group over the study period"

Refutes the claim that the added mass translates into strength. Recorded as a separate REFUTE item rather than folded into the SUPPORT item above, because the same study cuts both ways on different parts of the claim.

PMID:33264516 SUPPORT Human Clinical

"Bimagrumab was safe and well tolerated and demonstrated similar PK in older and obese adults."

Supports the tolerability statement for this investigational agent.

+ 4 more references

RANK-Ligand Inhibition (Denosumab)

Action: Pharmacotherapy NCIT:C15986

Agent: denosumab NCIT:C61313

Platform: Monoclonal antibody

Investigational repurposing of the anti-osteoporotic RANKL-inhibiting antibody denosumab for sarcopenia with underlying osteoporosis (osteosarcopenia). RANKL inhibition reduced muscle atrophy in earlier work, making it a candidate target. Under active randomised trial; no efficacy result in sarcopenia is available yet.

Show evidence (1 reference)

PMID:40760465 SUPPORT INDIRECT Other

"Previous studies showed that nuclear factor-κB ligand (RANKL) inhibition could reduce muscle atrophy and could be a therapeutic target for treating sarcopenia."

States the rationale for the target. Graded OTHER because the citation is a trial protocol reporting no results, and INDIRECT because the muscle effect is carried from prior studies rather than measured here.

ClC-1 Chloride Channel Inhibition

Action: Pharmacotherapy NCIT:C15986

Platform: Small molecule

Preclinical strategy that raises muscle fiber excitability by lowering the resting chloride conductance, compensating for the reduced postsynaptic NaV1.4 density rather than trying to restore it. In old rodents it improved neuromuscular transmission and muscle function. Distinctive because it targets the excitability lesion rather than muscle mass, and so predicts functional gain without mass gain — the converse of the myostatin-pathway drugs. No human data yet.

Mechanism Target:

Neuromuscular Junction Transmission Failure — Restores the safety factor for neuromuscular transmission.

Show evidence (2 references)

PMID:42424105 SUPPORT Model Organism

"ClC-1 chloride ion channel inhibition enhanced muscle excitability and improved NMJ transmission and muscle function in old rodents."

The preclinical result this treatment entry is based on.

PMID:42424105 SUPPORT Model Organism

"Together, these findings demonstrate that NMJ transmission deficits are a key, reversible driver of sarcopenia and reveal a novel therapeutic target for addressing muscle weakness in aging."

States the therapeutic-target claim underlying this entry.

Urolithin A (Mitophagy Activator)

Action: Nutritional Supplementation NCIT:C15425

Agent: urolithin A CHEBI:168442

Platform: Small molecule

Oral supplementation with urolithin A, a gut-microbial metabolite of dietary ellagitannins that activates mitophagy. It is one of the few agents in the sarcopenia pipeline with completed randomised trials in older adults, and the trials are instructive in opposite directions: a 4-month trial in middle-aged adults improved muscle strength but missed its primary endpoint of peak power output, and a 4-month trial in adults aged 65-90 improved muscle endurance but not its co-primary endpoints of 6-minute walk distance and maximal ATP production. Because it is produced from food polyphenols only by some gut microbiota, endogenous exposure varies widely between individuals.

Mechanism Target:

Mitochondrial Dysfunction and Oxidative Stress — Activates mitophagy, clearing damaged mitochondria that ageing muscle fails to turn over.

Show evidence (5 references)

PMID:35584623 SUPPORT Human Clinical

"The data show significant improvements in muscle strength"

The strength result from the randomised middle-aged cohort.

PMID:35584623 REFUTE Human Clinical

"do not notice a significant improvement on peak power output (primary endpoint)"

Refutes the broader claim that urolithin A improves muscle function as prespecified. Recorded separately from the SUPPORT item because the same trial cuts both ways: the secondary strength measure moved and the primary endpoint did not.

PMID:35050355 SUPPORT Human Clinical

"Urolithin A, compared with placebo, significantly improved muscle endurance"

The endurance result in the 65-90 year old cohort, the age range that matters for sarcopenia.

+ 2 more references

Trigonelline (NAD+ Precursor)

Action: Nutritional Supplementation NCIT:C15425

Agent: trigonelline CHEBI:18123

Platform: Small molecule

Naturally occurring alkaloid of coffee beans and fenugreek, also produced by the human gut microbiome, that enters the NAD+ pool through the Preiss-Handler pathway rather than through GPR109A. Serum trigonelline is lower in people with sarcopenia and tracks muscle strength, and dietary supplementation improves strength and fatigue resistance in ageing mice. No human interventional trial has been reported.

Mechanism Target:

Mitochondrial Dysfunction and Oxidative Stress — Raises the muscle NAD+ pool that declines with age, restoring mitochondrial respiration and biogenesis.

Show evidence (2 references)

PMID:38504132 SUPPORT INDIRECT Human Clinical

"In humans, serum trigonelline levels are reduced with sarcopenia and correlate positively with muscle strength and mitochondrial oxidative phosphorylation in skeletal muscle."

The human arm is observational: it establishes that trigonelline status tracks sarcopenia and strength, from which a therapeutic effect only follows by inference, hence INDIRECT.

PMID:38504132 SUPPORT Model Organism

"Dietary trigonelline supplementation in male mice enhances muscle strength and prevents fatigue during ageing."

The interventional result, which is rodent-only and male-only.

Nicotinamide Riboside (NAD+ Precursor)

Action: Nutritional Supplementation NCIT:C15425

Agent: nicotinamide riboside CHEBI:15927

Platform: Small molecule

Vitamin B3 form used as an oral NAD+ precursor. Chronic supplementation raises NAD+ in middle-aged and older adults and is well tolerated, so target engagement in humans is established; muscle benefit is not. Recorded here because that dissociation - a boosted NAD+ pool without a demonstrated strength gain - is the empirical constraint on the whole NAD+-repletion strategy in this disease.

Mechanism Target:

Mitochondrial Dysfunction and Oxidative Stress — Supplies precursor to the age-depleted muscle NAD+ pool.

Show evidence (1 reference)

PMID:29599478 SUPPORT INDIRECT Human Clinical

"chronic supplementation with the NAD+ precursor vitamin, nicotinamide riboside (NR), is well tolerated and effectively stimulates NAD+ metabolism in healthy middle-aged and older adults"

Establishes tolerability and target engagement in the relevant age group. INDIRECT for the treatment claim: the trial measured NAD+ metabolism, not muscle strength or mass.

Oleuropein (Mitochondrial Calcium Uniporter Activator)

Action: Nutritional Supplementation NCIT:C15425

Agent: oleuropein CHEBI:7747

Platform: Small molecule

Olive-derived polyphenol identified in a 5,000-molecule screen as a specific activator of the mitochondrial calcium uniporter, acting through MICU1 binding. It addresses a distinct mitochondrial lesion from the NAD+ agents: the regulator MCUR1 is downregulated in ageing human muscle and in sarcopenia, which limits the mitochondrial calcium uptake that is rate-limiting for mitochondrial activation during contraction. Preclinical only for muscle ageing.

Mechanism Target:

Mitochondrial Dysfunction and Oxidative Stress — Restores mitochondrial calcium uptake, the rate-limiting step for mitochondrial activation during contraction.

Show evidence (2 references)

PMID:39603237 SUPPORT Human Clinical

"we discovered a conserved downregulation of mitochondrial calcium uniporter regulator 1 (MCUR1) during skeletal muscle aging that associates with human sarcopenia and impairs mtCa2+ uptake and mitochondrial respiration"

Establishes the target lesion in human sarcopenic muscle, from profiling of human muscle biopsies, which is what makes this compound relevant to this disease rather than to muscle performance generally.

PMID:39603237 SUPPORT Model Organism

"Oleuropein activates mtCa2+ uptake and energy metabolism to enhance endurance and reduce fatigue in young and aged mice but not in muscle-specific MCU knockout (KO) mice."

The interventional result plus its genetic control: the absence of effect in MCU knockouts is what establishes that the benefit runs through the named target rather than through general polyphenol antioxidant activity.

Partial mTORC1 Inhibition (Rapamycin and Rapalogs)

Action: Pharmacotherapy NCIT:C15986

Agent: sirolimus (rapamycin) CHEBI:9168 everolimus (RAD001) NCIT:C48387

Platform: Small molecule

Counterintuitive strategy that treats sarcopenia by inhibiting, not stimulating, the canonical pro-growth kinase. Its premise is an empirical finding rather than a theoretical argument: mTORC1 is hyperactivated in sarcopenic muscle, and the chronic activation holds autophagy suppressed. Low doses of a rapalog in aged rats increased muscle mass and fiber cross-sectional area and reduced the transcriptional signature of neuromuscular junction denervation, so the effect reaches the neuromuscular arm and not only the myofibre. The dose is what separates this from immunosuppression; the immunosuppressive doses used in transplantation are not the regimen proposed here.

Mechanism Target:

Ubiquitin-Proteasome Myofibrillar Proteolysis — Restores autophagic flux that chronic mTORC1 activation suppresses, relieving the proteostatic burden on the myofiber.

Alpha Motor Neuron Loss and Muscle Fiber Denervation — Reduces expression of denervation-associated genes in aged muscle.

Type II Myofiber Atrophy and Fiber-Type Shift — Increases fiber cross-sectional area in aged muscle.

Show evidence (4 references)

PMID:31308131 SUPPORT Model Organism

"We found mTORC1 (mammalian target of rapamycin complex 1), a well-established positive modulator of muscle mass, to be surprisingly hyperactivated in sarcopenic muscle."

The observation that licenses inhibiting a growth kinase to treat a wasting disease.

PMID:31308131 SUPPORT Model Organism

"partial inhibition of the mTORC1 pathway counteracted sarcopenia, as determined by observing an increase in muscle mass and fiber type cross-sectional area in select muscle groups"

The mass result, with the qualification the authors themselves attach to it: select muscle groups, not all.

PMID:31308131 SUPPORT Model Organism

"gene expression indicators of neuromuscular junction denervation were diminished using a low dose of a"

Supports the denervation-arm target mechanism, and the low-dose qualifier this treatment turns on.

+ 1 more reference

15-PGDH Inhibition (Gerozyme Inhibition; MF-300)

Action: Pharmacotherapy NCIT:C15986

Platform: Small molecule

Small-molecule inhibition of 15-hydroxyprostaglandin dehydrogenase, the enzyme that degrades prostaglandin E2 and whose activity rises with age. Inhibiting the degradation rather than administering PGE2 restores PGE2 to the concentration found in young muscle, which is why the approach avoids the hypotension that exogenous PGE2 risks. It is the most pleiotropic agent in this entry and the one whose profile best matches the multifactorial aetiology: in aged mice a single target reaches the mitochondrial, proteostatic, satellite-cell and neuromuscular arms at once, and it increases specific force rather than mass alone. An orally available inhibitor (MF-300) has completed phase I.

Mechanism Target:

Muscle Satellite Cell Exhaustion — Restored PGE2 signalling increases muscle stem cell function and regenerative capacity.

Alpha Motor Neuron Loss and Muscle Fiber Denervation — Increases motor neuron viability and promotes motor axon regeneration in chronically denervated aged muscle.

Neuromuscular Junction Transmission Failure — Restores neuromuscular synapses after acute and chronic denervation.

Ubiquitin-Proteasome Myofibrillar Proteolysis — Decreases ubiquitin-proteasome pathway activity and TGF-beta signalling while restoring autophagy.

Mitochondrial Dysfunction and Oxidative Stress — Augments mitochondrial function and biogenesis in aged myofibers.

Loss of Skeletal Muscle Mass, Strength and Quality — Increases aged muscle mass, strength and exercise performance together.

Show evidence (5 references)

PMID:33303683 SUPPORT Model Organism

"We identifed increased amounts of 15-hydroxyprostaglandin dehydrogenase (15-PGDH), the prostaglandin E2 (PGE2)-degrading enzyme, as a hallmark of aged tissues, including skeletal muscle."

Establishes the target's age-dependence, which is what makes it a gerozyme rather than a general muscle target. Quoted verbatim including the source's "identifed" typo.

PMID:33303683 SUPPORT Model Organism

"Inhibition of 15-PGDH, by targeted genetic depletion or a small-molecule inhibitor, increased aged muscle mass, strength, and exercise performance."

The efficacy result, with genetic and pharmacological arms agreeing, which is what distinguishes on-target effect from compound effect.

PMID:33303683 SUPPORT Model Organism

"which augmented mitochondrial function and autophagy and decreased transforming growth factor"

Names the downstream arms this treatment's mitochondrial and proteolytic target mechanisms encode.

+ 2 more references

Myostatin Ligand Neutralization (Landogrozumab, Trevogrumab)

Action: Pharmacotherapy NCIT:C15986

Agent: landogrozumab (LY2495655) NCIT:C99640 trevogrumab (REGN1033) NCIT:C152733

Platform: Monoclonal antibody

Monoclonal antibodies that bind and neutralize myostatin itself, rather than the receptor bimagrumab blocks. In aged mice the approach raises muscle mass, strength and treadmill performance together. In the one phase 2 trial in the relevant population - adults 75 and over with recent falls and low strength and power - landogrozumab (LY2495655) met its primary endpoint of appendicular lean mass by 0.43 kg against placebo, and moved some but not all physical performance measures. Injection site reactions were markedly more common than with placebo.

Mechanism Target:

Myostatin and Activin Receptor Signalling — Neutralizes the ligand rather than the receptor, removing myostatin's restraint on muscle growth.

Show evidence (3 references)

PMID:26516121 SUPPORT Human Clinical

"Our findings show LY treatment increases lean mass and might improve functional measures of muscle power."

The trial's own conclusion. Note the authors' hedge on function ("might") against the unhedged claim on mass, which is the pattern this entry records across the whole myostatin-pathway programme.

PMID:26516121 REFUTE Human Clinical

"No effect was detected for other performance-based measures."

Refutes a general functional-improvement claim: some performance measures moved and others did not. Recorded separately from the SUPPORT item because the trial supports the mass claim and undercuts the broader function claim.

PMID:26457176 SUPPORT Model Organism

"In aged mice, REGN1033 increased muscle mass and strength and improved physical performance during treadmill exercise."

The preclinical aged-animal result for trevogrumab. Worth reading beside the human trial above: in mice mass and strength move together, in older adults they come apart, and that species gap is the central translational problem for this drug class.

Selective Androgen Receptor Modulation (Enobosarm, MK-0773)

Action: Pharmacotherapy NCIT:C15986

Agent: enobosarm NCIT:C69161 selective androgen receptor modulator NCIT:C147920

Platform: Small molecule

Non-steroidal androgen receptor ligands designed to be anabolic in muscle and bone while sparing prostate and hair-growth tissue, avoiding the supraphysiological testosterone doses that anabolic effect otherwise requires. Two phase II trials in the right population reached opposite conclusions about function: enobosarm improved both lean body mass and physical function in healthy elderly men and postmenopausal women over 12 weeks, whereas MK-0773 raised lean mass in sarcopenic frail elderly women over 6 months without any strength or function gain over placebo.

Mechanism Target:

Declining Anabolic Hormone Signalling — Substitutes for the age-related fall in testosterone by stimulating the androgen receptor selectively in muscle.

Negative Net Muscle Protein Balance — Androgen receptor stimulation raises muscle protein synthesis.

Show evidence (4 references)

PMID:22031847 SUPPORT Human Clinical

"GTx-024 treatment resulted in dose-dependent increases in total lean body mass that were statistically significant"

The primary endpoint result for enobosarm.

PMID:22031847 SUPPORT Human Clinical

"There were also significant improvements in physical function"

The functional result, which is the unusual part: most agents in this class move mass without moving function. Note the trial enrolled healthy elderly volunteers, not people with diagnosed sarcopenia.

PMID:23732550 REFUTE Human Clinical

"The MK-0773-induced increase in LBM did not translate to improvement in strength or function vs. placebo."

Refutes the claim that a SARM-driven lean-mass gain produces functional benefit, in the population that matters - women with diagnosed sarcopenia. This is the trial that most directly contradicts the enobosarm functional result above, and both are recorded rather than one being preferred.

+ 1 more reference

JAK-STAT Inhibition (Tofacitinib)

Action: Pharmacotherapy NCIT:C15986

Agent: tofacitinib NCIT:C95800

Platform: Small molecule

Repurposing of an approved JAK inhibitor to treat weakness as a consequence of inflammatory signalling. In a randomised human study, 48 hours of tofacitinib before biopsy raised the maximum specific force of individual diaphragm myofibers by about 16% against placebo, with the same direction of effect in serratus anterior, alongside reduced muscle protein oxidation and reduced FoxO-ubiquitin-proteasome signalling. Distinctive in this entry because it changes contractile quality over two days, on a timescale that cannot involve hypertrophy.

Mechanism Target:

Chronic Low-Grade Inflammation — Blocks JAK-STAT transduction of the inflammatory signals that drive the atrogene programme.

Ubiquitin-Proteasome Myofibrillar Proteolysis — Suppresses FoxO-ubiquitin-proteasome signalling and muscle protein oxidation.

Loss of Skeletal Muscle Mass, Strength and Quality — Raises single-fiber specific force, that is, contractile quality rather than quantity.

Show evidence (2 references)

PMID:39122555 SUPPORT Human Clinical

"with a 15.7% greater mean maximum specific force (P = 0.0016)"

The effect size, from patients randomised to tofacitinib or placebo for 48 hours before biopsy. Graded HUMAN_CLINICAL because the randomisation and dosing were in people; the force measurement itself was made on biopsied single fibers.

PMID:39122555 SUPPORT Human Clinical

"The increased force was associated with reduced muscle protein oxidation and FoxO-ubiquitination-proteasome signaling, and increased levels of smooth muscle MYLK."

The mechanistic correlates behind the inflammation and proteolysis target mechanisms recorded here.

Apelin Receptor Agonism

Action: Pharmacotherapy NCIT:C15986

Platform: Peptide

Replacement of an exerkine rather than blockade of a pathological signal. Apelin is a peptide released by contracting muscle whose production falls with age in both humans and rodents; mice lacking apelin or its receptor develop marked age-dependent muscle dysfunction, and restoring apelin signalling in aged mice improves muscle function through mitochondrial biogenesis, autophagy and anti-inflammatory pathways in myofibers while also acting on muscle stem cells. It is one of the mechanisms through which the review's vascular axis reaches muscle, since apelin acts on the endothelial APJ receptor.

Mechanism Target:

Capillary Rarefaction and Impaired Muscle Perfusion — Acts on the endothelial APJ receptor, the angiocrine arm of this treatment's effect.

Mitochondrial Dysfunction and Oxidative Stress — Triggers mitochondrial biogenesis and autophagy in aged myofibers.

Muscle Satellite Cell Exhaustion — Enhances regenerative capacity by acting on muscle stem cells.

Chronic Low-Grade Inflammation — Engages anti-inflammatory pathways in myofibers.

Show evidence (2 references)

PMID:30061698 SUPPORT INDIRECT Human Clinical

"production of the endogenous peptide apelin, induced by muscle contraction, is reduced in an age-dependent manner in humans and rodents and is positively associated with the beneficial effects of exercise in older persons"

The human arm, which establishes the deficiency this treatment would correct. INDIRECT: an age-dependent decline and an association with exercise benefit, not a trial of apelin administration.

PMID:30061698 SUPPORT Model Organism

"this peptide considerably enhanced muscle function by triggering mitochondriogenesis, autophagy and anti-inflammatory pathways in myofibers as well as enhancing the regenerative capacity by targeting muscle stem cells"

The interventional rodent result, and the source of all four target mechanisms recorded above.

VEGF Signalling Restoration

Action: Pharmacotherapy NCIT:C15986

Platform: Other

Preclinical strategy addressing the vascular contribution to muscle ageing rather than muscle itself. Age raises production of the soluble VEGF decoy receptor sFlt-1, so VEGFA-driven capillary sprouting becomes insufficient; in mice, low-dose VEGFA overexpression counteracts this, prevents capillary loss, improves perfusion, and ameliorates sarcopenia among several other ageing pathologies while extending life span. No human muscle data.

Mechanism Target:

Capillary Rarefaction and Impaired Muscle Perfusion — Restores the VEGFA signalling that age-related sFlt-1 production renders insufficient.

Show evidence (2 references)

PMID:34326210 SUPPORT Model Organism

"Increasing VEGF signaling prevented age-associated capillary loss, improved organ perfusion and function, and extended life span."

The mechanism this treatment asserts, measured in aged mice.

PMID:34326210 SUPPORT Model Organism

"amelioration of aging-associated pathologies including hepatic steatosis, sarcopenia, osteoporosis"

Names sarcopenia specifically among the conditions improved, which is what makes this a candidate treatment for this entry rather than a general longevity result.

Nicotinamide plus Pyridoxine (Muscle Stem Cell Nutrition)

Action: Nutritional Supplementation NCIT:C15425

Agent: nicotinamide CHEBI:17154 pyridoxine (vitamin B6) CHEBI:16709

Platform: Small molecule

Combination of two vitamins identified in a high-content imaging screen of food-derived molecules against human myogenic progenitors, so the target here is the muscle stem cell rather than the myofiber. The two synergize through CK1-mediated cytoplasmic beta-catenin activation and AKT signalling. Both decline with age and their levels associate with muscle mass and walking speed in older people; oral treatment accelerated regeneration and overcame age-related regenerative failure in mice. Both have a long history of safe human use, which is the practical argument for this combination over a novel chemical entity.

Mechanism Target:

Muscle Satellite Cell Exhaustion — Stimulates muscle stem cell amplification and differentiation, overcoming the regenerative failure of ageing.

Show evidence (2 references)

PMID:39531334 SUPPORT Model Organism

"Oral treatment with a combination of NAM and PN accelerated muscle regeneration in vivo by stimulating MuSCs, increased muscle strength during recovery, and overcame MuSC dysfunction and regenerative failure during aging."

The interventional result, including the ageing arm that makes it relevant to this disease rather than to injury repair generally.

PMID:39531334 SUPPORT INDIRECT Human Clinical

"Levels of NAM and bioactive PN spontaneously declined during aging in model organisms and interindependently associated with muscle mass and walking speed in a cohort of 186 aged people."

The human observational arm establishing the deficiency. INDIRECT: an association in a cohort of 186, not a supplementation trial.

BIO101 (20-Hydroxyecdysone)

Action: Pharmacotherapy NCIT:C15986

Agent: 20-hydroxyecdysone CHEBI:16587

Platform: Small molecule

Pharmaceutical-grade plant ecdysteroid that activates the MAS receptor, the protective arm of the renin-angiotensin-aldosterone system, and thereby AKT/mTOR-driven protein synthesis. In 22-month-old mice a 14-week oral course produced anabolic effects with improved running capacity and velocity; in vitro it also drives myoblast differentiation, and both effects are abolished by the MAS antagonist A779, which is what pins the mechanism to that receptor.

Mechanism Target:

Anabolic Resistance — Raises AKT/mTOR-driven protein synthesis through MAS receptor activation.

Muscle Satellite Cell Exhaustion — Promotes myoblast differentiation and fusion.

Show evidence (1 reference)

PMID:38064183 SUPPORT Model Organism

"Chronic BIO101 oral treatment induced AKT/mTOR activation and anabolic effects accompanied with improved physical performances in adult and old animals"

The in vivo result in adult and 22-month-old mice, covering both the signalling and the performance claims.

Angiotensin II Type 1 Receptor Blockade (Losartan)

Action: Pharmacotherapy NCIT:C15986

Agent: losartan CHEBI:6541

Platform: Small molecule

Repurposing of a common antihypertensive, on the argument that AT1 receptor blockade lowers TGF-beta signalling and raises IGF1/AKT/mTOR signalling in muscle. In sarcopenic mice losartan reduced fibrosis after injury and protected against disuse atrophy during hindlimb immobilization - and notably, the protection against disuse ran through IGF1/AKT/mTOR rather than through the TGF-beta pathway the strategy was designed around. In older men the acute human study was essentially null: no effect on satellite cell number or myogenic pathways after a single bout of heavy resistance exercise, with greater suppression of myostatin mRNA as the one positive signal.

Mechanism Target:

Myosteatosis and Intramuscular Fibro-Adipogenic Infiltration — Reduces fibrotic remodelling after injury by blunting canonical and non-canonical TGF-beta signalling.

Anabolic Resistance — Raises IGF1/AKT/mTOR signalling, the route by which it protected against disuse atrophy.

Show evidence (3 references)

PMID:21562229 SUPPORT Model Organism

"We showed that immobilized mice treated with losartan were protected against loss of muscle mass."

The disuse-atrophy result in aged mice, which is the strongest preclinical claim for this repurposing.

PMID:29040223 REFUTE Human Clinical

"In general, there does not seem to be any effect of AT1R blocking on satellite cell number or myogenic pathways in elderly men in the days after one bout of heavy-resistance exercise."

Refutes translation of the rodent myogenic effect to older men, in the acute setting the trial tested. Recorded as REFUTE rather than omitted because it is the only human evidence for this strategy in this entry.

PMID:29040223 SUPPORT INDIRECT Human Clinical

"losartan intake resulted in a greater suppression of myostatin messenger RNA"

The one positive human signal, and the authors' own basis for suggesting long-term hypertrophic potential. INDIRECT: a transcript-level change, not a mass or strength outcome.

Muscle-Sparing Co-therapy During GLP1 Receptor Agonist Weight Loss

Action: Pharmacotherapy NCIT:C15986

Agent: bimagrumab NCIT:C116852 trevogrumab NCIT:C152733 garetosmab NCIT:C170022 semaglutide NCIT:C152328

Platform: Monoclonal antibody

A preventative rather than a treatment for established sarcopenia. GLP1 receptor agonists produce large weight loss of which a substantial fraction is lean mass, and after the drug is stopped fat returns and muscle does not - so widespread incretin use is creating a new, iatrogenic route into sarcopenia in older people. Two co-therapy strategies have preclinical support: blocking the activin type II receptors or their ligands GDF8 and activin A alongside the incretin, which preserves or increases lean mass in obese mice and non-human primates while improving fat loss; and inhibiting 15-PGDH, which restores post-injury myofiber growth and force in semaglutide-treated obese mice without compromising weight loss.

Mechanism Target:

Myostatin and Activin Receptor Signalling — ActRII or dual GDF8/activin A blockade removes the growth restraint that caloric deficit otherwise leaves unopposed.

Muscle Satellite Cell Exhaustion — The 15-PGDH arm restores muscle stem cell function and myofiber growth during incretin-induced weight loss.

Loss of Skeletal Muscle Mass, Strength and Quality — Preserves lean mass and contractile force during pharmacologically induced weight loss.

Show evidence (4 references)

PMID:38218536 SUPPORT Model Organism

"Combination treatment with bimagrumab and semaglutide led to superior fat mass loss while simultaneously preserving lean mass despite reduced food intake."

The receptor-blockade arm, in diet-induced obese mice.

PMID:40360507 SUPPORT Model Organism

"we report that dual blockade can also prevent muscle loss associated with glucagon-like peptide-1 receptor agonists - and even increase muscle mass - in both obese mice and non-human primates"

The ligand-blockade arm, extended to non-human primates, which is the closest preclinical evidence to the human trials now running.

PMID:42228536 SUPPORT Model Organism

"In a high fat diet-induced mouse model of obesity, semaglutide alone caused significant loss of muscle mass, while preserving contractile function."

Establishes the harm this co-therapy is meant to prevent, and states the nuance: the mass loss came without a contractile-function loss in this model, so the risk is to reserve rather than to immediate strength.

+ 1 more reference

🌍

Environmental Factors

3

Sedentary lifestyle and physical inactivity

Chronic low physical activity, prolonged bed rest, and immobilisation withdraw the mechanical loading that maintains muscle protein synthesis and motor unit function. This is the dominant modifiable driver of secondary sarcopenia and accelerates the primary form.

Show evidence (1 reference)

PMID:40678078 SUPPORT Other

"Physical inactivity and immobility, often secondary to chronic illness or frailty, further accelerate sarcopenia by promoting disuse atrophy."

States that inactivity and immobility accelerate sarcopenia via disuse atrophy.

Mechanism Target:

EXACERBATES Negative Net Muscle Protein Balance — Unloading removes the principal physiological stimulus to muscle protein synthesis, tipping the balance further toward degradation.

Show evidence (1 reference)

PMID:38046952 SUPPORT Other

"Historically, factors like age, physical activity, and prevailing diseases have swayed protein dynamics."

Names physical activity as one of the determinants of the muscle protein synthesis/degradation balance this edge targets.

Inadequate dietary protein intake

Insufficient dietary protein and essential amino acids — from the anorexia of ageing, malabsorption, or restrictive diets — deprives ageing muscle of the anabolic substrate it already needs in larger quantities because of anabolic resistance. The two act together: the same intake that sufficed in youth is subthreshold in an old muscle.

Show evidence (1 reference)

PMID:40678078 SUPPORT Other

"Nutritional factors are also pivotal: anorexia of aging and reduced dietary protein intake lead to suboptimal nutrient availability. Compounding this is anabolic resistance, a hallmark of aging muscle, in which higher levels of dietary protein and amino acids are required to stimulate muscle..."

Supports reduced dietary protein intake as a nutritional driver in sarcopenia.

Mechanism Target:

EXACERBATES Anabolic Resistance — Low protein intake interacts with the raised anabolic threshold of ageing muscle, so the same deficit costs more synthesis than it would in youth.

Show evidence (1 reference)

PMID:40678078 SUPPORT Other

"Compounding this is anabolic resistance, a hallmark of aging muscle, in which higher levels of dietary protein and amino acids are required to stimulate muscle protein synthesis effectively."

States the raised protein requirement that makes inadequate intake act on the anabolic-resistance node specifically.

Regular resistance exercise

ECTO names every class as "exposure to X", which is why the bound label reads awkwardly; the preferred_term carries the human-readable name. ECTO:6000040 (a child of ECTO:6000039 exposure to Physical Activity) replaces the broader ECTO:6000002 exposure to exercise.

Habitual progressive resistance training, alone or within a multicomponent programme, is the strongest protective exposure, acting on several arms of the mechanism. Mechanical loading drives mTORC1-dependent protein synthesis, though older muscle needs a higher intensity for the same response. Training raises motor unit discharge rate, which is a neural contribution to strength that does not depend on added mass. It also partially reverses the mitochondrial transcriptional signature of ageing. Modelled as a protective exposure here and as an intervention under treatments.

Show evidence (1 reference)

PMID:42304276 SUPPORT Human Clinical

"Resistance exercise exerts significant beneficial effects on handgrip strength, ASMI, gait speed, and physical performance, as assessed by the five-times sit-to-stand test, in older adults with sarcopenia."

Meta-analytic support that resistance exercise improves the defining domains of sarcopenia.

Mechanism Target:

PROTECTS_AGAINST Negative Net Muscle Protein Balance — Loading is sensed by the myofiber and converges on mTORC1, which raises muscle protein synthesis and moves net balance back toward neutral. The intermediate is the load-sensing step recorded on the Blunted Load-Induced mTORC1 Signalling node; its age-related blunting is why older muscle needs a higher training intensity.

Show evidence (3 references)

PMID:30335577 SUPPORT REVIEW SYNTHESIS Other

"A large body of work shows that a mammalian target of rapamycin complex 1 (mTORC1)-mediated increase of muscle protein synthesis is the key, but not sole, mechanism by which resistance exercise causes muscle hypertrophy."

Names mTORC1-driven protein synthesis as the main route by which loading shifts protein balance.

PMID:38046952 SUPPORT Other

"Resistance training or anabolic hormonal stimuli can enhance protein synthesis, resulting in an increase in skeletal muscle cell protein synthesis, leading to an increase in muscle fiber size, a process known as skeletal muscle hypertrophy"

States the mechanism by which resistance training acts on muscle protein balance, which is the edge asserted here.

PMID:19001042 SUPPORT Human Clinical

"The results suggest that in the post-absorptive state: (i) MPS is dose dependant on intensity rising to a plateau at 60-90% 1 RM; (ii) older men show anabolic resistance of signalling and MPS to resistance exercise."

Shows the protective effect is intensity-dependent and attenuated with age, which is the basis for prescribing 60-80% 1RM in older adults.

PROTECTS_AGAINST Mitochondrial Dysfunction and Oxidative Stress — Six months of resistance training shifts the ageing muscle transcriptome, which is dominated by mitochondrial genes, back toward the young profile. Endurance and combined training are the stronger stimulus for respirometric oxidative capacity, so a multicomponent programme serves this arm better than resistance training alone.

Show evidence (2 references)

PMID:17520024 SUPPORT Human Clinical

"However, following exercise training the transcriptional signature of aging was markedly reversed back to that of younger levels for most genes that were affected by both age and exercise."

Direct human evidence that resistance training reverses the mitochondria-enriched ageing signature in muscle.

PMID:25599385 SUPPORT Human Clinical

"ET and CT significantly increased oxidative capacity and expression of mitochondrial proteins and transcription factors."

Names endurance and combined training, not resistance training alone, as the arms that raised measured oxidative capacity; supports the qualification in this edge's description.

PROTECTS_AGAINST Failure of Compensatory Motor Unit Remodeling — Lifelong high-level exercise is associated with more reinnervation of aged muscle, the rescue process whose failure this node records. The evidence is cross-sectional and concerns lifelong exercise in general, not a resistance-training intervention.

Show evidence (1 reference)

PMID:35234025 SUPPORT INDIRECT REVIEW SYNTHESIS Human Clinical

"In this short review we discuss those results in the light of the most recent advances confirming the occurrence of exercise-mediated reinnervation, ultimately preserving muscle structure and function in elderly people who exercise."

Supports exercise-associated reinnervation in old muscle; INDIRECT because the underlying data are lifelong athletes rather than a resistance-training trial in sarcopenia.

PROTECTS_AGAINST Loss of Skeletal Muscle Mass, Strength and Quality — Part of the strength gain is neural. In older adults, four weeks of strength training raised motor unit discharge rate and persistent inward currents, and these changes tracked the gain in maximal force. This is a route to strength that runs alongside hypertrophy, consistent with strength improving out of proportion to mass.

Show evidence (2 references)

PMID:41823343 SUPPORT Human Clinical

"This pattern suggests that enhanced intrinsic excitability and synaptic input to motor neurons contributed to improvements in strength."

Supports a neural contribution to the strength gain in older adults.

PMID:41823343 SUPPORT Human Clinical

"These results demonstrate that, despite age-related motor unit remodelling, the ageing nervous system remains responsive to targeted strength training, preserving the capacity for meaningful neural adaptations."

Supports that the neural route is preserved with age, unlike the blunted protein-synthetic route.

🔬

Biochemical Markers

3

Interleukin-6

Pathograph Readouts

Readout Of Chronic Low-Grade Inflammation Positive Monitoring

Circulating IL-6 is the one marker of the three in this section with evidence that it discriminates in older adults: a meta-analysis of 8,154 patients against 33,967 controls found it elevated with a significant odds-ratio signal, and concluded it is usable as a peripheral inflammation marker where TNF and IL-1-beta are not. MONITORING rather than DIAGNOSTIC because that evidence is across age-related comorbidities generally, not a sarcopenia case-finding study; it tracks the inflammatory state this node represents, and no sarcopenia decision threshold exists for it.

Show evidence (2 references)

PMID:42511674 SUPPORT Other

"Chronic inflammation, mediated primarily through IL-6 and TNF-α, further accelerates muscle catabolism and regenerative failure"

Supports the mapping this link encodes - IL-6 measures the inflammatory mechanism, rather than muscle mass directly.

PMID:38495887 SUPPORT Human Clinical

"The potential diagnostic usefulness of IL-6 was confirmed by odds ratio (OR) analysis (OR: 1.03, 95% CI (1.01; 1.05), p=0.0029)."

The quantitative basis for recording an endpoint context at all. Note how small the odds ratio is: the signal is real and the effect is marginal, which is consistent with the field's position that no single biomarker is yet usable alone.

Show evidence (1 reference)

PMID:42511674 SUPPORT Other

"Chronic inflammation, mediated primarily through IL-6 and TNF-α, further accelerates muscle catabolism and regenerative failure, whereas senescence-associated pathways impair satellite cell function and muscle repair."

Identifies IL-6 as a principal mediator of the inflammatory arm.

Tumor necrosis factor alpha

Pathograph Readouts

Readout Of Chronic Low-Grade Inflammation Positive

TNF-alpha mediates the inflammatory mechanism, so the mechanistic link is sound, but its performance as a circulating marker is not. The same meta-analysis that validated IL-6 found no significant difference in TNF between older patients with comorbidities and controls. endpoint_context is therefore deliberately omitted: there is no established use context to record, and tagging this MONITORING alongside IL-6 would assert a measurability the evidence contradicts.

Show evidence (3 references)

PMID:42511674 SUPPORT Other

"Chronic inflammation, mediated primarily through IL-6 and TNF-α, further accelerates muscle catabolism and regenerative failure"

Supports the mechanistic half of this link - TNF-alpha is a mediator of the node it is mapped to.

PMID:38495887 REFUTE Human Clinical

"For TNF, however, the difference was statistically insignificant."

Refutes the measurement half: circulating TNF did not separate older patients from controls in a meta-analysis of over 42,000 subjects. Recorded as REFUTE on the readout link rather than on the biomarker entry, because what fails is the claim that this analyte reports the node, not the claim that TNF-alpha participates in it.

PMID:38495887 REFUTE Human Clinical

"IL-6, unlike TNF and IL-1β, could be a useful and convenient marker of peripheral inflammation in older adults with various comorbidities."

The authors' own conclusion, stated as a contrast that singles TNF out. Kept as a second REFUTE item because it generalizes the null above from one comparison to a usability verdict.

Show evidence (1 reference)

PMID:42511674 SUPPORT Other

"Among the candidate biomarkers, GDF-15, FGF-21, IL-6, TNF-α, CAF22, p16INK4a, p21/CDKN1A, IGF-1, and myostatin appear particularly promising for characterizing the biological heterogeneity of sarcopenia."

Lists TNF-alpha among the leading candidate biomarkers for sarcopenia.

Insulin-like growth factor 1

Pathograph Readouts

Readout Of Declining Anabolic Hormone Signalling Negative

Direction is NEGATIVE because the linked node is a decline: higher circulating IGF-1 tracks with less of it, not more. endpoint_context is omitted - the human evidence here is a genetic association in UK Biobank rather than a study of IGF-1 measurement in a clinical pathway, so no use context has been established.

Show evidence (2 references)

PMID:38046952 SUPPORT Other

"The IGF-1/PI3K/AKT pathway, by inhibiting FOXO, prevents the upregulation of Atrogin-1 and suppresses muscle atrophy"

Establishes that IGF-1 is the ligand of the signalling axis this node names, which is what makes measuring it a readout of the node rather than a correlate of it.

PMID:36771461 SUPPORT INDIRECT Human Clinical

"whereas protective alleles were positively associated with bone mineral density, serum testosterone, IGF1, and 25-hydroxyvitamin D levels"

Supports the NEGATIVE direction from the human side: alleles protective against sarcopenia track higher serum IGF-1. INDIRECT because this is a genetic association, not a measurement of IGF-1 against the mechanism.

Show evidence (1 reference)

PMID:42511674 SUPPORT Other

"Among the candidate biomarkers, GDF-15, FGF-21, IL-6, TNF-α, CAF22, p16INK4a, p21/CDKN1A, IGF-1, and myostatin appear particularly promising for characterizing the biological heterogeneity of sarcopenia."

Lists IGF-1 among the leading candidate biomarkers for sarcopenia.

🔬

Diagnosis

2

Dual-energy X-ray absorptiometry for appendicular lean mass

DXA-derived appendicular skeletal muscle mass indexed to height is the reference method for the muscle-quantity criterion. Office-based bioimpedance is the practical substitute; in a pilot comparison one consumer BIA scale captured every low-mass participant DXA identified.

dual-energy X-ray absorptiometry NCIT:C48789

Show evidence (2 references)

PMID:38045877 SUPPORT Human Clinical

"OMRON captured all low MM participants identified by DXA plus all on DXA diagnostic borderline."

Supports office bioimpedance as a usable substitute for DXA in identifying low muscle mass, with DXA as the stated gold standard.

PMID:38045877 SUPPORT Human Clinical

"Sarcopenia diagnostic criteria include muscle mass (MM) and function assessments. ... However, MM requires dual-energy X-ray absorptiometry (DXA) Body Composition (BC) or other costly tools, not readily available. ... This study’s objective was, therefore, to look at two types of practical,..."

Links sarcopenia muscle-quantity assessment to height-indexed appendicular muscle mass, DXA as the reference method and practical bioimpedance assessment. Ellipses mark omitted text in source order. The excerpt quotes the authors' all-participants conclusion; their discussion separately reports OMRON sensitivity of 93.3%, so that conclusion should not be read as a general sensitivity estimate.

SARC-F screening questionnaire

Five-item self-report screen recommended by EWGSOP2 for case-finding. The conventional cut-off of 4 or more is specific but insensitive; a cross-sectional primary-care study argues for lowering it to 2 or more.

Show evidence (2 references)

PMID:40711821 SUPPORT Human Clinical

"The recommended threshold of ≥4 has low sensitivity and high specificity in identifying probable sarcopenia."

Records the sensitivity limitation of the conventional SARC-F threshold.

PMID:40711821 SUPPORT Human Clinical

"A SARC-F cut point of ≥2 yielded an area under the curve of 0.77 (95% CI 0.67-0.88), with sensitivity of 0.78, specificity of 0.75, accuracy of 0.77, positive predictive value of 0.31, and negative predictive value of 0.96."

Gives the operating characteristics of the proposed lower threshold. Note the positive predictive value of 0.31, which is why SARC-F screens rather than diagnoses.

📈

Progression

2

Peak muscle mass and gradual decline

Age: 20-60 years

Muscle mass and strength peak in the third to fourth decade, plateau, then decline gradually from roughly age 40. Recorded from the deep-research report's synthesis; no single primary source for the trajectory was snippet-verified in this session, so no evidence item is attached.

Accelerated decline and clinical sarcopenia

Age: 60+ years

Decline accelerates after 60-70, when prevalence rises steeply and the diagnostic thresholds are crossed. Falls are the outcome most consistently attributable to sarcopenia in this phase.

Show evidence (2 references)

PMID:40898141 SUPPORT Human Clinical

"Sarcopenia significantly increased the risk of falls (adjusted HR: 2.38, 95% CI: 1.06-5.35, P = 0.036) but was not associated with hospital readmissions (adjusted HR: 0.87, 95% CI: 0.49-1.53, P = 0.630), fractures (adjusted HR: 1.01, 95% CI: 0.20-3.92, P = 0.992), or all-cause mortality..."

Quantifies the fall risk and, importantly, records the null results for fracture, readmission, and mortality in this cohort. Quoted in full rather than trimmed to the positive finding, because the consensus literature attributes all four outcomes to sarcopenia and this study supports only one of them.

PMID:40898141 SUPPORT Human Clinical

"Impaired gait speed was a strong predictor of increased fall risk (adjusted HR: 5.00, 95%CI: 1.27 ~ 19.90, P = 0.022)"

Supports the physical-performance domain as the component carrying the fall risk, consistent with EWGSOP2 using it to grade severity.

📊

Prevalence

2

Worldwide, community and clinical cohorts (mean age 68.5 years)

Point Prevalence 18500.0 per 100,000 (10000.0–27000.0) >1 in 1,000

Pooled across 151 studies (n = 692,056). The 10-27% band is criterion-dependent rather than a true range of biological risk; the midpoint is recorded as the normalized rate.

Show evidence (1 reference)

PMID:34816624 SUPPORT Human Clinical

"Using different classifications and cut-off points, the prevalence of sarcopenia varied between 10% and 27% in the studies included for meta-analysis."

Source of the pooled global prevalence band.

Worldwide, severe sarcopenia

Point Prevalence 5500.0 per 100,000 (2000.0–9000.0) >1 in 1,000

Severe sarcopenia (low strength plus low mass plus poor physical performance).

Show evidence (1 reference)

PMID:34816624 SUPPORT Human Clinical

"Finally, the prevalence of severe sarcopenia ranged from 2% to 9%."

Source of the severe-sarcopenia prevalence band.

🔀

Differential Diagnoses

3

Conditions with similar clinical presentations that must be differentiated from Sarcopenia:

Cachexia

Overlapping Features Distinguished by weight loss: cachexia requires at least 5% weight loss in 12 months or less plus additional criteria, and is typically a late-stage manifestation of chronic disease. Sarcopenia can occur at stable or even increased body weight (sarcopenic obesity).

Show evidence (1 reference)

PMID:38225199 SUPPORT Other

"Cachexia, a systemic wasting condition, is typically considered a late‐stage manifestation of chronic diseases, such as cancer, organ failure, or infections"

States the distinction between cachexia and sarcopenia used here.

Frailty

Overlapping Features A broader multisystem syndrome of reduced physiological reserve; sarcopenia is its principal muscular component but frailty additionally spans cognition, nutrition, and comorbidity.

Show evidence (1 reference)

PMID:27891296 SUPPORT Other

"Sarcopenia is the most important cause of frailty in older persons."

Establishes the part-whole relationship that distinguishes the two constructs.

Primary myopathy or muscular dystrophy

Overlapping Features Inherited or inflammatory muscle disease presenting with weakness and atrophy, but typically with a distinctive distribution, earlier onset, raised creatine kinase, or a causal genotype — none of which characterise sarcopenia. Note that some acquired neuromuscular conditions are formally included within secondary sarcopenia rather than excluded by it.

Show evidence (1 reference)

PMID:38225199 SUPPORT Other

"In contrast, secondary sarcopenia is associated with various diseases (Figure 1) (Bauer et al., 2019; Chen et al., 2020; Nishikawa et al., 2016), such as intensive care unit‐acquired weakness (ICU‐AW), amyotrophic lateral sclerosis (ALS), and muscular atrophy due to inadequate exercise and..."

Supports the caveat that neuromuscular disease can fall inside the secondary-sarcopenia category rather than being a clean exclusion.

📊

Related Datasets

5

Unraveling the Epigenetic Landscape of Sarcopenic Obesity: Insights into DNA Methylation Mechanisms from a Pilot Study in Older Women geo:GSE303899

DNA methylation profiling in sarcopenic obesity, the only human dataset among the candidates surfaced for this entry. Relevant to has_subtypes#Sarcopenic obesity and to the epigenetic component of the ageing muscle phenotype.

human METHYLATION n=32

PMID:41578880

Selected by manual relevance triage from `just discover-datasets Sarcopenia` and accession-verified with `just verify-datasets`. No evidence block: an evidence item needs an exact quote from the cited abstract supporting a specific claim, and this record asserts only that the dataset exists and is on topic.

Association between elevated expression of GDF15/GFRAL and sarcopenia risk geo:GSE316316

Single-cell RNA-seq addressing GDF-15/GFRAL signalling, one of the leading candidate circulating biomarkers of sarcopenia and a readout of the mitochondrial-stress arm modelled in pathophysiology#Mitochondrial Dysfunction and Oxidative Stress.

mouse SINGLE CELL RNA SEQ n=5

PMID:41797911

Mouse data; small n. Selected by manual relevance triage and accession-verified. No evidence block, as above.

IGF2 deficiency induces sarcopenia and muscle functional decline geo:GSE281658

Single-cell RNA-seq of an IGF2-deficiency model producing sarcopenia and functional decline, bearing on pathophysiology#Declining Anabolic Hormone Signalling.

mouse SINGLE CELL RNA SEQ n=6

Mouse data, no linked publication in the GEO record. Selected by manual relevance triage and accession-verified. No evidence block, as above.

TRalpha Deficiency Drives Sarcopenia by Disrupting Perimitochondrial Targeting of Pink1 mRNA and Mitophagy geo:GSE318551

Spatial transcriptomics linking thyroid hormone receptor alpha deficiency to sarcopenia through PINK1-dependent mitophagy, bearing directly on the defective-mitophagy component of pathophysiology#Mitochondrial Dysfunction and Oxidative Stress.

mouse SPATIAL TRANSCRIPTOMICS n=6

Mouse data, no linked publication in the GEO record. Selected by manual relevance triage and accession-verified. No evidence block, as above.

Chronic circadian misalignment accelerates sarcopenia progression in mice geo:GSE296198

Bulk RNA-seq testing circadian misalignment as an accelerant of sarcopenia progression; the largest of the candidate mouse datasets.

mouse BULK RNA SEQ n=30

PMID:41321491

Mouse data. Selected by manual relevance triage and accession-verified. Candidates rejected in triage: geo:GSE279051 (cortical bone metabolism, not muscle), geo:GSE276208 (sarcopenia as the exposure driving tumorigenesis, not the subject), and geo:GSE304351 / geo:GSE304464 / geo:GSE315575, which name sarcopenia only in the summary and study muscle atrophy or lifespan more broadly. No evidence block, as above.

🔬

Clinical Trials

7

NCT06643780 UNKNOWN

Randomized, double-blind, double-dummy, active-controlled trial of denosumab (RANKL inhibition) for sarcopenia in patients with underlying osteoporosis.

Show evidence (2 references)

PMID:40760465 SUPPORT Other

"This study aims to investigate the effects of denosumab to treat sarcopenia in patients with underlying osteoporosis."

States the trial's objective, from the published protocol.

clinicaltrials:NCT06643780 SUPPORT Other

"The objective of this study was to conduct a randomized, double-blind, double-dummy active controlled trial to determine the efficacy of denosumab in treating sarcopenia with underlying osteoporosis."

The ClinicalTrials.gov registration record establishing the trial's identity and design.

NCT02582138 NOT_APPLICABLE UNKNOWN

SPRINTT. Randomised multicomponent intervention (moderate-intensity physical activity with technology support plus nutritional counselling) against healthy-ageing education in 1,519 adults aged 70 or older with physical frailty and sarcopenia across 11 European countries. Primary outcome: mobility disability.

Show evidence (2 references)

clinicaltrials:NCT02582138 SUPPORT Other

"The SPRINTT study will evaluate the efficacy of a multicomponent intervention programme (physical activity, nutritional counselling/dietary intervention, and information and communications technology intervention) compared with a healthy aging lifestyle education programme on mobility..."

ClinicalTrials.gov registration record establishing the trial's identity and design.

PMID:35545258 SUPPORT Human Clinical

"Among participants with SPPB scores of 3-7, mobility disability occurred in 283/605 (46.8%) assigned to the multicomponent intervention and 316/600 (52.7%) controls (hazard ratio 0.78, 95% confidence interval 0.67 to 0.92; P=0.005)."

Primary result of the trial.

NCT04355299 NOT_APPLICABLE COMPLETED

Short-term mixed exercise programme for sarcopenia in hospitalised patients aged 80 and over. It targets the oldest and frailest stratum, which most exercise trials, run in relatively healthy community-dwelling adults, exclude.

Show evidence (1 reference)

clinicaltrials:NCT04355299 SUPPORT Other

"Therefore, the investigators aimed to assess the effectiveness of short-term exercise for treating sarcopenia in hospitalized older patients aged 80 years and over."

ClinicalTrials.gov registration record establishing the trial's objective and population.

NCT03752359 NOT_APPLICABLE COMPLETED

Whey protein versus placebo, each combined with 12 weeks of supervised resistance training, in older women with sarcopenic obesity.

Show evidence (2 references)

clinicaltrials:NCT03752359 SUPPORT Other

"The main purpose of the present study was to investigate the effects of whey protein following resistance training on body composition, muscular strength, functional capacity, and plasma-metabolism biomarkers in older women with sarcopenic obesity."

ClinicalTrials.gov registration record establishing the trial's identity.

PMID:31221297 SUPPORT Human Clinical

"Both groups demonstrated improved (P < 0.05) scores for muscular strength, waist-hip ratio, functional capacity, and other plasma-metabolism biomarkers without significant differences between conditions."

Resistance training improved strength and function in both arms; protein added lean tissue but not strength.

NCT01489930 NOT_APPLICABLE COMPLETED

Randomised comparison of 8 weeks of endurance, resistance, or combined training in young (18-30) and older (65 and over) adults, with muscle-protein synthesis and mitochondrial physiology as outcomes. It tests directly whether training adaptations depend on age.

Show evidence (2 references)

clinicaltrials:NCT01489930 SUPPORT Other

"to determine whether changes in protein synthesis in response to resistance exercise programs are dependent on age"

ClinicalTrials.gov registration record stating the age-dependence hypothesis.

PMID:25599385 SUPPORT Human Clinical

"Importantly, most of the adaptations to training occurred independent of age."

Published result of the trial.

NCT07513025 NOT_APPLICABLE RECRUITING

Twelve weeks of twice-weekly progressive elastic-band resistance training for older adults in rural long-term care facilities in Taiwan. It tests a low-equipment, low-staff delivery format.

Show evidence (1 reference)

clinicaltrials:NCT07513025 SUPPORT Other

"The goal of this clinical trial is to evaluate the effectiveness of progressive resistance training using elastic bands in treating and delaying the progression of sarcopenia among older adults in long-term care facilities."

ClinicalTrials.gov registration record establishing the trial's objective.

NCT07821164 NOT_APPLICABLE COMPLETED

Exercise snacks (short bouts spread through the day) versus home-based resistance training versus no exercise for 8 weeks in older adults with possible sarcopenia.

Show evidence (1 reference)

clinicaltrials:NCT07821164 SUPPORT Other

"Participants will be randomly assigned to an exercise snacks group, a home-based resistance training group, or a non-exercise control group."

ClinicalTrials.gov registration record establishing the trial's design.

🐁

Animal Models

3

Naturally aged C57BL/6 mouse (28 months)

Chronological-ageing model with a time course of phenotypic and transcriptomic measurements in gastrocnemius muscle, analysed alongside matched rat and human data. Its value is the cross-species comparison: it identifies which arms of human sarcopenia rodents actually reproduce.

Species

Mouse

Genotype

Wild-type C57BL/6, aged to 28 months

Publication

PMID:33580198

Pathograph links

Loss of Skeletal Muscle Mass, Strength and Quality recapitulates fidelity: moderate Aged mice lose muscle mass and grip strength together, reproducing the defining human combination rather than mass loss alone.

Limitations: Chronological age is a poor proxy for sarcopenia status even within the model; the authors argue muscle mass is the better indicator. Mouse lifespan compresses decades of human exposure, and laboratory mice lack the comorbidity burden that drives most human secondary sarcopenia.

Readouts

All-limb grip strength

Direction: DECREASED

Interpretation: Functional correlate of the strength domain of the human triad.

Show evidence (1 reference)

PMID:33580198 SUPPORT Model Organism

"All-limb grip strength decreased in parallel with muscle mass, reaching a 34.2 ± 3.4% loss in 28 months-old mice compared to 8–18 months-old mice"

Reports the measured grip-strength decrement in this model.

Show evidence (1 reference)

PMID:33580198 SUPPORT Model Organism

"Our study demonstrates that phenotypic measurements, such as muscle mass, are better indicators of muscle health than chronological age and should be considered when analyzing aging-related molecular data."

Attests what makes this model informative for the mass/strength node specifically: its muscle-phenotype measurements, rather than the animals' chronological age, are what track muscle health.

Mitochondrial Dysfunction and Oxidative Stress recapitulates fidelity: moderate Transcriptomic comparison shows the mitochondrial arm of human sarcopenia is reproduced in rodents.

Limitations: Inflammatory changes are conserved only at pathway level, not gene level, so this model is a poor vehicle for the inflammaging arm specifically.

Readouts

Muscle transcriptome mitochondrial gene signature

Direction: ALTERED

Interpretation: Cross-species conserved transcriptomic correlate of the mitochondrial node.

Show evidence (1 reference)

PMID:33580198 SUPPORT Model Organism

"We found that rodents recapitulate mitochondrial changes observed in human sarcopenia, while inflammatory responses are conserved at pathway but not gene level."

Establishes both the conserved mitochondrial signature and the limitation noted above.

Show evidence (1 reference)

PMID:33580198 SUPPORT Model Organism

"We found that rodents recapitulate mitochondrial changes observed in human sarcopenia, while inflammatory responses are conserved at pathway but not gene level."

States directly that the mitochondrial changes of human sarcopenia are reproduced in rodents, which is the claim this link makes; the same sentence carries the inflammatory-arm limitation recorded above.

Show evidence (1 reference)

PMID:33580198 SUPPORT Model Organism

"Here we generated a time series of phenotypic measurements and RNA sequencing data in mouse gastrocnemius muscle and analyzed them alongside analogous data from rats and humans."

Describes the model and the cross-species design that makes it informative for human sarcopenia.

Naturally occurring sarcopenia in aged companion dogs and cats

Spontaneous, naturally occurring age-related loss of lean body mass in pet dogs and cats. Its value is that it is not an induced model: the animals age in a shared human environment, over a lifespan long enough for the process to develop, and the veterinary literature separates it from disease-driven cachexia in the same species. That separation is the useful part — it is the same primary-versus-secondary distinction this entry draws, made independently in another species.

Species

Dog

Genotype

Outbred companion animals, no genetic modification

Publication

PMID:22111652

Pathograph links

Loss of Skeletal Muscle Mass, Strength and Quality partially recapitulates fidelity: low Reproduces age-related lean body mass loss arising without an underlying disease, in a long-lived outbred species sharing the human environment.

Limitations: The cited source is a veterinary review reporting lean body mass, not the strength and physical-performance measures that define human sarcopenia under EWGSOP2, so only the mass component of the target node is supported. No fibre-type, motor-unit, or neuromuscular-junction data are cited, and the review's principal subject is cachexia rather than sarcopenia. Graded LOW fidelity and PARTIALLY_RECAPITULATES for those reasons.

Show evidence (1 reference)

PMID:22111652 SUPPORT Model Organism

"Sarcopenia, the loss of LBM that occurs with aging, is a related syndrome, although sarcopenia occurs in the absence of disease."

Supports the link claim directly: what this model carries is age-related, disease-independent lean-mass loss, which is what makes it informative for the primary form of the target node rather than for secondary sarcopenia.

Recorded under `species: Dog` because the slot is single-valued; the cited source covers dogs and cats together and the claim is not dog-specific.

Show evidence (1 reference)

PMID:22111652 SUPPORT Model Organism

"As many of the diseases associated with muscle loss are more common in aging, cachexia and sarcopenia often are concurrent problems."

Establishes the model population and its principal confound: in aged companion animals the age-related and disease-driven forms co-occur, so individual animals are not cleanly one or the other. This is a different claim from the link-level evidence, which is about what the model is informative for.

Aged rat neuromuscular transmission model

Aged rats used to localise the sarcopenic transmission defect and to test both a sufficiency manipulation (acute NaV1.4 blockade in young adults) and a rescue (ClC-1 inhibition in old animals).

Species

Rat

Genotype

Wild-type, aged

Publication

PMID:42424105

Pathograph links

Neuromuscular Junction Transmission Failure recapitulates fidelity: high Reproduces the human finding of NMJ transmission failure and adds the electrophysiological localisation to post-synaptic fiber excitability that human studies could not provide.

Limitations: The human arm establishes correlation with weakness severity but not the rescue; the ClC-1 benefit is rodent-only, so translation of the therapeutic claim is untested.

Readouts

Neuromuscular junction transmission safety factor

Direction: RESTORED

Interpretation: ClC-1 inhibition reverses the transmission deficit, supporting the excitability mechanism rather than fiber loss as its cause.

Show evidence (1 reference)

PMID:42424105 SUPPORT Model Organism

"ClC-1 chloride ion channel inhibition enhanced muscle excitability and improved NMJ transmission and muscle function in old rodents."

The rescue result this readout records.

Show evidence (1 reference)

PMID:42424105 SUPPORT Model Organism

"Preclinical experiments showed similar NMJ transmission failure in aged rodents that was associated with localized loss of muscle fiber excitability at the NMJ."

Supports treating the aged rodent as informative for the human transmission node.

Show evidence (1 reference)

PMID:42424105 SUPPORT Model Organism

"Acute NaV1.4 inhibition with μ-conotoxin GIIIB in adult rats reproduced findings of NMJ transmission failure observed in aged rodents and humans."

Establishes the rat preparation as reproducing the human transmission phenotype under a defined manipulation.

🧮

Computational Models

1

Multiscale kinetic model of leucine-stimulated muscle protein metabolism MATLAB KINETIC

A mechanistic kinetic model linking leucine ingestion and absorption, insulin secretion, intracellular mTORC1-p70S6K signalling, and muscle protein synthesis and breakdown in human skeletal muscle. It was extended to represent anabolic resistance: the ageing-related impairments were parameterised individually and in combination, and a virtual population was classified as anabolic-sensitive or anabolic-resistant. The model was then used to simulate single-target and multi-target interventions.

Repository ↗ PMID:42464764

Pathograph links

Anabolic Resistance recapitulates fidelity: moderate observes: cellular Reproduces the reduced protein-synthetic response to feeding in older adults, and only when several impairments are combined.

Limitations: Calibrated against two small human feeding studies, developed from male data only, feeding-only, and focused on protein turnover rather than strength or function.

Divergences from the human mechanism

boundary omission qualifying

Mechanical loading and the exercise arm of anabolic resistance are outside the model boundary; only the leucine-feeding stimulus is represented.

population mismatch qualifying

Parameters come from studies in men. Sex differences in ageing-related protein metabolism are reported in some studies but not others, so the results may not transfer to older women, who are the majority of sarcopenia trial participants.

calibration provenance qualifying

The anabolic-resistant phenotype was evaluated against two small cohort studies, so the size of each simulated impairment is weakly constrained given how variable anabolic resistance is between individuals.

Show evidence (2 references)

PMID:42464764 SUPPORT Computational

"Virtual population simulations of MPS responses to amino acid feeding were classified as anabolic sensitive or anabolic resistant."

Establishes that the model represents the anabolic-resistant phenotype this node describes.

+ 1 more reference

Findings

No single age-related impairment reproduced the reduced protein synthesis of older adults; the anabolic-resistant phenotype appeared only when several impairments acted together.

Show evidence (1 reference)

PMID:42464764 SUPPORT Computational

"No single dysregulated mechanism reproduced age-related reductions in MPS."

States the single-mechanism negative result.

Restoring protein synthesis when all impairments were present required coordinated multi-target interventions; single targets proximal to mTORC1 were sufficient only against isolated impairments.

Show evidence (1 reference)

PMID:42464764 SUPPORT Computational

"Restoring MPS from multifactorial dysregulation required co-ordinated, multitarget therapeutic strategies."

States the intervention-simulation result.

The stimulus represented is protein feeding. Resistance exercise and mechanical loading are not in the model, so it says nothing directly about the Blunted Load-Induced mTORC1 Signalling node; the authors note that exercise enhances muscle sensitivity to protein feeding, which is the interaction a loading extension would need to capture.

Show evidence (1 reference)

PMID:42464764 SUPPORT Computational

"Here, we applied a mechanistic, multiscale kinetic model of leucine-mediated signalling and protein metabolism in human skeletal muscle to study anabolic resistance mechanisms."

Identifies the model type and scope.

{ }

Source YAML

click to show

name: Sarcopenia
creation_date: "2026-08-31T00:00:00Z"
category: Complex
parents:
- Musculoskeletal Disease
description: >-
  Sarcopenia is a progressive, generalised skeletal muscle disorder in which
  muscle strength, mass, and quality decline together, producing weakness, slow
  gait, falls, fractures, disability, and excess mortality. Contemporary
  consensus (EWGSOP2, AWGS 2019) treats it as a muscle disease — "muscle
  failure" — rather than an inevitable feature of ageing, and places low muscle
  strength, not low muscle mass, at the centre of the diagnosis. Primary
  (age-related) sarcopenia is diagnosed when ageing is the only apparent cause;
  secondary sarcopenia is driven by inactivity, undernutrition, or chronic
  disease (organ failure, malignancy, inflammatory disease), and is the more
  common form. Mechanistically the entry models a convergent chain in which
  motor neuron loss and neuromuscular junction transmission failure, mitochondrial
  dysfunction, inflammaging, satellite-cell exhaustion, anabolic resistance, and
  ubiquitin-proteasome proteolysis together tip muscle protein balance negative
  and preferentially destroy type II fibers.
synonyms:
- age-related muscle loss
- age-related sarcopenia
- primary sarcopenia
- muscle failure

notes: >-
  No MONDO term is bound. MONDO:0006516 ("sarcopenia") was obsoleted with the
  reason "out of scope - MONDO:excludeBiologicalProcess. This term represent a
  natural aging process, and not a disease.", so binding it would assert a
  retired class, and MONDO offers no replacement. The KB nonetheless treats
  sarcopenia as in scope: it carries its own billable ICD-10-CM code (M62.84,
  recorded under mappings), the EWGSOP2 consensus explicitly reclassifies it as
  a muscle disease rather than a normal ageing correlate, and it has a
  literature-grounded causal mechanism, which is the §1 scope test in
  docs/explanation/design-decisions.md. This is a live disagreement with MONDO,
  not an oversight — it is surfaced here rather than silently resolved, and is
  worth an upstream MONDO ticket, which has not been filed. See tracked_issues
  for what the MONDO tracker does and does not record here: the obsoletion came
  out of a bulk muscle-tissue-disorder branch review rather than an individually
  argued decision, and has not been challenged since.
  NCIT does code Sarcopenia (NCIT:C186726) and
  Acute Sarcopenia (NCIT:C189016), but both sit under NCIT:C3367 (Finding) and
  are not reachable from NCIT:C2991 (Disease or Disorder), so they fail the
  NCITDiseaseOrFindingTerm dynamic enum and are recorded here in prose rather
  than in mappings.ncit_mappings. No HPO term for sarcopenia as a whole exists
  either; the diagnostic triad is represented by component HP terms in
  phenotypes (HP:0003324, HP:0003199, HP:0001288).
  This entry follows Volumetric_Muscle_Loss in omitting disease_term rather than
  binding an inaccurate one.

mappings:
  icd10cm_mappings:
  - term:
      id: ICD10CM:M62.84
      label: Sarcopenia
    mapping_predicate: skos:exactMatch
    mapping_source: manual curation
    mapping_justification: >-
      ICD-10-CM M62.84 is the billable diagnosis code created for sarcopenia in
      2016; the obsoleted MONDO:0006516 also carried it as an exact match xref.
references:
- reference: PMID:30312372
  title: "Sarcopenia: revised European consensus on definition and diagnosis."
- reference: PMID:32033882
  title: "Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment."

has_subtypes:
- name: Primary
  display_name: Primary (age-related) sarcopenia
  description: >-
    Sarcopenia diagnosed when advancing age is the only apparent cause, with no
    identifiable contributing disease, immobilisation, or nutritional deficit.
  evidence:
  - reference: PMID:35053049
    reference_title: "Effect of Exercise on Secondary Sarcopenia: A Comprehensive Literature Review."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Sarcopenia is diagnosed as primary when there are no other specific causes."
    explanation: States the definitional criterion that separates primary from secondary sarcopenia.
- name: Secondary
  display_name: Secondary sarcopenia
  description: >-
    Sarcopenia attributable to an identifiable driver beyond ageing — disuse and
    immobilisation, inadequate energy or protein intake, or chronic disease such
    as organ failure, malignancy, or inflammatory disease. More common than the
    primary form.
  evidence:
  - reference: PMID:35053049
    reference_title: "Effect of Exercise on Secondary Sarcopenia: A Comprehensive Literature Review."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "However, secondary sarcopenia occurs if other factors, including malignancy or organ failure, are evident in addition to aging."
    explanation: Defines secondary sarcopenia by the presence of a driver additional to ageing.
  - reference: PMID:35053049
    reference_title: "Effect of Exercise on Secondary Sarcopenia: A Comprehensive Literature Review."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The prevalence of secondary sarcopenia is far greater than that of primary sarcopenia and requires special attention."
    explanation: Supports the claim that the secondary form is the more common one.
- name: T2DM-related
  display_name: Type 2 diabetes-related sarcopenia
  description: >-
    Muscle loss in type 2 diabetes, argued to be pathologically distinct from
    both primary sarcopenia and disuse atrophy. The distinguishing feature is a
    reduction in type I (slow oxidative) fibers, which inverts the type II
    preferential atrophy that characterises the primary form and is modelled in
    pathophysiology#Type II Myofiber Atrophy and Fiber-Type Shift. Insulin
    resistance, inflammation, and oxidative stress are the proposed drivers, and
    the mechanism is explicitly unresolved.
  review_notes: >-
    Recorded as a subtype rather than folded into Secondary because the fibre-type
    divergence is a mechanistic claim, not just an etiological label: the
    pathograph's type II atrophy node does not hold for it. No separate
    pathophysiology nodes are curated for this subtype, so the divergence is
    documented here rather than modelled; that is the honest state and a
    follow-up pass should either model it or demote this to a note under
    Secondary. Surfaced by the automated PR review on #10268.
  evidence:
  - reference: PMID:38854688
    reference_title: "Type 2 diabetes mellitus related sarcopenia: a type of muscle loss distinct from sarcopenia and disuse muscle atrophy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Unlike sarcopenia, T2DM-related sarcopenia is characterized by a reduction in type I fibers, and it differs from disuse muscle atrophy as well."
    explanation: >-
      States the fibre-type divergence that justifies separating this subtype,
      and that it is distinct from disuse atrophy as well as from primary
      sarcopenia.
  - reference: PMID:38854688
    reference_title: "Type 2 diabetes mellitus related sarcopenia: a type of muscle loss distinct from sarcopenia and disuse muscle atrophy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The mechanism involving insulin resistance, inflammatory status, and oxidative stress remains unclear."
    explanation: >-
      Records that the proposed drivers are named but the mechanism is
      unresolved, which is why no pathophysiology nodes are curated for it.
- name: Sarcopenic obesity
  display_name: Sarcopenic obesity
  description: >-
    Concurrent low muscle mass/strength and excess adiposity, in which
    adipose-derived inflammatory signalling and ectopic intramuscular lipid
    amplify anabolic resistance. Outcomes are worse than for either component
    alone.
  evidence:
  - reference: PMID:27891296
    reference_title: "Welcome to the ICD-10 code for sarcopenia."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "He also established that obese persons with sarcopenia had worse outcomes than non-obese persons with sarcopenia and obese persons with intact muscle mass."
    explanation: Establishes sarcopenic obesity as a distinct stratum with worse outcomes.

prevalence:
- population: Worldwide, community and clinical cohorts (mean age 68.5 years)
  measure_type: POINT_PREVALENCE
  prevalence_class: ABOVE_1_IN_1000
  rate_per_100000: 18500.0
  rate_low: 10000.0
  rate_high: 27000.0
  notes: >-
    Pooled across 151 studies (n = 692,056). The 10-27% band is criterion-dependent
    rather than a true range of biological risk; the midpoint is recorded as the
    normalized rate.
  evidence:
  - reference: PMID:34816624
    reference_title: "Global prevalence of sarcopenia and severe sarcopenia: a systematic review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Using different classifications and cut-off points, the prevalence of sarcopenia varied between 10% and 27% in the studies included for meta-analysis."
    explanation: Source of the pooled global prevalence band.
- population: Worldwide, severe sarcopenia
  measure_type: POINT_PREVALENCE
  prevalence_class: ABOVE_1_IN_1000
  rate_per_100000: 5500.0
  rate_low: 2000.0
  rate_high: 9000.0
  notes: Severe sarcopenia (low strength plus low mass plus poor physical performance).
  evidence:
  - reference: PMID:34816624
    reference_title: "Global prevalence of sarcopenia and severe sarcopenia: a systematic review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Finally, the prevalence of severe sarcopenia ranged from 2% to 9%."
    explanation: Source of the severe-sarcopenia prevalence band.

pathophysiology:
- name: Alpha Motor Neuron Loss and Muscle Fiber Denervation
  description: >-
    Progressive age-related attrition of spinal alpha motor neurons withdraws
    innervation from the muscle fibers of the lost motor units. Denervated fibers
    are either rescued by collateral sprouting from a surviving neighbouring
    motor neuron or are lost, so motor neuron number sets an upper bound on how
    much contractile tissue can be maintained. Fast-twitch (type II) fibers are
    preferentially affected.
  biological_scale: CELLULAR
  role: trigger
  cell_types:
  - preferred_term: alpha motor neuron
    term:
      id: CL:0008038
      label: alpha motor neuron
  - preferred_term: skeletal muscle fiber
    term:
      id: CL:0008002
      label: skeletal muscle fiber
  locations:
  - preferred_term: skeletal muscle tissue
    term:
      id: UBERON:0001134
      label: skeletal muscle tissue
  biological_processes:
  - preferred_term: response to denervation
    term:
      id: GO:0014894
      label: response to denervation involved in regulation of muscle adaptation
    modifier: INCREASED
  evidence:
  - reference: PMID:29527694
    reference_title: "Failure to expand the motor unit size to compensate for declining motor unit numbers distinguishes sarcopenic from non-sarcopenic older men."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The age-related loss of muscle mass is related to the loss of innervating motor neurons and denervation of muscle fibres."
    explanation: States motor neuron loss and denervation as the substrate of age-related muscle loss.
  - reference: PMID:29527694
    reference_title: "Failure to expand the motor unit size to compensate for declining motor unit numbers distinguishes sarcopenic from non-sarcopenic older men."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The motor unit numbers were reduced in all groups of old compared with young men"
    explanation: Reports the measured reduction in motor unit number with age in humans.
  - reference: PMID:40678078
    reference_title: "Molecular constraints of sarcopenia in the ageing muscle."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Neurodegeneration and age-related muscle fibers denervation further exacerbate muscle loss, particularly affecting fast-twitch fibers, and reduce motor unit integrity."
    explanation: Supports the preferential effect on fast-twitch fibers and on motor unit integrity.
  downstream:
  - target: Neuromuscular Junction Transmission Failure
    causal_link_type: DIRECT
    description: >-
      Withdrawal and remodelling of motor nerve terminals destabilises the
      junction before frank fiber loss.
  - target: Failure of Compensatory Motor Unit Remodeling
    causal_link_type: DIRECT
    description: >-
      Declining motor neuron number is the deficit that collateral reinnervation
      must compensate for.

- name: Neuromuscular Junction Transmission Failure
  description: >-
    Transmission across the neuromuscular junction fails intermittently in weak
    older people and in aged rodents, in proportion to the severity of weakness.
    The lesion is postsynaptic and electrical rather than cholinergic: the
    skeletal-muscle voltage-gated sodium channel NaV1.4 is locally depleted from
    the post-synaptic membrane, so the endplate potential less reliably reaches
    threshold for a propagated action potential. Pharmacological NaV1.4 blockade
    in young adult rats reproduces the phenotype, and lowering the competing
    chloride conductance by inhibiting ClC-1 restores it — making this a
    reversible driver of weakness rather than a downstream marker of fiber loss.
  biological_scale: CELLULAR
  role: driver
  cell_types:
  - preferred_term: skeletal muscle fiber
    term:
      id: CL:0008002
      label: skeletal muscle fiber
  cellular_components:
  - preferred_term: neuromuscular junction
    term:
      id: GO:0031594
      label: neuromuscular junction
  evidence:
  - reference: PMID:42424105
    reference_title: "Neuromuscular junction failure in sarcopenia is linked to NaV1.4 loss and reversed by ClC-1 inhibition."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Here, we demonstrate that weak older individuals exhibit NMJ transmission failure that correlates with muscle weakness severity."
    explanation: Establishes NMJ transmission failure in humans and its correlation with weakness severity.
  - reference: PMID:42424105
    reference_title: "Neuromuscular junction failure in sarcopenia is linked to NaV1.4 loss and reversed by ClC-1 inhibition."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Preclinical experiments showed similar NMJ transmission failure in aged rodents that was associated with localized loss of muscle fiber excitability at the NMJ."
    explanation: Localises the defect to muscle fiber excitability at the junction in aged rodents.
  - reference: PMID:38225199
    reference_title: "Unraveling the causes of sarcopenia: Roles of neuromuscular junction impairment and mitochondrial dysfunction."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "NMJ instability is considered to be an initiating and driving factor of the pathology of sarcopenia"
    explanation: Review support for placing NMJ instability upstream rather than as a consequence.
  downstream:
  - target: Type II Myofiber Atrophy and Fiber-Type Shift
    causal_link_type: DIRECT
  - target: Loss of Skeletal Muscle Mass, Strength and Quality
    causal_link_type: DIRECT
    description: >-
      Intermittent transmission failure reduces force output independently of how
      much contractile tissue remains, which is one reason strength falls faster
      than mass.
    evidence:
    - reference: PMID:42424105
      reference_title: "Neuromuscular junction failure in sarcopenia is linked to NaV1.4 loss and reversed by ClC-1 inhibition."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "ClC-1 chloride ion channel inhibition enhanced muscle excitability and improved NMJ transmission and muscle function in old rodents."
      explanation: >-
        Rescuing transmission improves muscle function in old animals, which
        supports the edge from transmission failure to functional loss rather
        than merely their co-occurrence.

- name: Postsynaptic NaV1.4 Depletion
  description: >-
    Immunohistochemistry across humans and rodents shows a localized reduction of
    the skeletal-muscle voltage-gated sodium channel NaV1.4 (SCN4A) at the
    post-synaptic membrane of the neuromuscular junction. Acute pharmacological
    inhibition of NaV1.4 in adult rats is sufficient to reproduce the aged
    transmission phenotype, establishing the channel loss as a cause of the
    excitability defect rather than a correlate.
  biological_scale: MOLECULAR
  molecular_functions:
  - preferred_term: voltage-gated sodium channel activity
    term:
      id: GO:0005248
      label: voltage-gated sodium channel activity
    modifier: DECREASED
  evidence:
  - reference: PMID:42424105
    reference_title: "Neuromuscular junction failure in sarcopenia is linked to NaV1.4 loss and reversed by ClC-1 inhibition."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Across species, immunohistochemistry identified a localized reduction in the voltage-gated sodium channel specific for skeletal muscle (NaV1.4) at the post-synaptic NMJ membrane."
    explanation: Reports the cross-species localisation of NaV1.4 loss to the postsynaptic membrane.
  downstream:
  - target: Neuromuscular Junction Transmission Failure
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:42424105
      reference_title: "Neuromuscular junction failure in sarcopenia is linked to NaV1.4 loss and reversed by ClC-1 inhibition."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Acute NaV1.4 inhibition with μ-conotoxin GIIIB in adult rats reproduced findings of NMJ transmission failure observed in aged rodents and humans."
      explanation: >-
        A sufficiency experiment: blocking the channel in young animals produces
        the transmission failure, which is evidence for this edge specifically.

- name: Failure of Compensatory Motor Unit Remodeling
  description: >-
    Healthy ageing muscle offsets motor neuron loss by collateral reinnervation,
    enlarging the surviving motor units — measurable as larger motor unit
    potentials. Sarcopenic muscle does not: motor unit potentials in sarcopenic
    older men resemble those of young men rather than those of healthy or
    pre-sarcopenic older men. The distinguishing lesion in sarcopenia is
    therefore not denervation itself, which is near-universal with age, but the
    failure of the rescue mechanism.
  biological_scale: TISSUE
  locations:
  - preferred_term: musculature of limb
    term:
      id: UBERON:0004480
      label: musculature of limb
  evidence:
  - reference: PMID:29527694
    reference_title: "Failure to expand the motor unit size to compensate for declining motor unit numbers distinguishes sarcopenic from non-sarcopenic older men."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These findings suggest that a failure to expand the motor unit size distinguishes sarcopenic from pre-sarcopenic muscles."
    explanation: States the study's central finding, which is the claim of this node.
  - reference: PMID:29527694
    reference_title: "Failure to expand the motor unit size to compensate for declining motor unit numbers distinguishes sarcopenic from non-sarcopenic older men."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Reinnervation of denervated muscle fibres probably expands the motor unit size in the non-sarcopenic and pre-sarcopenic old, but not in the sarcopenic old."
    explanation: Contrasts successful with failed reinnervation across the sarcopenia spectrum.
  downstream:
  - target: Type II Myofiber Atrophy and Fiber-Type Shift
    causal_link_type: DIRECT
    description: Fibers not rescued by reinnervation atrophy and are lost.

- name: Mitochondrial Dysfunction and Oxidative Stress
  description: >-
    Ageing myofibers accumulate mitochondrial damage with reduced biogenesis,
    impaired oxidative phosphorylation, defective mitophagy, and excess reactive
    oxygen species. Because mitochondria are enriched on both sides of the
    neuromuscular junction and support its transmission, this deficit both
    destabilises the junction and lowers the ATP available for contraction and
    for protein synthesis, placing it upstream of several other arms of the chain.
  biological_scale: CELLULAR
  conforms_to: "mitochondrial_dysfunction#Bioenergetic Decline and Oxidative Stress"
  role: driver
  cell_types:
  - preferred_term: skeletal muscle fiber
    term:
      id: CL:0008002
      label: skeletal muscle fiber
  cellular_components:
  - preferred_term: mitochondrion
    term:
      id: GO:0005739
      label: mitochondrion
  biological_processes:
  - preferred_term: cellular respiration
    term:
      id: GO:0045333
      label: cellular respiration
    modifier: DECREASED
  evidence:
  - reference: PMID:42511674
    reference_title: "Biomarkers and Early Mechanisms of Sarcopenia: Central Roles of Mitochondrial Dysfunction, Inflammaging, Cellular Senescence, and Neuromuscular Degeneration."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Mitochondrial dysfunction appears to represent an early upstream event that promotes excessive reactive oxygen species production, defective mitophagy, inflammatory activation, and cellular senescence."
    explanation: Supports placing mitochondrial dysfunction upstream of inflammation and senescence in this chain.
  - reference: PMID:33580198
    reference_title: "Molecular and phenotypic analysis of rodent models reveals conserved and species-specific modulators of human sarcopenia."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "We found that rodents recapitulate mitochondrial changes observed in human sarcopenia, while inflammatory responses are conserved at pathway but not gene level."
    explanation: Cross-species transcriptomic support that mitochondrial change is a conserved feature of sarcopenic muscle.
  downstream:
  - target: Neuromuscular Junction Transmission Failure
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:38225199
      reference_title: "Unraveling the causes of sarcopenia: Roles of neuromuscular junction impairment and mitochondrial dysfunction."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Mitochondrial dysfunction is increasingly recognized as a critical contributor to NMJ instability, which leads to skeletal muscle atrophy"
      explanation: Asserts the mitochondria-to-NMJ causal direction that this edge encodes.
  - target: Chronic Low-Grade Inflammation
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: Muscle Satellite Cell Exhaustion
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES

- name: Chronic Low-Grade Inflammation
  description: >-
    Persistent sterile elevation of circulating IL-6 and TNF-alpha ("inflammaging")
    activates NF-kappaB signalling in myofibers, which drives the atrogene program
    and suppresses myogenic differentiation. It is a systemic input to muscle
    rather than a muscle-intrinsic lesion, which is why it links sarcopenia to the
    wider multimorbidity of ageing.
  biological_scale: ORGANISM
  conforms_to: "inflammaging#Chronic Low-Grade Sterile Inflammation"
  role: amplifier
  biological_processes:
  - preferred_term: positive regulation of NF-kappaB signalling
    term:
      id: GO:0043123
      label: positive regulation of canonical NF-kappaB signal transduction
    modifier: INCREASED
  evidence:
  - reference: PMID:42511674
    reference_title: "Biomarkers and Early Mechanisms of Sarcopenia: Central Roles of Mitochondrial Dysfunction, Inflammaging, Cellular Senescence, and Neuromuscular Degeneration."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Chronic inflammation, mediated primarily through IL-6 and TNF-α, further accelerates muscle catabolism and regenerative failure, whereas senescence-associated pathways impair satellite cell function and muscle repair."
    explanation: Names the mediators and the two consequences this node routes to downstream.
  - reference: PMID:38046952
    reference_title: "Ubiquitin-proteasome pathway in skeletal muscle atrophy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Various studies suggest that the gene expression of Atrogin-1 and MuRF1 is differentially regulated by FOXO and NF-κB pathways"
    explanation: >-
      Substantiates the NF-kappaB half of this node's claim and its GO
      annotation: NF-kappaB is one of the two pathways regulating the atrogene
      program, which the mediator snippet above does not itself state.
  downstream:
  - target: Ubiquitin-Proteasome Myofibrillar Proteolysis
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: Muscle Satellite Cell Exhaustion
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES

- name: Muscle Satellite Cell Exhaustion
  description: >-
    Skeletal muscle satellite cells — the resident stem cells that repair and
    regenerate myofibers — decline in number and in proliferative and
    differentiative capacity with age, in a niche degraded by chronic inflammation,
    mitochondrial dysfunction, and accumulating senescent cells. Regenerative
    failure converts what would be recoverable injury into permanent fiber loss.
  biological_scale: CELLULAR
  conforms_to: "stem_cell_exhaustion#Decline in Stem Cell Self-Renewal and Function"
  cell_types:
  - preferred_term: skeletal muscle satellite cell
    term:
      id: CL:0000594
      label: skeletal muscle satellite cell
  biological_processes:
  - preferred_term: skeletal muscle satellite cell proliferation
    term:
      id: GO:0014841
      label: skeletal muscle satellite cell proliferation
    modifier: DECREASED
  - preferred_term: skeletal muscle tissue regeneration
    term:
      id: GO:0043403
      label: skeletal muscle tissue regeneration
    modifier: DECREASED
  evidence:
  - reference: PMID:40678078
    reference_title: "Molecular constraints of sarcopenia in the ageing muscle."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "With age, both the structure and function of these components deteriorate: myonuclei become disorganized, gene expression skews toward catabolic, inflammatory, and fibrotic pathways, and satellite cell numbers and activity decline."
    explanation: Supports the decline in satellite cell number and activity with age.
  downstream:
  - target: Type II Myofiber Atrophy and Fiber-Type Shift
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: Myosteatosis and Intramuscular Fibro-Adipogenic Infiltration
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES

- name: Declining Anabolic Hormone Signalling
  description: >-
    Circulating growth hormone, IGF-1, testosterone, and estrogen fall with age
    (the sex-hormone half of that claim is what the cited evidence covers
    directly; the GH/IGF-1 decline is stated by the same reviews but is not
    separately quoted here). Because IGF-1 signalling through PI3K/AKT is the principal positive regulator
    of muscle protein content — driving mTOR-dependent synthesis while restraining
    FOXO-driven atrogene transcription — its withdrawal simultaneously weakens
    synthesis and releases the brake on degradation.
  biological_scale: ORGANISM
  role: driver
  evidence:
  - reference: PMID:40724988
    reference_title: "Sarcopenia: Current Insights into Molecular Mechanisms, Diagnostics, and Emerging Interventional Approaches."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Particular attention is given to the role of declining sex hormones, such as testosterone and estrogen, as key drivers of anabolic resistance and muscle loss during aging."
    explanation: Supports declining sex hormones as drivers of anabolic resistance and muscle loss.
  - reference: PMID:38046952
    reference_title: "Ubiquitin-proteasome pathway in skeletal muscle atrophy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The IGF-1/PI3K/AKT pathway, by inhibiting FOXO, prevents the upregulation of Atrogin-1 and suppresses muscle atrophy"
    explanation: >-
      Establishes the mechanism by which loss of IGF-1 signalling releases the
      atrogene program, linking this node to proteolysis downstream.
  downstream:
  - target: Anabolic Resistance
    causal_link_type: DIRECT
  - target: Ubiquitin-Proteasome Myofibrillar Proteolysis
    causal_link_type: DIRECT

- name: Blunted Load-Induced mTORC1 Signalling
  conforms_to: "skeletal_muscle_mechanotransduction#Impaired Load-Dependent mTORC1 Activation"
  description: >-
    Resistance exercise is sensed mechanically by the myofiber. Load converges on
    mTORC1 via candidate mechanosensors: costamere and integrin deformation acting
    through FAK-TSC2-Rheb, a DGKzeta-phosphatidic acid axis, and filamin C-BAG3
    signalling at the Z-disc. mTORC1 then drives muscle protein synthesis. In
    older muscle the same bout of exercise produces a smaller rise in mTOR, S6K1
    and 4E-BP1 phosphorylation and in protein synthesis. The dose-response curve
    is flattened rather than abolished: older muscle still responds, but needs
    higher intensity to approach the young response. This node is the loading arm
    of anabolic resistance; the feeding arm is captured on the Anabolic Resistance
    node itself.
  biological_scale: CELLULAR
  role: driver
  notes: >-
    Which mechanosensor is primary in human muscle is not settled. The cited
    review calls the filamin C-BAG3 route plausible but incompletely
    characterised, so no gene is bound to this node. The age deficit is
    established downstream of the sensor, at mTORC1 effector phosphorylation and
    protein synthesis; where between sensor and mTORC1 it arises has not been
    localised in human muscle.
  cell_types:
  - preferred_term: skeletal muscle fiber
    term:
      id: CL:0008002
      label: skeletal muscle fiber
  biological_processes:
  - preferred_term: cellular response to mechanical stimulus
    term:
      id: GO:0071260
      label: cellular response to mechanical stimulus
    modifier: DECREASED
  - preferred_term: load-induced TORC1 signaling
    term:
      id: GO:0038202
      label: TORC1 signaling
    modifier: DECREASED
  evidence:
  - reference: PMID:30335577
    reference_title: "Stimuli and sensors that initiate skeletal muscle hypertrophy following resistance exercise."
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: "A large body of work shows that a mammalian target of rapamycin complex 1 (mTORC1)-mediated increase of muscle protein synthesis is the key, but not sole, mechanism by which resistance exercise causes muscle hypertrophy."
    explanation: Establishes mTORC1-driven protein synthesis as the pathway that resistance loading acts through.
  - reference: PMID:30335577
    reference_title: "Stimuli and sensors that initiate skeletal muscle hypertrophy following resistance exercise."
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: "Mechanical signals are the prime hypertrophy stimuli candidates, and a filamin-C-BAG3-dependent regulation of mTORC1, Hippo, and autophagy signaling is a plausible albeit still incompletely characterized hypertrophy sensor."
    explanation: Names mechanical load as the stimulus and filamin C-BAG3 as a candidate sensor, and records that the sensor is not settled.
  - reference: PMID:27909410
    reference_title: "Mechanosensitive Molecular Networks Involved in Transducing Resistance Exercise-Signals into Muscle Protein Accretion."
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: "This may e.g. implicate mechanical activation of signaling through a diacylglycerol kinase (DGKζ)-phosphatidic acid (PA) axis or implicate integrin deformation to signal through a Focal adhesion kinase (FAK)-Tuberous Sclerosis Complex 2 (TSC2)-Ras homolog enriched in brain (Rheb) axis."
    explanation: Names the two further candidate mechanotransduction routes to mTORC1 listed in the description.
  - reference: PMID:21798089
    reference_title: "Aging impairs contraction-induced human skeletal muscle mTORC1 signaling and protein synthesis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Increased phosphorylation was seen only in the younger group (P< 0.05) for several key signaling proteins after exercise, including mammalian target of rapamycin (mTOR), ribosomal S6 kinase (S6K)1, eukaryotic initiation factor 4E-binding protein (4E-BP)1 and extracellular signal-regulated kinase (ERK)1/2, with no changes seen in the older group (P >0.05)."
    explanation: Direct human biopsy evidence that the mTORC1 response to a resistance bout is blunted in older adults.
  - reference: PMID:19001042
    reference_title: "Age-related differences in the dose-response relationship of muscle protein synthesis to resistance exercise in young and old men."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In each group, there was a sigmoidal dose-response relationship between MPS at 1-2 h post-exercise and exercise intensity, which was blunted (P < 0.05) in the older men."
    explanation: Supports a flattened rather than abolished dose-response in older muscle.
  downstream:
  - target: Anabolic Resistance
    causal_link_type: DIRECT
    description: >-
      A blunted protein-synthetic response to loading is one of the two stimulus
      arms that make up anabolic resistance.
    evidence:
    - reference: PMID:21798089
      reference_title: "Aging impairs contraction-induced human skeletal muscle mTORC1 signaling and protein synthesis."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "These age-related differences may contribute to the blunted hypertrophic response seen after resistance-exercise training in older adults, and highlight the mTORC1 pathway as a key therapeutic target to prevent sarcopenia."
      explanation: Links the blunted acute mTORC1 response to the reduced training response that defines anabolic resistance to exercise.

- name: Anabolic Resistance
  description: >-
    Ageing muscle mounts a blunted muscle-protein-synthesis response to the same
    anabolic stimulus — dietary protein and leucine, or a bout of resistance
    exercise — so that a larger dose is needed to reach the same synthetic rate.
    Systems-level analysis indicates that no single age-related impairment
    accounts for it; the resistant phenotype emerges only when several dysregulated
    nutrient-sensing and signalling processes act together, which is why
    single-target interventions under-perform.
  biological_scale: CELLULAR
  role: driver
  notes: >-
    Deliberately not conformed to deregulated_nutrient_sensing. The closest
    module node, "Autophagy Suppression and Anabolic Bias", describes *active*
    mTORC1 holding autophagy suppressed; anabolic resistance is the inverse — a
    blunted mTORC1 response to feeding, annotated here as TORC1 signaling
    DECREASED. Conforming would assert the opposite of what this node claims.
    A module node for blunted anabolic signalling would be the right target if
    one is added.
  cell_types:
  - preferred_term: skeletal muscle fiber
    term:
      id: CL:0008002
      label: skeletal muscle fiber
  biological_processes:
  - preferred_term: TORC1 signaling
    term:
      id: GO:0038202
      label: TORC1 signaling
    modifier: DECREASED
  evidence:
  - reference: PMID:42464764
    reference_title: "Multifactorial nature of anabolic resistance in ageing skeletal muscle: A systems modelling study."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "Sarcopenia, the age-related loss of skeletal muscle mass and function, is primarily caused by anabolic resistance, which is the blunted stimulation of muscle protein synthesis (MPS) and impaired suppression of muscle protein breakdown following anabolic stimuli such as feeding."
    explanation: Defines anabolic resistance as modelled here and places it upstream of muscle loss.
  - reference: PMID:42464764
    reference_title: "Multifactorial nature of anabolic resistance in ageing skeletal muscle: A systems modelling study."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "Instead, anabolic resistance emerged only when multiple impairments operated together."
    explanation: >-
      Supports the multifactorial claim in this node's description; the finding
      comes from a kinetic simulation, not a human feeding study.
  - reference: PMID:40678078
    reference_title: "Molecular constraints of sarcopenia in the ageing muscle."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Compounding this is anabolic resistance, a hallmark of aging muscle, in which higher levels of dietary protein and amino acids are required to stimulate muscle protein synthesis effectively."
    explanation: Independent review support for the raised anabolic threshold.
  downstream:
  - target: Negative Net Muscle Protein Balance
    causal_link_type: DIRECT

- name: Myostatin and Activin Receptor Signalling
  description: >-
    Myostatin (GDF8) and activins signal through the type II activin receptors
    (ActRIIA/ActRIIB) and SMAD2/3 to restrain muscle growth, opposing
    IGF-1/AKT/mTOR anabolic signalling and reinforcing atrogene expression. The
    axis is the leading pharmacological target class in sarcopenia. Antibody
    blockade of the receptors increased thigh muscle volume and lean body mass in
    a phase-1 study of 24 healthy older and obese adults, which is the available
    evidence that the pathway restrains mass in ageing muscle — though that study
    did not reach significance on appendicular lean mass specifically, and no
    trial has yet shown the pathway is over-active in sarcopenia rather than
    merely blockable.
  biological_scale: MOLECULAR
  molecular_functions:
  - preferred_term: activin receptor activity
    term:
      id: GO:0017002
      label: activin receptor activity
  evidence:
  - reference: PMID:33264516
    reference_title: "Safety and pharmacokinetics of bimagrumab in healthy older and obese adults with body composition changes in the older cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Bimagrumab is a human monoclonal antibody that blocks the ActRIIs, preventing the activity of myostatin and other negative skeletal muscle regulators."
    explanation: Identifies the receptor and ligands of the axis modelled by this node.
  - reference: PMID:33264516
    reference_title: "Safety and pharmacokinetics of bimagrumab in healthy older and obese adults with body composition changes in the older cohort."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "A single dose of bimagrumab rapidly increased TMV and LBM and decreased body adiposity in older adults."
    explanation: >-
      Therapeutic blockade increasing muscle volume and lean mass in older adults
      supports the pathway restraining mass; the inference runs from the drug
      response back to the mechanism, hence INDIRECT.
  downstream:
  - target: Anabolic Resistance
    causal_link_type: DIRECT
  - target: Ubiquitin-Proteasome Myofibrillar Proteolysis
    causal_link_type: DIRECT

- name: Ubiquitin-Proteasome Myofibrillar Proteolysis
  description: >-
    FOXO3, de-repressed by weakened IGF-1/PI3K/AKT signalling and driven further
    by NF-kappaB, transcribes the muscle-specific E3 ubiquitin ligases atrogin-1
    (FBXO32) and MuRF1 (TRIM63), which ubiquitinate myofibrillar proteins for
    proteasomal destruction. This is the dominant degradative route in skeletal
    muscle atrophy, acting alongside autophagy-lysosomal, calpain, and caspase
    systems.
  biological_scale: MOLECULAR
  biological_processes:
  - preferred_term: proteasome-mediated ubiquitin-dependent protein catabolic process
    term:
      id: GO:0043161
      label: proteasome-mediated ubiquitin-dependent protein catabolic process
    modifier: INCREASED
  evidence:
  - reference: PMID:38046952
    reference_title: "Ubiquitin-proteasome pathway in skeletal muscle atrophy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Atrogin-1 and MuRF1 are significantly upregulated by FOXO3 in all muscle atrophy scenarios"
    explanation: Names the transcription factor and the two E3 ligases central to this node.
  - reference: PMID:38046952
    reference_title: "Ubiquitin-proteasome pathway in skeletal muscle atrophy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "the ubiquitin-proteasome pathway emerges as an especially cardinal avenue for intracellular protein degradation, wielding pronounced influence over the muscle atrophy trajectory"
    explanation: Supports treating the ubiquitin-proteasome route as the dominant degradative arm.
  downstream:
  - target: Negative Net Muscle Protein Balance
    causal_link_type: DIRECT

- name: Negative Net Muscle Protein Balance
  description: >-
    The convergence point of the anabolic and catabolic arms: when degradation
    persistently exceeds synthesis, myofiber protein content falls and atrophy
    follows. Muscle mass is maintained only while this balance is neutral, so both
    a blunted synthetic response and an accelerated degradative one produce the
    same result.
  biological_scale: CELLULAR
  cell_types:
  - preferred_term: skeletal muscle fiber
    term:
      id: CL:0008002
      label: skeletal muscle fiber
  evidence:
  - reference: PMID:38046952
    reference_title: "Ubiquitin-proteasome pathway in skeletal muscle atrophy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Under catabolic conditions, protein degradation surpasses synthesis, leading to muscle weakness and atrophy."
    explanation: States the balance claim that defines this node.
  downstream:
  - target: Type II Myofiber Atrophy and Fiber-Type Shift
    causal_link_type: DIRECT

- name: Type II Myofiber Atrophy and Fiber-Type Shift
  description: >-
    Fast-twitch type II fibers lose cross-sectional area preferentially, while
    fibers rescued by collateral reinnervation from slow motor neurons take on
    type I properties, producing fiber-type grouping and a net shift toward slow
    phenotype. Because type II fibers generate the highest power, this
    disproportionately costs explosive strength — the capacity needed to arrest a
    stumble — which is part of why strength declines faster than mass.
  biological_scale: TISSUE
  cell_types:
  - preferred_term: type II (fast) skeletal muscle fiber
    term:
      id: CL:0000190
      label: fast muscle cell
  locations:
  - preferred_term: skeletal muscle tissue
    term:
      id: UBERON:0001134
      label: skeletal muscle tissue
  biological_processes:
  - preferred_term: skeletal muscle atrophy
    term:
      id: GO:0014732
      label: skeletal muscle atrophy
    modifier: INCREASED
  notes: >-
    This node does not hold for every subtype. has_subtypes#T2DM-related reports
    preferential loss of type I rather than type II fibers, which inverts the
    claim made here. The schema has no subtype-scoping slot on a pathophysiology
    node, so the exception is recorded in prose at both ends rather than modelled;
    a future pass should either add T2DM-specific nodes or demote that subtype.
  evidence:
  - reference: PMID:40678078
    reference_title: "Molecular constraints of sarcopenia in the ageing muscle."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Neurodegeneration and age-related muscle fibers denervation further exacerbate muscle loss, particularly affecting fast-twitch fibers, and reduce motor unit integrity."
    explanation: Supports the preferential loss of fast-twitch fibers via denervation.
  downstream:
  - target: Loss of Skeletal Muscle Mass, Strength and Quality
    causal_link_type: DIRECT

- name: Myosteatosis and Intramuscular Fibro-Adipogenic Infiltration
  description: >-
    Space vacated by lost myofibers is filled by adipose and fibrous tissue, and
    lipid also accumulates ectopically within fibers. Intramuscular ceramide
    accumulation impairs insulin signalling and suppresses protein synthesis via
    eIF2-alpha phosphorylation, so myosteatosis is not merely a passive
    radiological marker of poor muscle quality but feeds back onto anabolic
    resistance. This arm is amplified in sarcopenic obesity.
  biological_scale: TISSUE
  locations:
  - preferred_term: skeletal muscle tissue
    term:
      id: UBERON:0001134
      label: skeletal muscle tissue
  evidence:
  - reference: PMID:25139155
    reference_title: "Muscle ectopic fat deposition contributes to anabolic resistance in obese sarcopenic old rats through eIF2α activation."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Hence, OR were more prone to ectopic muscle lipid accumulation than YR, leading to decreased muscle protein anabolism."
    explanation: >-
      Old rats accumulate ectopic muscle lipid and lose protein anabolism,
      supporting the feedback from myosteatosis to reduced anabolism.
  downstream:
  - target: Anabolic Resistance
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:25139155
      reference_title: "Muscle ectopic fat deposition contributes to anabolic resistance in obese sarcopenic old rats through eIF2α activation."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "In C2C12 cells, palmitate-induced ceramide accumulation was associated with a decreased protein synthesis together with upregulated eIF2α phosphorylation."
      explanation: >-
        Gives the molecular step (ceramide to eIF2-alpha phosphorylation to
        reduced synthesis) that this edge asserts.
  - target: Loss of Skeletal Muscle Mass, Strength and Quality
    causal_link_type: DIRECT

- name: Capillary Rarefaction and Impaired Muscle Perfusion
  description: >-
    Skeletal muscle capillary density falls with age and the endothelial
    glycocalyx regulating exchange across the capillaries that remain is
    compromised, so less oxygen, substrate, insulin and amino acid reaches the
    myofiber for a given cardiac output. The proposed proximate cause is a
    signalling insufficiency rather than an endothelial one: production of the
    soluble VEGF decoy receptor sFlt-1 rises with age, leaving VEGFA-driven
    capillary sprouting unable to keep pace. This is a delivery lesion, not a
    contractile one, which is why it appears here upstream of anabolic
    resistance and of the bioenergetic deficit rather than alongside them.
  biological_scale: TISSUE
  role: contributor
  cell_types:
  - preferred_term: capillary endothelial cell
    term:
      id: CL:0002144
      label: capillary endothelial cell
  locations:
  - preferred_term: skeletal muscle tissue
    term:
      id: UBERON:0001134
      label: skeletal muscle tissue
  biological_processes:
  - preferred_term: angiogenesis
    term:
      id: GO:0001525
      label: angiogenesis
    modifier: DECREASED
  evidence:
  - reference: PMID:24577061
    reference_title: "Skeletal muscle capillary density and microvascular function are compromised with aging and type 2 diabetes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Skeletal muscle capillary density is reduced with aging and type 2 diabetes and accompanied by impairments in endothelial glycocalyx function, which is indicative of compromised vascular function."
    explanation: >-
      The direct human measurement this node asserts, in healthy older men
      compared with young men, covering both the density loss and the
      glycocalyx-function component.
  - reference: PMID:24577061
    reference_title: "Skeletal muscle capillary density and microvascular function are compromised with aging and type 2 diabetes."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "Adequate muscle perfusion is required for the maintenance of skeletal muscle mass."
    explanation: >-
      Supports treating perfusion as load-bearing for muscle mass, which is what
      places this node upstream rather than making it an incidental correlate.
      INDIRECT because the sentence states the premise the study was designed
      around rather than a result it measured.
  - reference: PMID:34326210
    reference_title: "Counteracting age-related VEGF signaling insufficiency promotes healthy aging and extends life span."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Increasing VEGF signaling prevented age-associated capillary loss, improved organ perfusion and function, and extended life span."
    explanation: >-
      The interventional counterpart in mice: restoring VEGF signalling reverses
      the capillary loss, which supports the sFlt-1/VEGF-insufficiency mechanism
      this node's description names.
  downstream:
  - target: Anabolic Resistance
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: Mitochondrial Dysfunction and Oxidative Stress
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  notes: >-
    Curated from PMID:42706321, which treats maintenance of vascularization as
    one of its therapeutic axes. The node exists so that the VEGF and apelin
    treatments have a mechanism to act on; before it was added, this entry had
    no vascular arm at all. The sFlt-1 attribution in the description is the
    review's account and is not separately snippet-verified here.

- name: Loss of Skeletal Muscle Mass, Strength and Quality
  description: >-
    The clinical convergence node. Reduced contractile tissue, degraded muscle
    quality, and unreliable neuromuscular transmission together produce the
    measurable triad on which the diagnosis rests: low strength (the primary
    criterion), low muscle quantity or quality (confirmatory), and poor physical
    performance (which grades severity). Strength falls out of proportion to mass,
    which is why EWGSOP2 moved strength to the front of the definition.
  biological_scale: ORGANISM
  locations:
  - preferred_term: skeletal muscle organ
    term:
      id: UBERON:0014892
      label: skeletal muscle organ, vertebrate
  evidence:
  - reference: PMID:30312372
    reference_title: "Sarcopenia: revised European consensus on definition and diagnosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Sarcopenia is a progressive and generalised skeletal muscle disorder that is associated with increased likelihood of adverse outcomes including falls, fractures, physical disability and mortality."
    explanation: The consensus statement of the clinical endpoint this node represents.
  - reference: PMID:30312372
    reference_title: "Sarcopenia: revised European consensus on definition and diagnosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In these revised guidelines, muscle strength comes to the forefront, as it is recognised that strength is better than mass in predicting adverse outcomes"
    explanation: Supports the strength-over-mass claim made in this node's description.

mechanistic_hypotheses:
- hypothesis_group_id: nmj_excitability_failure
  hypothesis_label: Neuromuscular Junction Excitability Failure as a Reversible Driver
  status: EMERGING
  description: >-
    Holds that a substantial and pharmacologically reversible share of age-related
    weakness comes not from lost contractile tissue but from failure to reliably
    excite the tissue that remains — postsynaptic NaV1.4 depletion lowering the
    safety factor for neuromuscular transmission. Its distinguishing prediction is
    that restoring fiber excitability improves strength without changing muscle
    mass. Evidence is strong in aged rodents; the human data establish that
    transmission failure tracks weakness severity but do not yet include a
    therapeutic trial, so this is recorded as emerging rather than canonical.
  evidence:
  - reference: PMID:42424105
    reference_title: "Neuromuscular junction failure in sarcopenia is linked to NaV1.4 loss and reversed by ClC-1 inhibition."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Together, these findings demonstrate that NMJ transmission deficits are a key, reversible driver of sarcopenia and reveal a novel therapeutic target for addressing muscle weakness in aging."
    explanation: >-
      The paper's own summary claim, which is the hypothesis this group states.
      Graded MODEL_ORGANISM because the reversibility half of the claim rests on
      the rodent rescue arm.
  - reference: PMID:42424105
    reference_title: "Neuromuscular junction failure in sarcopenia is linked to NaV1.4 loss and reversed by ClC-1 inhibition."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "This excitability defect, distinct from potential synaptic cholinergic transmission abnormalities, represents a novel disease mechanism of sarcopenia."
    explanation: >-
      Supports the specific claim that distinguishes this hypothesis: the lesion
      is one of fiber excitability rather than cholinergic transmission.
- hypothesis_group_id: canonical_multifactorial_convergence
  hypothesis_label: Canonical Multifactorial Convergence on Muscle Protein Balance
  status: CANONICAL
  description: >-
    The mainstream account: denervation, mitochondrial dysfunction, inflammaging,
    hormonal decline, satellite-cell exhaustion, and anabolic resistance are
    partially independent inputs that converge on a persistently negative muscle
    protein balance and on regenerative failure. It explains why single-target
    interventions have repeatedly failed to restore function and why exercise —
    which acts on many arms at once — remains the most effective treatment.
  evidence:
  - reference: PMID:38225199
    reference_title: "Unraveling the causes of sarcopenia: Roles of neuromuscular junction impairment and mitochondrial dysfunction."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Sarcopenia is caused by complex and interdependent pathophysiological mechanisms, including aging, neuromuscular junction impairment, mitochondrial dysfunction, insulin resistance, lipotoxicity, endocrine factors, oxidative stress, and inflammation."
    explanation: Enumerates the interdependent inputs this hypothesis group asserts converge.
  - reference: PMID:42464764
    reference_title: "Multifactorial nature of anabolic resistance in ageing skeletal muscle: A systems modelling study."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "Clinically, interventions targeting single mechanisms are unlikely to fully restore muscle anabolism in older adults, particularly when multiple impairments coexist."
    explanation: >-
      Supports the hypothesis's distinguishing prediction that single-target
      interventions under-perform; derived from simulation rather than trial data.

phenotypes:
- category: Musculoskeletal
  name: Low Muscle Strength
  description: >-
    Reduced maximal voluntary force, operationalised as handgrip dynamometry or
    the chair-stand test. This is the primary EWGSOP2 diagnostic criterion and is
    sufficient on its own for "probable sarcopenia".
  phenotype_term:
    preferred_term: Low muscle strength (grip strength or chair-stand)
    term:
      id: HP:0003324
      label: Generalized muscle weakness
    clinical_course: PROGRESSIVE
  frequency: VERY_FREQUENT
  diagnostic: true
  evidence:
  - reference: PMID:30312372
    reference_title: "Sarcopenia: revised European consensus on definition and diagnosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "focuses on low muscle strength as a key characteristic of sarcopenia, uses detection of low muscle quantity and quality to confirm the sarcopenia diagnosis, and identifies poor physical performance as indicative of severe sarcopenia"
    explanation: Establishes low muscle strength as the primary diagnostic criterion.
  - reference: PMID:32033882
    reference_title: "Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "low muscle strength is defined as handgrip strength <28 kg for men and <18 kg for women"
    explanation: Gives the AWGS 2019 operational cut-offs for this phenotype.

- category: Musculoskeletal
  name: Decreased Muscle Mass
  description: >-
    Reduced appendicular skeletal muscle mass, indexed to height (ASMI) and
    measured by DXA, BIA, CT, or MRI. Confirmatory rather than primary under
    EWGSOP2.
  phenotype_term:
    preferred_term: Low appendicular skeletal muscle mass index
    term:
      id: HP:0003199
      label: Decreased muscle mass
    clinical_course: PROGRESSIVE
  diagnostic: true
  notes: >-
    No frequency is recorded. Low muscle mass is confirmatory rather than
    primary under EWGSOP2, so by construction it is absent in "probable"
    sarcopenia; the cited snippet gives diagnostic cut-offs, not a frequency.
  evidence:
  - reference: PMID:32033882
    reference_title: "Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "AWGS 2019 retains the original cutoffs for height-adjusted muscle mass: dual-energy X-ray absorptiometry, <7.0 kg/m2 in men and <5.4 kg/m2 in women"
    explanation: Gives the operational cut-offs defining low muscle mass.

- category: Musculoskeletal
  name: Type 2 Muscle Fiber Atrophy
  description: >-
    Histological preferential atrophy of fast-twitch type II fibers, with
    fiber-type grouping reflecting cycles of denervation and reinnervation.
  phenotype_term:
    preferred_term: Type 2 muscle fiber atrophy
    term:
      id: HP:0003554
      label: Type 2 muscle fiber atrophy
  evidence:
  - reference: PMID:40678078
    reference_title: "Molecular constraints of sarcopenia in the ageing muscle."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Neurodegeneration and age-related muscle fibers denervation further exacerbate muscle loss, particularly affecting fast-twitch fibers, and reduce motor unit integrity."
    explanation: Supports preferential involvement of fast-twitch (type II) fibers.

- category: Neurological
  name: Impaired Physical Performance
  description: >-
    Slow gait speed, low Short Physical Performance Battery score, prolonged
    Timed-Up-and-Go, or inability to complete a 400 m walk. Under EWGSOP2 this
    grades severity rather than establishing the diagnosis.
  phenotype_term:
    preferred_term: Slow gait speed and impaired physical performance
    term:
      id: HP:0001288
      label: Gait disturbance
  diagnostic: true
  evidence:
  - reference: PMID:32033882
    reference_title: "Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "criteria for low physical performance are 6-m walk <1.0 m/s, Short Physical Performance Battery score ≤9, or 5-time chair stand test ≥12 seconds"
    explanation: Gives the operational thresholds for the physical-performance domain.

- category: Musculoskeletal
  name: Falls
  description: Increased incidence of falls, a direct consequence of weakness and impaired gait.
  phenotype_term:
    preferred_term: Falls
    term:
      id: HP:0002527
      label: Falls
  evidence:
  - reference: PMID:30312372
    reference_title: "Sarcopenia: revised European consensus on definition and diagnosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Sarcopenia is a progressive and generalised skeletal muscle disorder that is associated with increased likelihood of adverse outcomes including falls, fractures, physical disability and mortality."
    explanation: Names falls among the adverse outcomes associated with sarcopenia.

- category: Constitutional
  name: Frailty
  description: >-
    Sarcopenia is the principal muscular substrate of the frailty phenotype;
    the two constructs overlap without being identical.
  phenotype_term:
    preferred_term: Frailty
    term:
      id: HP:0033675
      label: Frailty
  evidence:
  - reference: PMID:27891296
    reference_title: "Welcome to the ICD-10 code for sarcopenia."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Sarcopenia is the most important cause of frailty in older persons."
    explanation: Supports the relationship between sarcopenia and frailty asserted here.

- category: Constitutional
  name: Physical Disability and Loss of Independence
  description: >-
    Impaired activities of daily living, reduced quality of life, need for
    long-term care placement, and increased mortality.
  phenotype_term:
    preferred_term: Physical disability and loss of independence
  notes: >-
    Deliberately unbound. HPO has no term for acquired physical disability or
    loss of independence in an older adult; the nearest candidates
    (HP:0012759 Neurodevelopmental abnormality, HP:0001288 Gait disturbance)
    name something else, and the dismech term contract prefers no term to a
    wrong one. Revisit if a suitable HP or functional-status term appears.
  evidence:
  - reference: PMID:30312372
    reference_title: "Sarcopenia: revised European consensus on definition and diagnosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "impairs ability to perform activities of daily living"
    explanation: States the ADL impairment recorded by this phenotype.

genetic:
- name: ACTN3
  gene_term:
    preferred_term: ACTN3
    term:
      id: hgnc:165
      label: ACTN3
  relationship_type: UNKNOWN
  variant_origin: GERMLINE
  evidence:
  - reference: PMID:27861536
    reference_title: "Muscle-Related Polymorphisms (MSTN rs1805086 and ACTN3 rs1815739) Are Not Associated with Exceptional Longevity in Japanese Centenarians."
    supports: NO_EVIDENCE
    evidence_source: HUMAN_CLINICAL
    snippet: "No definite conclusions can be inferred in relation to EL owing to its lack of association with both rs1815739 and rs1805086."
    explanation: >-
      Recorded as NO_EVIDENCE, not REFUTE. This study genotypes the same ACTN3
      R577X polymorphism but tests it against exceptional longevity, not against
      sarcopenia, so it does not bear on the claim either way. It is cited to
      record that the nearest cached primary source was examined and found not
      to be about this disease, rather than leaving the gene silently unsourced.
  notes: >-
    The common R577X null polymorphism abolishes alpha-actinin-3, a structural
    protein of the fast-twitch (type II) fiber Z-disc. Because type II fibers are
    the ones sarcopenia preferentially destroys, the XX genotype is a plausible
    susceptibility allele for reduced muscle mass and power in old age -- a
    common-variant susceptibility factor, not a causal Mendelian locus.
    Recorded from the deep-research report as a lead: no primary-source snippet
    for the ACTN3-sarcopenia association was verified in this session, so no
    evidence item is attached rather than one manufactured, and the claim is
    deliberately scoped to plausibility. relationship_type is UNKNOWN rather
    than SUSCEPTIBILITY: the latter is defined in the schema as a variant
    conferring susceptibility and is the reading a machine query would take,
    which is more than the sourcing here supports. Tracked by the
    genetic-susceptibility knowledge gap in discussions.
- name: MSTN
  notes: >-
    Myostatin, the secreted TGF-beta-superfamily ligand that signals through the
    type II activin receptors to restrain muscle growth. It is the target of the
    leading investigational drug class in sarcopenia, so the gene is recorded here
    as the pharmacological entry point to the pathway modelled in
    pathophysiology#Myostatin and Activin Receptor Signalling.
    relationship_type is UNKNOWN because no variant-level gene-disease claim is
    made here: every value in GeneDiseaseRelationshipEnum except BIOMARKER and
    UNKNOWN is defined in terms of variants, and the evidence attached is a
    drug-mechanism statement, not a genetic finding. MSTN K153R (rs1805086)
    association studies exist and are cached (PMID:21283721, PMID:36360291) but
    test athletic strength phenotypes rather than sarcopenia, so they were not
    used.
  gene_term:
    preferred_term: MSTN
    term:
      id: hgnc:4223
      label: MSTN
  relationship_type: UNKNOWN
  evidence:
  - reference: PMID:33264516
    reference_title: "Safety and pharmacokinetics of bimagrumab in healthy older and obese adults with body composition changes in the older cohort."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "Bimagrumab is a human monoclonal antibody that blocks the ActRIIs, preventing the activity of myostatin and other negative skeletal muscle regulators."
    explanation: >-
      Identifies myostatin as a negative regulator of skeletal muscle acting via
      ActRIIs; the relevance to sarcopenia is via the therapeutic response, so
      the support is indirect.
- name: SCN4A
  notes: >-
    Encodes NaV1.4, the skeletal-muscle voltage-gated sodium channel whose
    localized depletion from the post-synaptic neuromuscular junction membrane
    underlies the excitability defect in pathophysiology#Postsynaptic NaV1.4
    Depletion. Implicated through protein-level loss in ageing muscle, not
    through a sarcopenia-associated germline variant — so relationship_type is
    BIOMARKER ("gene whose expression ... status serves as a ... biomarker
    without a required causal role") rather than MODIFIER, which the schema
    defines in terms of variants and which would contradict this note. The
    causal role of the lost gene product is modelled in the pathograph instead.
  gene_term:
    preferred_term: SCN4A
    term:
      id: hgnc:10591
      label: SCN4A
  relationship_type: BIOMARKER
  evidence:
  - reference: PMID:42424105
    reference_title: "Neuromuscular junction failure in sarcopenia is linked to NaV1.4 loss and reversed by ClC-1 inhibition."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Across species, immunohistochemistry identified a localized reduction in the voltage-gated sodium channel specific for skeletal muscle (NaV1.4) at the post-synaptic NMJ membrane."
    explanation: Documents the loss of the SCN4A gene product at the junction in sarcopenia.

- name: Polygenic sarcopenia risk loci (UK Biobank)
  gene_term:
    preferred_term: IRS1
    term:
      id: hgnc:6125
      label: IRS1
  relationship_type: SUSCEPTIBILITY
  variant_origin: GERMLINE
  evidence:
  - reference: PMID:36771461
    reference_title: "Identification and Characterization of Genomic Predictors of Sarcopenia and Sarcopenic Obesity Using UK Biobank Data."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "By combining summary statistics of genome-wide association studies (GWAS) of handgrip strength, lean mass and walking pace, we have identified 78 independent SNPs (from 73 loci) associated with all three traits with consistent effect directions."
    explanation: >-
      Establishes the polygenic architecture recorded by this entry: 78 SNPs
      across 73 loci associated with all three sarcopenia-defining traits in the
      same direction.
  - reference: PMID:36771461
    reference_title: "Identification and Characterization of Genomic Predictors of Sarcopenia and Sarcopenic Obesity Using UK Biobank Data."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Of the 78 SNPs, 55 polymorphisms were also associated with body fat percentage and 25 polymorphisms with type 2 diabetes (T2D), indicating that sarcopenia, obesity and T2D share many common risk alleles."
    explanation: >-
      Supports shared genetic architecture with adiposity and type 2 diabetes,
      which is the genetic counterpart of the sarcopenic-obesity subtype.
  notes: >-
    This is a stand-in record for a polygenic signal rather than a single-gene
    claim: the schema's genetic[] entries are gene-keyed, so IRS1 is used as the
    representative locus and the evidence describes the aggregate GWAS result.
    The other reported lean-mass loci (FTO, HSD17B11, VCAN, ADAMTSL3) and
    handgrip loci (ESR1, NOS3, KLF5, HLA-DQA1) are named here rather than given
    separate entries, because no per-gene primary source was verified for them
    in this session. Effect sizes are not recorded; a polygenic risk score is
    not clinically actionable for sarcopenia today.

environmental:
- name: Sedentary lifestyle and physical inactivity
  description: >-
    Chronic low physical activity, prolonged bed rest, and immobilisation
    withdraw the mechanical loading that maintains muscle protein synthesis and
    motor unit function. This is the dominant modifiable driver of secondary
    sarcopenia and accelerates the primary form.
  exposure_term:
    preferred_term: exposure to sedentary lifestyle
    term:
      id: ECTO:6000004
      label: exposure to sedentary lifestyle
  effect: Accelerates muscle loss through disuse atrophy.
  evidence:
  - reference: PMID:40678078
    reference_title: "Molecular constraints of sarcopenia in the ageing muscle."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Physical inactivity and immobility, often secondary to chronic illness or frailty, further accelerate sarcopenia by promoting disuse atrophy."
    explanation: States that inactivity and immobility accelerate sarcopenia via disuse atrophy.
  influences_mechanisms:
  - target: Negative Net Muscle Protein Balance
    environmental_effect: EXACERBATES
    causal_link_type: DIRECT
    description: >-
      Unloading removes the principal physiological stimulus to muscle protein
      synthesis, tipping the balance further toward degradation.
    evidence:
    - reference: PMID:38046952
      reference_title: "Ubiquitin-proteasome pathway in skeletal muscle atrophy."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Historically, factors like age, physical activity, and prevailing diseases have swayed protein dynamics."
      explanation: >-
        Names physical activity as one of the determinants of the muscle protein
        synthesis/degradation balance this edge targets.

- name: Inadequate dietary protein intake
  description: >-
    Insufficient dietary protein and essential amino acids — from the anorexia of
    ageing, malabsorption, or restrictive diets — deprives ageing muscle of the
    anabolic substrate it already needs in larger quantities because of anabolic
    resistance. The two act together: the same intake that sufficed in youth is
    subthreshold in an old muscle.
  exposure_term:
    preferred_term: exposure to decreased protein in food
    term:
      id: ECTO:0400019
      label: exposure to decreased protein in food
  effect: Deprives ageing muscle of anabolic substrate.
  evidence:
  - reference: PMID:40678078
    reference_title: "Molecular constraints of sarcopenia in the ageing muscle."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Nutritional factors are also pivotal: anorexia of aging and reduced dietary protein
      intake lead to suboptimal nutrient availability. Compounding this is anabolic
      resistance, a hallmark of aging muscle, in which higher levels of dietary protein and
      amino acids are required to stimulate muscle protein synthesis effectively.
    explanation: Supports reduced dietary protein intake as a nutritional driver in sarcopenia.
  influences_mechanisms:
  - target: Anabolic Resistance
    environmental_effect: EXACERBATES
    causal_link_type: DIRECT
    description: >-
      Low protein intake interacts with the raised anabolic threshold of ageing
      muscle, so the same deficit costs more synthesis than it would in youth.
    evidence:
    - reference: PMID:40678078
      reference_title: "Molecular constraints of sarcopenia in the ageing muscle."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Compounding this is anabolic resistance, a hallmark of aging muscle, in which higher levels of dietary protein and amino acids are required to stimulate muscle protein synthesis effectively."
      explanation: >-
        States the raised protein requirement that makes inadequate intake act on
        the anabolic-resistance node specifically.

- name: Regular resistance exercise
  description: >-
    Habitual progressive resistance training, alone or within a multicomponent
    programme, is the strongest protective exposure, acting on several arms of
    the mechanism. Mechanical loading drives mTORC1-dependent protein synthesis,
    though older muscle needs a higher intensity for the same response. Training
    raises motor unit discharge rate, which is a neural contribution to strength
    that does not depend on added mass. It also partially reverses the
    mitochondrial transcriptional signature of ageing. Modelled as a protective
    exposure here and as an intervention under treatments.
  exposure_term:
    preferred_term: regular resistance training
    term:
      id: ECTO:6000040
      label: exposure to Resistance Training
  effect: Protective against progression of muscle loss and weakness.
  notes: >-
    ECTO names every class as "exposure to X", which is why the bound label reads
    awkwardly; the preferred_term carries the human-readable name. ECTO:6000040
    (a child of ECTO:6000039 exposure to Physical Activity) replaces the broader
    ECTO:6000002 exposure to exercise.
  evidence:
  - reference: PMID:42304276
    reference_title: "The intervention effects of resistance exercise on sarcopenia in older adults: a systematic review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Resistance exercise exerts significant beneficial effects on handgrip strength, ASMI, gait speed, and physical performance, as assessed by the five-times sit-to-stand test, in older adults with sarcopenia."
    explanation: Meta-analytic support that resistance exercise improves the defining domains of sarcopenia.
  influences_mechanisms:
  - target: Negative Net Muscle Protein Balance
    environmental_effect: PROTECTS_AGAINST
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Loading is sensed by the myofiber and converges on mTORC1, which raises
      muscle protein synthesis and moves net balance back toward neutral. The
      intermediate is the load-sensing step recorded on the Blunted Load-Induced
      mTORC1 Signalling node; its age-related blunting is why older muscle needs
      a higher training intensity.
    evidence:
    - reference: PMID:30335577
      reference_title: "Stimuli and sensors that initiate skeletal muscle hypertrophy following resistance exercise."
      supports: SUPPORT
      evidence_source: OTHER
      quote_role: REVIEW_SYNTHESIS
      snippet: "A large body of work shows that a mammalian target of rapamycin complex 1 (mTORC1)-mediated increase of muscle protein synthesis is the key, but not sole, mechanism by which resistance exercise causes muscle hypertrophy."
      explanation: Names mTORC1-driven protein synthesis as the main route by which loading shifts protein balance.
    - reference: PMID:38046952
      reference_title: "Ubiquitin-proteasome pathway in skeletal muscle atrophy."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Resistance training or anabolic hormonal stimuli can enhance protein synthesis, resulting in an increase in skeletal muscle cell protein synthesis, leading to an increase in muscle fiber size, a process known as skeletal muscle hypertrophy"
      explanation: >-
        States the mechanism by which resistance training acts on muscle protein
        balance, which is the edge asserted here.
    - reference: PMID:19001042
      reference_title: "Age-related differences in the dose-response relationship of muscle protein synthesis to resistance exercise in young and old men."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The results suggest that in the post-absorptive state: (i) MPS is dose dependant on intensity rising to a plateau at 60-90% 1 RM; (ii) older men show anabolic resistance of signalling and MPS to resistance exercise."
      explanation: >-
        Shows the protective effect is intensity-dependent and attenuated with
        age, which is the basis for prescribing 60-80% 1RM in older adults.
  - target: Mitochondrial Dysfunction and Oxidative Stress
    environmental_effect: PROTECTS_AGAINST
    causal_link_type: DIRECT
    description: >-
      Six months of resistance training shifts the ageing muscle transcriptome,
      which is dominated by mitochondrial genes, back toward the young profile.
      Endurance and combined training are the stronger stimulus for
      respirometric oxidative capacity, so a multicomponent programme serves
      this arm better than resistance training alone.
    evidence:
    - reference: PMID:17520024
      reference_title: "Resistance exercise reverses aging in human skeletal muscle."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "However, following exercise training the transcriptional signature of aging was markedly reversed back to that of younger levels for most genes that were affected by both age and exercise."
      explanation: >-
        Direct human evidence that resistance training reverses the
        mitochondria-enriched ageing signature in muscle.
    - reference: PMID:25599385
      reference_title: "Combined training enhances skeletal muscle mitochondrial oxidative capacity independent of age."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "ET and CT significantly increased oxidative capacity and expression of mitochondrial proteins and transcription factors."
      explanation: >-
        Names endurance and combined training, not resistance training alone, as
        the arms that raised measured oxidative capacity; supports the
        qualification in this edge's description.
  - target: Failure of Compensatory Motor Unit Remodeling
    environmental_effect: PROTECTS_AGAINST
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Lifelong high-level exercise is associated with more reinnervation of
      aged muscle, the rescue process whose failure this node records. The
      evidence is cross-sectional and concerns lifelong exercise in general,
      not a resistance-training intervention.
    evidence:
    - reference: PMID:35234025
      reference_title: "Exercise-mediated reinnervation of skeletal muscle in elderly people: An update."
      supports: SUPPORT
      directness: INDIRECT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: "In this short review we discuss those results in the light of the most recent advances confirming the occurrence of exercise-mediated reinnervation, ultimately preserving muscle structure and function in elderly people who exercise."
      explanation: >-
        Supports exercise-associated reinnervation in old muscle; INDIRECT
        because the underlying data are lifelong athletes rather than a
        resistance-training trial in sarcopenia.
  - target: Loss of Skeletal Muscle Mass, Strength and Quality
    environmental_effect: PROTECTS_AGAINST
    causal_link_type: DIRECT
    description: >-
      Part of the strength gain is neural. In older adults, four weeks of
      strength training raised motor unit discharge rate and persistent inward
      currents, and these changes tracked the gain in maximal force. This is a
      route to strength that runs alongside hypertrophy, consistent with
      strength improving out of proportion to mass.
    evidence:
    - reference: PMID:41823343
      reference_title: "Ageing does not impair motor neuron adaptations: comparable motor unit responses to strength training in young and older adults."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "This pattern suggests that enhanced intrinsic excitability and synaptic input to motor neurons contributed to improvements in strength."
      explanation: Supports a neural contribution to the strength gain in older adults.
    - reference: PMID:41823343
      reference_title: "Ageing does not impair motor neuron adaptations: comparable motor unit responses to strength training in young and older adults."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "These results demonstrate that, despite age-related motor unit remodelling, the ageing nervous system remains responsive to targeted strength training, preserving the capacity for meaningful neural adaptations."
      explanation: Supports that the neural route is preserved with age, unlike the blunted protein-synthetic route.

inheritance:
- name: Polygenic inheritance
  description: >-
    Sarcopenia risk is distributed across many common variants of small effect
    interacting with age, activity, nutrition, and comorbidity. There is no
    Mendelian mode of inheritance, and penetrance in the monogenic sense does
    not apply.
  inheritance_term:
    preferred_term: Polygenic inheritance
    term:
      id: HP:0010982
      label: Polygenic inheritance
  evidence:
  - reference: PMID:36771461
    reference_title: "Identification and Characterization of Genomic Predictors of Sarcopenia and Sarcopenic Obesity Using UK Biobank Data."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The substantial decline in skeletal muscle mass, strength, and gait speed is a sign of severe sarcopenia, which may partly depend on genetic risk factors."
    explanation: >-
      Supports a partial, multi-locus genetic contribution rather than a
      Mendelian one; the same study's 73-locus result is cited under genetic.

treatments:
- name: Progressive Resistance Exercise Training
  description: >-
    Moderate-to-high intensity progressive resistance training, typically three
    sessions weekly at 60-80% of one-repetition maximum, is the cornerstone
    intervention and the only one that reliably improves strength, mass, and
    physical performance together. Benefit is demonstrable even in frail
    nonagenarians. Response varies widely between individuals, but in a pooled
    analysis of 195 older adults every participant improved on at least one
    outcome, and longer programmes produced more responders. Differences by age,
    sex, reproductive status and baseline function are recorded under
    effect_modifiers. A SPRINTT sex result pointing the other way is kept in
    the evidence, because it rests on separate within-sex results.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: progressive resistance training
    term:
      id: NCIT:C62739
      label: Exercise Intervention
  notes: >-
    NCIT:C154219 Resistance Training would be the more specific term but sits
    under NCIT:C17708 Physical Activity, not NCIT:C25218 Clinical Intervention or
    Procedure, so it is outside the TreatmentActionTerm enum.
  effect_modifiers:
  - effect_modifier_type: AGE
    stratum: age 75 years or younger
    comparator_stratum: older than 75 years
    modified_outcome: gait speed
    effect_in_stratum: LARGER_EFFECT
    modification_analysis: META_ANALYSIS_SUBGROUP
    description: >-
      Subgroup analysis in a meta-analysis restricted to older adults with
      sarcopenia. The same analysis reported higher heterogeneity in the
      larger-effect subgroups, so the gradient is suggestive rather than settled.
    evidence:
    - reference: PMID:42304276
      reference_title: "The intervention effects of resistance exercise on sarcopenia in older adults: a systematic review and meta-analysis."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Subgroup analysis of gait speed indicated that shorter intervention cycles (≤12 weeks), younger age (≤75 years), and a weekly training frequency of three sessions yielded larger effect sizes with higher heterogeneity"
      explanation: Reports the age gradient for gait speed in a sarcopenic population.
  - effect_modifier_type: AGE
    stratum: older men (about 70 years)
    comparator_stratum: young men (about 25 years)
    modified_outcome: acute muscle protein synthesis and mTORC1 signalling after a resistance bout
    effect_in_stratum: SMALLER_EFFECT
    modification_analysis: CROSS_STRATUM_COMPARISON
    description: >-
      Acute tracer and biopsy studies rather than training trials. The
      dose-response is flattened rather than abolished, which is the basis for
      prescribing higher intensity to older adults. The mechanism is recorded as
      the Blunted Load-Induced mTORC1 Signalling node.
    evidence:
    - reference: PMID:19001042
      reference_title: "Age-related differences in the dose-response relationship of muscle protein synthesis to resistance exercise in young and old men."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "In each group, there was a sigmoidal dose-response relationship between MPS at 1-2 h post-exercise and exercise intensity, which was blunted (P < 0.05) in the older men."
      explanation: Blunted synthetic response to the same relative load in older men.
    - reference: PMID:21798089
      reference_title: "Aging impairs contraction-induced human skeletal muscle mTORC1 signaling and protein synthesis."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "After exercise, MPS increased from baseline only in the younger group (P< 0.05), with MPS being significantly greater than that in the older group (P <0.05)."
      explanation: Independent replication of the age difference in acute protein synthesis.
  - effect_modifier_type: AGE
    stratum: older adults (65 years and over)
    comparator_stratum: young adults (18-30 years)
    modified_outcome: strength, body composition and mitochondrial adaptations to 8 weeks of training
    effect_in_stratum: NO_DIFFERENCE
    modification_analysis: CROSS_STRATUM_COMPARISON
    description: >-
      Each age group was randomised to endurance, resistance or combined
      training. Most training adaptations did not differ by age, which sits
      alongside the blunted acute response: older muscle adapts, at a higher
      stimulus cost per bout.
    evidence:
    - reference: PMID:25599385
      reference_title: "Combined training enhances skeletal muscle mitochondrial oxidative capacity independent of age."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Importantly, most of the adaptations to training occurred independent of age."
      explanation: Reports age-independence of most training adaptations.
  - effect_modifier_type: SEX
    stratum: women over 65
    comparator_stratum: men over 65
    modified_outcome: knee extensor maximal torque and muscle quality
    effect_in_stratum: SMALLER_EFFECT
    modification_analysis: CROSS_STRATUM_COMPARISON
    interaction_tested: true
    description: >-
      18 weeks of supervised resistance training with no untrained control
      arm. Muscle cross-sectional area did not differ by sex, so the gap is in
      strength per unit muscle rather than in hypertrophy. SPRINTT reported
      the opposite pattern for a multicomponent programme; that result is in the
      treatment evidence, not here, because it rests on separate within-sex
      results without an interaction test.
    evidence:
    - reference: PMID:27354538
      reference_title: "Sex differences in the response to resistance exercise training in older people."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Maximal torque increased by 15.8 ± 10.6% in women and 41.7 ± 25.5% in men, whereas muscle quality increased by 8.8 ± 17.5% in women and by 33.7 ± 25.6% in men."
      explanation: Quantifies the smaller torque and muscle-quality gains in women.
    - reference: PMID:27354538
      reference_title: "Sex differences in the response to resistance exercise training in older people."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "There were no interaction effects with sex for muscle ACSA or muscle fat, but an interaction effect was observed for muscle quality"
      explanation: Records the formal sex interaction tests and the absence of a sex difference in muscle size.
  - effect_modifier_type: REPRODUCTIVE_STATUS
    stratum: postmenopausal women
    comparator_stratum: premenopausal women
    modified_outcome: muscular strength and functional mass
    effect_in_stratum: NO_DIFFERENCE
    modification_analysis: META_ANALYSIS_SUBGROUP
    interaction_tested: true
    description: >-
      Meta-analysis of 126 studies in healthy women; age, training duration and
      frequency also did not moderate the response.
    evidence:
    - reference: PMID:41963141
      reference_title: "It's never too late: The impact of resistance training on strength and body composition in females across the lifespan - A systematic review and meta-analysis."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Resistance training significantly improved muscular strength in both premenopausal (standardized mean difference = 1.50 [95% confidence interval: 1.28-1.73]) and postmenopausal women (standardized mean difference = 1.46 [95% confidence interval: 1.26-1.67]), with no subgroup difference (p = 0.520)."
      explanation: Formal subgroup comparison by menopausal status, null.
  - effect_modifier_type: BASELINE_SEVERITY
    stratum: SPPB score 8-9
    comparator_stratum: SPPB score 3-7
    modified_outcome: incident mobility disability
    effect_in_stratum: NO_EFFECT
    modification_analysis: POST_HOC_SUBGROUP
    interaction_tested: true
    description: >-
      In SPRINTT, the programme reduced mobility disability only in participants
      with lower baseline function. The separate SPPB 8-9 analysis was run
      because a qualitative interaction with SPPB category was found. SPRINTT's
      intervention was multicomponent (moderate-intensity physical activity plus
      nutritional counselling), so this records effect modification for that
      programme; whether progressive resistance training alone behaves the same
      way is not established.
    evidence:
    - reference: PMID:35545258
      reference_title: "Multicomponent intervention to prevent mobility disability in frail older adults: randomised controlled trial (SPRINTT project)."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "In participants with SPPB scores of 8 or 9, mobility disability occurred in 46/155 (29.7%) in the multicomponent intervention and 38/159 (23.9%) controls (hazard ratio 1.25, 95% confidence interval 0.79 to 1.95; P=0.34)."
      explanation: No benefit in the higher-function stratum.
    - reference: PMID:35545258
      reference_title: "Multicomponent intervention to prevent mobility disability in frail older adults: randomised controlled trial (SPRINTT project)."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "As a qualitative interaction between SPPB category and intervention arm was found when the cumulative event curves for participants with SPPB scores of 3-7 and a score of 8 or 9 were compared, we analysed those with an SPPB score of 8 or 9 separately."
      explanation: Records the interaction between baseline function and treatment arm.
  target_mechanisms:
  - target: Negative Net Muscle Protein Balance
    description: Restores muscle protein balance by stimulating synthesis.
  - target: Loss of Skeletal Muscle Mass, Strength and Quality
    description: Directly improves the strength, mass, and performance domains.
  evidence:
  - reference: PMID:42304276
    reference_title: "The intervention effects of resistance exercise on sarcopenia in older adults: a systematic review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The pooled mean differences (MD) were 2.95 kg for handgrip strength, 0.15 m/s for gait speed, 0.25 kg/m² for ASMI, and -1.79 s for the five-times sit-to-stand test (all P<0.0001)."
    explanation: Quantifies the pooled effect of resistance exercise across all four outcome domains.
  - reference: PMID:41566419
    reference_title: "Optimizing prescription of resistance training for body composition, muscle strength, and physical performance in older adults with sarcopenia: a systematic review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Clinicians and exercise practitioners should tailor intensity (60-80% 1RM), frequency, and progression to optimize adherence, effectiveness, and long-term functional outcomes in sarcopenia management."
    explanation: Source for the 60-80% 1RM intensity range, from 25 RCTs in sarcopenic older adults.
  - reference: PMID:2342214
    reference_title: "High-intensity strength training in nonagenarians. Effects on skeletal muscle."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We conclude that high-resistance weight training leads to significant gains in muscle strength, size, and functional mobility among frail residents of nursing homes up to 96 years of age."
    explanation: Shows the intervention remains effective in the oldest and frailest stratum.
  - reference: PMID:40028215
    reference_title: "Sex differences in absolute and relative changes in muscle size following resistance training in healthy adults: a systematic review with Bayesian meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Absolute increases in muscle size slightly favoured males compared to females (SMD = 0.19 (95% HDI: 0.11 to 0.28); pd = 100%), however, relative increases in muscle size were similar between sexes (Exp. % Change of lnRR = 0.69% (95% HDI: -1.50% to 2.88%))."
    explanation: >-
      Similar relative hypertrophy in both sexes. Included participants were
      18-45 years old, so this is background for the sex question in older
      adults rather than an effect modifier for this population, and it is not
      recorded under effect_modifiers.
  - reference: PMID:35545258
    reference_title: "Multicomponent intervention to prevent mobility disability in frail older adults: randomised controlled trial (SPRINTT project)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The decline in handgrip strength at 24 months was smaller in women assigned to the multicomponent intervention than those assigned to lifestyle education (0.9 kg, 95% confidence interval 0.1 to 1.6 kg; P=0.028). No significant between group differences were observed in men."
    explanation: >-
      Sex-stratified SPRINTT result: a grip-strength benefit in women and none
      detected in men. Kept out of effect_modifiers because it rests on separate
      within-sex results with no reported sex-by-arm interaction, and because
      the intervention was multicomponent rather than resistance training
      alone. It points the opposite way to the 18-week training trial's male
      advantage; see the sex-difference discussion.
  - reference: PMID:35545258
    reference_title: "Multicomponent intervention to prevent mobility disability in frail older adults: randomised controlled trial (SPRINTT project)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Women in the multicomponent intervention arm lost 0.24 kg and 0.49 kg less appendicular lean mass than controls at 24 months (95% confidence interval 0.10 to 0.39 kg; P<0.001) and 36 months (0.26 to 0.73 kg; P<0.001), respectively."
    explanation: >-
      Lean-mass benefit reported in women in SPRINTT; same caveats as the grip
      result above.
  - reference: PMID:25717010
    reference_title: "There Are No Nonresponders to Resistance-Type Exercise Training in Older Men and Women."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Nonresponsiveness was not apparent in any subject, as a positive adaptive response on at least one training outcome was apparent in every subject."
    explanation: Supports wide inter-individual variation without true nonresponders.
  - reference: PMID:25717010
    reference_title: "There Are No Nonresponders to Resistance-Type Exercise Training in Older Men and Women."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The level of responsiveness was strongly affected by the duration of the exercise intervention, with more positive responses following more prolonged exercise training."
    explanation: Supports programme duration as a modifier of individual response.

- name: Dietary Protein and Leucine Supplementation
  description: >-
    Increased daily protein intake (roughly 1.0-1.2 g/kg/day, higher with
    inflammatory disease) using high-quality leucine-rich protein, aimed at
    overcoming the raised anabolic threshold of ageing muscle. Most effective
    combined with resistance training rather than alone.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: NCIT:C15447
      label: Dietary Intervention
  target_mechanisms:
  - target: Anabolic Resistance
    description: Supplies substrate above the raised anabolic threshold.
  evidence:
  - reference: PMID:40678078
    reference_title: "Molecular constraints of sarcopenia in the ageing muscle."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: OTHER
    snippet: "Compounding this is anabolic resistance, a hallmark of aging muscle, in which higher levels of dietary protein and amino acids are required to stimulate muscle protein synthesis effectively."
    explanation: >-
      Gives the rationale for raising protein intake; it states the requirement
      rather than reporting a supplementation trial outcome, hence INDIRECT.
  notes: >-
    The precise intake targets in the description come from consensus and
    guideline sources not individually cited here. Treat the numbers as guidance
    rather than as a curated, snippet-verified claim.

- name: Vitamin D Repletion
  description: >-
    Correction of vitamin D deficiency, recommended where a deficit is
    documented rather than as universal supplementation. Vitamin D status is one
    of the traits positively associated with the protective allele set in
    sarcopenia GWAS, and repletion is a standard adjunct alongside resistance
    training and protein intake.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: cholecalciferol (vitamin D3)
      term:
        id: CHEBI:28940
        label: calciol
  evidence:
  - reference: PMID:36771461
    reference_title: "Identification and Characterization of Genomic Predictors of Sarcopenia and Sarcopenic Obesity Using UK Biobank Data."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "whereas protective alleles were positively associated with bone mineral density, serum testosterone, IGF1, and 25-hydroxyvitamin D levels, height, intelligence, cognitive performance, educational attainment, income, physical activity, ground coffee drinking"
    explanation: >-
      Genetically protective alleles track higher 25-hydroxyvitamin D, which
      supports vitamin D status as relevant to sarcopenia risk. INDIRECT: this
      is a genetic association, not a supplementation trial.
  notes: >-
    No interventional trial of vitamin D in sarcopenia is cited here. The
    deep-research report describes a 2024 RCT (eldecalcitol, DPVD ancillary
    study) reporting reduced sarcopenia onset in prediabetes, but that paper was
    not fetched or snippet-verified in this session, so the claim is not made.
    This treatment is therefore recorded on mechanism and association grounds
    only and should be strengthened with trial evidence.

- name: Bimagrumab (Anti-Activin Type II Receptor Antibody)
  description: >-
    Investigational human monoclonal antibody blocking the type II activin
    receptors, preventing myostatin and related ligands from restraining muscle
    growth. In a phase-1 study of 24 healthy older and obese volunteers it
    increased thigh muscle volume and lean body mass while reducing fat mass,
    although appendicular lean mass did not reach significance. Critically, the
    same study detected no
    accompanying change in muscle strength — the mass-versus-function dissociation
    that has recurred across the myostatin-pathway programme and is the main reason
    no drug is yet approved for sarcopenia.
  therapeutic_modality: MONOCLONAL_ANTIBODY
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: bimagrumab
      term:
        id: NCIT:C116852
        label: Bimagrumab
  target_mechanisms:
  - target: Myostatin and Activin Receptor Signalling
    description: Blocks the receptor through which myostatin and activins restrain muscle growth.
  evidence:
  - reference: PMID:33264516
    reference_title: "Safety and pharmacokinetics of bimagrumab in healthy older and obese adults with body composition changes in the older cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A single dose of bimagrumab rapidly increased TMV and LBM and decreased body adiposity in older adults."
    explanation: Supports the muscle mass and body composition effect in the target population.
  - reference: PMID:33264516
    reference_title: "Safety and pharmacokinetics of bimagrumab in healthy older and obese adults with body composition changes in the older cohort."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "No change in muscle strength was detected in either bimagrumab group over the study period"
    explanation: >-
      Refutes the claim that the added mass translates into strength. Recorded as
      a separate REFUTE item rather than folded into the SUPPORT item above,
      because the same study cuts both ways on different parts of the claim.
  - reference: PMID:33264516
    reference_title: "Safety and pharmacokinetics of bimagrumab in healthy older and obese adults with body composition changes in the older cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Bimagrumab was safe and well tolerated and demonstrated similar PK in older and obese adults."
    explanation: Supports the tolerability statement for this investigational agent.
  - reference: PMID:41248895
    reference_title: "Bimagrumab: Novel Medical Therapy for Inclusion Body Myositis, Sarcopenia, and Medication-Induced Lean Body Mass Loss."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "It has improved muscle mass in patients with sarcopenia and posthip fracture recovery, while only showing minimal improvements in mobility and strength."
    explanation: >-
      A second, independent source for the mass-versus-function dissociation,
      and one that extends it beyond the phase-1 study to sarcopenia patients and
      post-hip-fracture recovery. Recorded as SUPPORT for the dissociation claim
      the description makes; the REFUTE item above carries the strength null from
      the primary trial.
  - reference: PMID:33074327
    reference_title: "Bimagrumab vs Optimized Standard of Care for Treatment of Sarcopenia in Community-Dwelling Older Adults: A Randomized Clinical Trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Bimagrumab was safe and well-tolerated and increased lean body mass by 7%"
    explanation: >-
      The mass effect measured in the population that matters - community-dwelling
      adults 70 and over meeting gait-speed and muscle criteria for sarcopenia -
      rather than in the healthy and obese volunteers of the phase 1 study.
  - reference: PMID:33074327
    reference_title: "Bimagrumab vs Optimized Standard of Care for Treatment of Sarcopenia in Community-Dwelling Older Adults: A Randomized Clinical Trial."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "This randomized clinical trial found no significant difference between participants treated with bimagrumab vs placebo among older adults with sarcopenia"
    explanation: >-
      The definitive negative result for this drug in this disease: a 6-month
      randomised trial whose primary endpoint was physical function, in which the
      7% lean-mass gain above did not produce a functional difference. This is
      the strongest single piece of evidence in the entry for the
      mass-versus-function dissociation, and it supersedes the phase 1 strength
      null as the reason no myostatin-pathway drug is approved.
  - reference: PMID:28653345
    reference_title: "Treatment of Sarcopenia with Bimagrumab: Results from a Phase II, Randomized, Controlled, Proof-of-Concept Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Participants with slower walking speed at baseline receiving bimagrumab had clinically meaningful and statistically significantly greater improvements in gait speed (mean 0.15 m/s, P = .009) and 6MWD (mean 82 m, P = .022) than those receiving placebo at Week 16."
    explanation: >-
      The one positive functional result for this drug in this disease, and the
      reason the dissociation recorded above is stated as a pattern rather than
      a law: in the slowest-walking participants of the earlier phase 2 study,
      the mass gain did come with a gait-speed and walking-distance gain. It is
      a subgroup finding in 40 participants, so it is recorded as a qualification
      and not as a refutation of the larger trial's null.

- name: RANK-Ligand Inhibition (Denosumab)
  description: >-
    Investigational repurposing of the anti-osteoporotic RANKL-inhibiting
    antibody denosumab for sarcopenia with underlying osteoporosis
    (osteosarcopenia). RANKL inhibition reduced muscle atrophy in earlier work,
    making it a candidate target. Under active randomised trial; no efficacy
    result in sarcopenia is available yet.
  therapeutic_modality: MONOCLONAL_ANTIBODY
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: denosumab
      term:
        id: NCIT:C61313
        label: Denosumab
  evidence:
  - reference: PMID:40760465
    reference_title: "RANK-ligand inhibition to combat sarcopenia with underlying osteoporosis: a study protocol for a randomized, double-blind, double-dummy, active-controlled trial."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: OTHER
    snippet: "Previous studies showed that nuclear factor-κB ligand (RANKL) inhibition could reduce muscle atrophy and could be a therapeutic target for treating sarcopenia."
    explanation: >-
      States the rationale for the target. Graded OTHER because the citation is
      a trial protocol reporting no results, and INDIRECT because the muscle
      effect is carried from prior studies rather than measured here.
  notes: >-
    Rationale-stage only. The cited document is a protocol; see
    clinical_trials#NCT06643780 for the trial itself.

- name: ClC-1 Chloride Channel Inhibition
  description: >-
    Preclinical strategy that raises muscle fiber excitability by lowering the
    resting chloride conductance, compensating for the reduced postsynaptic NaV1.4
    density rather than trying to restore it. In old rodents it improved
    neuromuscular transmission and muscle function. Distinctive because it targets
    the excitability lesion rather than muscle mass, and so predicts functional
    gain without mass gain — the converse of the myostatin-pathway drugs. No human
    data yet.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  target_mechanisms:
  - target: Neuromuscular Junction Transmission Failure
    description: Restores the safety factor for neuromuscular transmission.
  evidence:
  - reference: PMID:42424105
    reference_title: "Neuromuscular junction failure in sarcopenia is linked to NaV1.4 loss and reversed by ClC-1 inhibition."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "ClC-1 chloride ion channel inhibition enhanced muscle excitability and improved NMJ transmission and muscle function in old rodents."
    explanation: The preclinical result this treatment entry is based on.
  - reference: PMID:42424105
    reference_title: "Neuromuscular junction failure in sarcopenia is linked to NaV1.4 loss and reversed by ClC-1 inhibition."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Together, these findings demonstrate that NMJ transmission deficits are a key, reversible driver of sarcopenia and reveal a novel therapeutic target for addressing muscle weakness in aging."
    explanation: States the therapeutic-target claim underlying this entry.
  notes: >-
    Preclinical only. The compound used is NMD670; no NCIT or CHEBI term for it
    was found, so therapeutic_agent is left unbound rather than bound to a
    broader class that would lose the identity. No clinical trial of ClC-1
    inhibition in sarcopenia was registered as of this entry's creation, so no
    clinical_trials record accompanies it.

- name: Urolithin A (Mitophagy Activator)
  description: >-
    Oral supplementation with urolithin A, a gut-microbial metabolite of dietary
    ellagitannins that activates mitophagy. It is one of the few agents in the
    sarcopenia pipeline with completed randomised trials in older adults, and the
    trials are instructive in opposite directions: a 4-month trial in middle-aged
    adults improved muscle strength but missed its primary endpoint of peak power
    output, and a 4-month trial in adults aged 65-90 improved muscle endurance
    but not its co-primary endpoints of 6-minute walk distance and maximal ATP
    production. Because it is produced from food polyphenols only by some gut
    microbiota, endogenous exposure varies widely between individuals.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Nutritional Supplementation
    term:
      id: NCIT:C15425
      label: Nutritional Supplementation
    therapeutic_agent:
    - preferred_term: urolithin A
      term:
        id: CHEBI:168442
        label: Urolithin A
  target_mechanisms:
  - target: Mitochondrial Dysfunction and Oxidative Stress
    description: Activates mitophagy, clearing damaged mitochondria that ageing muscle fails to turn over.
  evidence:
  - reference: PMID:35584623
    reference_title: "Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The data show significant improvements in muscle strength"
    explanation: The strength result from the randomised middle-aged cohort.
  - reference: PMID:35584623
    reference_title: "Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "do not notice a significant improvement on peak power output (primary endpoint)"
    explanation: >-
      Refutes the broader claim that urolithin A improves muscle function as
      prespecified. Recorded separately from the SUPPORT item because the same
      trial cuts both ways: the secondary strength measure moved and the primary
      endpoint did not.
  - reference: PMID:35050355
    reference_title: "Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults: A Randomized Clinical Trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Urolithin A, compared with placebo, significantly improved muscle endurance"
    explanation: The endurance result in the 65-90 year old cohort, the age range that matters for sarcopenia.
  - reference: PMID:35050355
    reference_title: "Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults: A Randomized Clinical Trial."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "These results showed no significant improvement with urolithin A supplementation compared with placebo."
    explanation: >-
      The null on this trial's primary endpoints (6-minute walk distance and
      maximal ATP production). Paired with the SUPPORT item above so the entry
      does not read as a clean positive trial, which it was not.
  - reference: PMID:32694802
    reference_title: "The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We show that UA has a favourable safety profile (primary outcome)."
    explanation: First-in-human safety result in healthy sedentary elderly individuals, the basis for the later efficacy trials.
  notes: >-
    Two randomised trials, neither of which met its primary endpoint, both of
    which moved a secondary muscle-function measure. That pattern is recorded
    here rather than smoothed over, because it is the same mass-versus-function
    problem this entry's other pipeline treatments run into, reached from the
    opposite direction.

- name: Trigonelline (NAD+ Precursor)
  description: >-
    Naturally occurring alkaloid of coffee beans and fenugreek, also produced by
    the human gut microbiome, that enters the NAD+ pool through the
    Preiss-Handler pathway rather than through GPR109A. Serum trigonelline is
    lower in people with sarcopenia and tracks muscle strength, and dietary
    supplementation improves strength and fatigue resistance in ageing mice. No
    human interventional trial has been reported.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Nutritional Supplementation
    term:
      id: NCIT:C15425
      label: Nutritional Supplementation
    therapeutic_agent:
    - preferred_term: trigonelline
      term:
        id: CHEBI:18123
        label: N-methylnicotinate
  target_mechanisms:
  - target: Mitochondrial Dysfunction and Oxidative Stress
    description: Raises the muscle NAD+ pool that declines with age, restoring mitochondrial respiration and biogenesis.
  evidence:
  - reference: PMID:38504132
    reference_title: "Trigonelline is an NAD(+) precursor that improves muscle function during ageing and is reduced in human sarcopenia."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "In humans, serum trigonelline levels are reduced with sarcopenia and correlate positively with muscle strength and mitochondrial oxidative phosphorylation in skeletal muscle."
    explanation: >-
      The human arm is observational: it establishes that trigonelline status
      tracks sarcopenia and strength, from which a therapeutic effect only
      follows by inference, hence INDIRECT.
  - reference: PMID:38504132
    reference_title: "Trigonelline is an NAD(+) precursor that improves muscle function during ageing and is reduced in human sarcopenia."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Dietary trigonelline supplementation in male mice enhances muscle strength and prevents fatigue during ageing."
    explanation: The interventional result, which is rodent-only and male-only.
  notes: >-
    The mouse supplementation arm was conducted in male mice only; the entry does
    not claim a sex-general effect.

- name: Nicotinamide Riboside (NAD+ Precursor)
  description: >-
    Vitamin B3 form used as an oral NAD+ precursor. Chronic supplementation
    raises NAD+ in middle-aged and older adults and is well tolerated, so target
    engagement in humans is established; muscle benefit is not. Recorded here
    because that dissociation - a boosted NAD+ pool without a demonstrated
    strength gain - is the empirical constraint on the whole NAD+-repletion
    strategy in this disease.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Nutritional Supplementation
    term:
      id: NCIT:C15425
      label: Nutritional Supplementation
    therapeutic_agent:
    - preferred_term: nicotinamide riboside
      term:
        id: CHEBI:15927
        label: N-ribosylnicotinamide
  target_mechanisms:
  - target: Mitochondrial Dysfunction and Oxidative Stress
    description: Supplies precursor to the age-depleted muscle NAD+ pool.
  evidence:
  - reference: PMID:29599478
    reference_title: "Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD(+) in healthy middle-aged and older adults."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "chronic supplementation with the NAD+ precursor vitamin, nicotinamide riboside (NR), is well tolerated and effectively stimulates NAD+ metabolism in healthy middle-aged and older adults"
    explanation: >-
      Establishes tolerability and target engagement in the relevant age group.
      INDIRECT for the treatment claim: the trial measured NAD+ metabolism, not
      muscle strength or mass.
  notes: >-
    PMID:42706321 states that efficacy appears limited, citing trials that found
    limited or no improvement in muscle strength and no benefit on regeneration
    after eccentric injury. Those primary trials were not fetched in this
    session, so the negative result is described here rather than asserted with
    a snippet. The same review records a further complication: an inducible
    muscle-specific Nampt knockout that lowered muscle NAD+ by 85% in adult mice
    produced no deficit in exercise capacity or myofibre size, which questions
    how much of the sarcopenia phenotype low NAD+ actually explains.

- name: Oleuropein (Mitochondrial Calcium Uniporter Activator)
  description: >-
    Olive-derived polyphenol identified in a 5,000-molecule screen as a specific
    activator of the mitochondrial calcium uniporter, acting through MICU1
    binding. It addresses a distinct mitochondrial lesion from the NAD+ agents:
    the regulator MCUR1 is downregulated in ageing human muscle and in
    sarcopenia, which limits the mitochondrial calcium uptake that is
    rate-limiting for mitochondrial activation during contraction. Preclinical
    only for muscle ageing.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Nutritional Supplementation
    term:
      id: NCIT:C15425
      label: Nutritional Supplementation
    therapeutic_agent:
    - preferred_term: oleuropein
      term:
        id: CHEBI:7747
        label: oleuropein
  target_mechanisms:
  - target: Mitochondrial Dysfunction and Oxidative Stress
    description: Restores mitochondrial calcium uptake, the rate-limiting step for mitochondrial activation during contraction.
  evidence:
  - reference: PMID:39603237
    reference_title: "Mitochondrial calcium uptake declines during aging and is directly activated by oleuropein to boost energy metabolism and skeletal muscle performance."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "we discovered a conserved downregulation of mitochondrial calcium uniporter regulator 1 (MCUR1) during skeletal muscle aging that associates with human sarcopenia and impairs mtCa2+ uptake and mitochondrial respiration"
    explanation: >-
      Establishes the target lesion in human sarcopenic muscle, from profiling of
      human muscle biopsies, which is what makes this compound relevant to this
      disease rather than to muscle performance generally.
  - reference: PMID:39603237
    reference_title: "Mitochondrial calcium uptake declines during aging and is directly activated by oleuropein to boost energy metabolism and skeletal muscle performance."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Oleuropein activates mtCa2+ uptake and energy metabolism to enhance endurance and reduce fatigue in young and aged mice but not in muscle-specific MCU knockout (KO) mice."
    explanation: >-
      The interventional result plus its genetic control: the absence of effect
      in MCU knockouts is what establishes that the benefit runs through the
      named target rather than through general polyphenol antioxidant activity.

- name: Partial mTORC1 Inhibition (Rapamycin and Rapalogs)
  description: >-
    Counterintuitive strategy that treats sarcopenia by inhibiting, not
    stimulating, the canonical pro-growth kinase. Its premise is an empirical
    finding rather than a theoretical argument: mTORC1 is hyperactivated in
    sarcopenic muscle, and the chronic activation holds autophagy suppressed. Low
    doses of a rapalog in aged rats increased muscle mass and fiber
    cross-sectional area and reduced the transcriptional signature of
    neuromuscular junction denervation, so the effect reaches the neuromuscular
    arm and not only the myofibre. The dose is what separates this from
    immunosuppression; the immunosuppressive doses used in transplantation are not
    the regimen proposed here.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: sirolimus (rapamycin)
      term:
        id: CHEBI:9168
        label: sirolimus
    - preferred_term: everolimus (RAD001)
      term:
        id: NCIT:C48387
        label: Everolimus
  target_mechanisms:
  - target: Ubiquitin-Proteasome Myofibrillar Proteolysis
    description: Restores autophagic flux that chronic mTORC1 activation suppresses, relieving the proteostatic burden on the myofiber.
  - target: Alpha Motor Neuron Loss and Muscle Fiber Denervation
    description: Reduces expression of denervation-associated genes in aged muscle.
  - target: Type II Myofiber Atrophy and Fiber-Type Shift
    description: Increases fiber cross-sectional area in aged muscle.
  evidence:
  - reference: PMID:31308131
    reference_title: "Partial Inhibition of mTORC1 in Aged Rats Counteracts the Decline in Muscle Mass and Reverses Molecular Signaling Associated with Sarcopenia."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "We found mTORC1 (mammalian target of rapamycin complex 1), a well-established positive modulator of muscle mass, to be surprisingly hyperactivated in sarcopenic muscle."
    explanation: The observation that licenses inhibiting a growth kinase to treat a wasting disease.
  - reference: PMID:31308131
    reference_title: "Partial Inhibition of mTORC1 in Aged Rats Counteracts the Decline in Muscle Mass and Reverses Molecular Signaling Associated with Sarcopenia."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "partial inhibition of the mTORC1 pathway counteracted sarcopenia, as determined by observing an increase in muscle mass and fiber type cross-sectional area in select muscle groups"
    explanation: >-
      The mass result, with the qualification the authors themselves attach to
      it: select muscle groups, not all.
  - reference: PMID:31308131
    reference_title: "Partial Inhibition of mTORC1 in Aged Rats Counteracts the Decline in Muscle Mass and Reverses Molecular Signaling Associated with Sarcopenia."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "gene expression indicators of neuromuscular junction denervation were diminished using a low dose of a"
    explanation: Supports the denervation-arm target mechanism, and the low-dose qualifier this treatment turns on.
  - reference: PMID:29486228
    reference_title: "Long term rapamycin treatment improves mitochondrial DNA quality in aging mice."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: MODEL_ORGANISM
    snippet: "we observed a 57% decrease in deletion frequency, a 2.8-fold decrease in ETC deficient fibers, and a 3.4-fold increase in the number of mice without electron transport chain deficient fibers"
    explanation: >-
      Chronic rapamycin improves mitochondrial DNA quality in aged mouse
      quadriceps. INDIRECT for a sarcopenia treatment claim: the readout is
      mtDNA deletion burden and ETC-deficient fiber counts, not strength or mass.
  notes: >-
    No human trial in sarcopenia. PMID:42706321 notes that low-dose RAD001 trials
    in healthy older adults improved systemic inflammation and immune function
    and reduced infection rates, and argues intermittent low-dose regimens are
    the way around the immunosuppression that higher doses cause in an already
    immunosenescent population. Those trials were not fetched here.

- name: 15-PGDH Inhibition (Gerozyme Inhibition; MF-300)
  description: >-
    Small-molecule inhibition of 15-hydroxyprostaglandin dehydrogenase, the
    enzyme that degrades prostaglandin E2 and whose activity rises with age.
    Inhibiting the degradation rather than administering PGE2 restores PGE2 to
    the concentration found in young muscle, which is why the approach avoids the
    hypotension that exogenous PGE2 risks. It is the most pleiotropic agent in
    this entry and the one whose profile best matches the multifactorial
    aetiology: in aged mice a single target reaches the mitochondrial,
    proteostatic, satellite-cell and neuromuscular arms at once, and it increases
    specific force rather than mass alone. An orally available inhibitor
    (MF-300) has completed phase I.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  target_mechanisms:
  - target: Muscle Satellite Cell Exhaustion
    description: Restored PGE2 signalling increases muscle stem cell function and regenerative capacity.
  - target: Alpha Motor Neuron Loss and Muscle Fiber Denervation
    description: Increases motor neuron viability and promotes motor axon regeneration in chronically denervated aged muscle.
  - target: Neuromuscular Junction Transmission Failure
    description: Restores neuromuscular synapses after acute and chronic denervation.
  - target: Ubiquitin-Proteasome Myofibrillar Proteolysis
    description: Decreases ubiquitin-proteasome pathway activity and TGF-beta signalling while restoring autophagy.
  - target: Mitochondrial Dysfunction and Oxidative Stress
    description: Augments mitochondrial function and biogenesis in aged myofibers.
  - target: Loss of Skeletal Muscle Mass, Strength and Quality
    description: Increases aged muscle mass, strength and exercise performance together.
  evidence:
  - reference: PMID:33303683
    reference_title: "Inhibition of prostaglandin-degrading enzyme 15-PGDH rejuvenates aged muscle mass and strength."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "We identifed increased amounts of 15-hydroxyprostaglandin dehydrogenase (15-PGDH), the prostaglandin E2 (PGE2)-degrading enzyme, as a hallmark of aged tissues, including skeletal muscle."
    explanation: >-
      Establishes the target's age-dependence, which is what makes it a gerozyme
      rather than a general muscle target. Quoted verbatim including the source's
      "identifed" typo.
  - reference: PMID:33303683
    reference_title: "Inhibition of prostaglandin-degrading enzyme 15-PGDH rejuvenates aged muscle mass and strength."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Inhibition of 15-PGDH, by targeted genetic depletion or a small-molecule inhibitor, increased aged muscle mass, strength, and exercise performance."
    explanation: >-
      The efficacy result, with genetic and pharmacological arms agreeing, which
      is what distinguishes on-target effect from compound effect.
  - reference: PMID:33303683
    reference_title: "Inhibition of prostaglandin-degrading enzyme 15-PGDH rejuvenates aged muscle mass and strength."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "which augmented mitochondrial function and autophagy and decreased transforming growth factor"
    explanation: Names the downstream arms this treatment's mitochondrial and proteolytic target mechanisms encode.
  - reference: PMID:37820010
    reference_title: "Regeneration of neuromuscular synapses after acute and chronic denervation by inhibiting the gerozyme 15-prostaglandin dehydrogenase."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "In aged mice with chronic denervation of muscles, treatment with the 15-PGDH inhibitor increased motor neuron viability and restored neuromuscular junctions and function."
    explanation: >-
      The neuromuscular arm in the ageing context specifically, which is the
      evidence behind the denervation and NMJ target mechanisms.
  - reference: PMID:37820010
    reference_title: "Regeneration of neuromuscular synapses after acute and chronic denervation by inhibiting the gerozyme 15-prostaglandin dehydrogenase."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Treating mice with a small-molecule inhibitor of 15-PGDH promoted regeneration of motor axons and formation of neuromuscular synapses leading to an acceleration in recovery of force after an acute nerve crush injury."
    explanation: The acute-denervation arm, establishing that the effect includes motor axon regrowth and not only postsynaptic repair.
  notes: >-
    No published human efficacy data. PMID:42706321 reports that MF-300
    significantly increased strength and specific force after 12 weeks in aged
    mice, that a phase I trial found it safe, and that phase IIb trials are
    planned; the phase I and the aged-mouse dosing study are conference
    abstracts and a company release rather than indexed papers, so they are
    described here and not cited as evidence. No CHEBI or NCIT term for MF-300
    was found, so therapeutic_agent is omitted rather than bound to a broader
    class that would lose the identity.

- name: Myostatin Ligand Neutralization (Landogrozumab, Trevogrumab)
  description: >-
    Monoclonal antibodies that bind and neutralize myostatin itself, rather than
    the receptor bimagrumab blocks. In aged mice the approach raises muscle mass,
    strength and treadmill performance together. In the one phase 2 trial in the
    relevant population - adults 75 and over with recent falls and low strength
    and power - landogrozumab (LY2495655) met its primary endpoint of appendicular
    lean mass by 0.43 kg against placebo, and moved some but not all physical
    performance measures. Injection site reactions were markedly more common than
    with placebo.
  therapeutic_modality: MONOCLONAL_ANTIBODY
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: landogrozumab (LY2495655)
      term:
        id: NCIT:C99640
        label: Landogrozumab
    - preferred_term: trevogrumab (REGN1033)
      term:
        id: NCIT:C152733
        label: Trevogrumab
  target_mechanisms:
  - target: Myostatin and Activin Receptor Signalling
    description: Neutralizes the ligand rather than the receptor, removing myostatin's restraint on muscle growth.
  evidence:
  - reference: PMID:26516121
    reference_title: "Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Our findings show LY treatment increases lean mass and might improve functional measures of muscle power."
    explanation: >-
      The trial's own conclusion. Note the authors' hedge on function ("might")
      against the unhedged claim on mass, which is the pattern this entry records
      across the whole myostatin-pathway programme.
  - reference: PMID:26516121
    reference_title: "Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "No effect was detected for other performance-based measures."
    explanation: >-
      Refutes a general functional-improvement claim: some performance measures
      moved and others did not. Recorded separately from the SUPPORT item because
      the trial supports the mass claim and undercuts the broader function claim.
  - reference: PMID:26457176
    reference_title: "Myostatin blockade with a fully human monoclonal antibody induces muscle hypertrophy and reverses muscle atrophy in young and aged mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "In aged mice, REGN1033 increased muscle mass and strength and improved physical performance during treadmill exercise."
    explanation: >-
      The preclinical aged-animal result for trevogrumab. Worth reading beside
      the human trial above: in mice mass and strength move together, in older
      adults they come apart, and that species gap is the central translational
      problem for this drug class.
  notes: >-
    Trevogrumab has no reported sarcopenia trial; it appears here for the aged
    mouse result and because it is the agent now being tested with semaglutide
    for GLP1RA-associated muscle loss (see the muscle-sparing co-therapy entry).

- name: Selective Androgen Receptor Modulation (Enobosarm, MK-0773)
  description: >-
    Non-steroidal androgen receptor ligands designed to be anabolic in muscle and
    bone while sparing prostate and hair-growth tissue, avoiding the
    supraphysiological testosterone doses that anabolic effect otherwise requires.
    Two phase II trials in the right population reached opposite conclusions about
    function: enobosarm improved both lean body mass and physical function in
    healthy elderly men and postmenopausal women over 12 weeks, whereas MK-0773
    raised lean mass in sarcopenic frail elderly women over 6 months without any
    strength or function gain over placebo.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: enobosarm
      term:
        id: NCIT:C69161
        label: Enobosarm
    - preferred_term: selective androgen receptor modulator
      term:
        id: NCIT:C147920
        label: Selective Androgen Receptor Modulator
  target_mechanisms:
  - target: Declining Anabolic Hormone Signalling
    description: Substitutes for the age-related fall in testosterone by stimulating the androgen receptor selectively in muscle.
  - target: Negative Net Muscle Protein Balance
    description: Androgen receptor stimulation raises muscle protein synthesis.
  evidence:
  - reference: PMID:22031847
    reference_title: "The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "GTx-024 treatment resulted in dose-dependent increases in total lean body mass that were statistically significant"
    explanation: The primary endpoint result for enobosarm.
  - reference: PMID:22031847
    reference_title: "The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "There were also significant improvements in physical function"
    explanation: >-
      The functional result, which is the unusual part: most agents in this class
      move mass without moving function. Note the trial enrolled healthy elderly
      volunteers, not people with diagnosed sarcopenia.
  - reference: PMID:23732550
    reference_title: "A phase IIA randomized, placebo-controlled clinical trial to study the efficacy and safety of the selective androgen receptor modulator (SARM), MK-0773 in female participants with sarcopenia."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "The MK-0773-induced increase in LBM did not translate to improvement in strength or function vs. placebo."
    explanation: >-
      Refutes the claim that a SARM-driven lean-mass gain produces functional
      benefit, in the population that matters - women with diagnosed sarcopenia.
      This is the trial that most directly contradicts the enobosarm functional
      result above, and both are recorded rather than one being preferred.
  - reference: PMID:23732550
    reference_title: "A phase IIA randomized, placebo-controlled clinical trial to study the efficacy and safety of the selective androgen receptor modulator (SARM), MK-0773 in female participants with sarcopenia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A greater number of participants experienced elevated transaminases in the MK-0773 group vs. placebo, which resolved after discontinuation of study therapy."
    explanation: The hepatic safety signal, which is the specific long-term concern this class carries.
  notes: >-
    The two trials differ in population, duration, sex and background therapy, so
    the conflict on function is not necessarily a contradiction. The MK-0773
    trial gave every participant vitamin D and protein supplementation, and its
    authors attribute part of the placebo group's improvement to that, which
    would compress the between-group difference. MK-0773 has no NCIT term that
    resolved here, so the class term is bound alongside enobosarm rather than
    fabricating one.

- name: JAK-STAT Inhibition (Tofacitinib)
  description: >-
    Repurposing of an approved JAK inhibitor to treat weakness as a consequence of
    inflammatory signalling. In a randomised human study, 48 hours of tofacitinib
    before biopsy raised the maximum specific force of individual diaphragm
    myofibers by about 16% against placebo, with the same direction of effect in
    serratus anterior, alongside reduced muscle protein oxidation and reduced
    FoxO-ubiquitin-proteasome signalling. Distinctive in this entry because it
    changes contractile quality over two days, on a timescale that cannot involve
    hypertrophy.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: tofacitinib
      term:
        id: NCIT:C95800
        label: Tofacitinib
  target_mechanisms:
  - target: Chronic Low-Grade Inflammation
    description: Blocks JAK-STAT transduction of the inflammatory signals that drive the atrogene programme.
  - target: Ubiquitin-Proteasome Myofibrillar Proteolysis
    description: Suppresses FoxO-ubiquitin-proteasome signalling and muscle protein oxidation.
  - target: Loss of Skeletal Muscle Mass, Strength and Quality
    description: Raises single-fiber specific force, that is, contractile quality rather than quantity.
  evidence:
  - reference: PMID:39122555
    reference_title: "JAK inhibition with tofacitinib rapidly increases contractile force in human skeletal muscle."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "with a 15.7% greater mean maximum specific force (P = 0.0016)"
    explanation: >-
      The effect size, from patients randomised to tofacitinib or placebo for 48
      hours before biopsy. Graded HUMAN_CLINICAL because the randomisation and
      dosing were in people; the force measurement itself was made on biopsied
      single fibers.
  - reference: PMID:39122555
    reference_title: "JAK inhibition with tofacitinib rapidly increases contractile force in human skeletal muscle."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The increased force was associated with reduced muscle protein oxidation and FoxO-ubiquitination-proteasome signaling, and increased levels of smooth muscle MYLK."
    explanation: The mechanistic correlates behind the inflammation and proteolysis target mechanisms recorded here.
  notes: >-
    Not a sarcopenia trial. Participants were surgical patients, not older adults
    with diagnosed sarcopenia, so this is evidence that JAK inhibition raises
    contractile force in human muscle, not that it treats this disease.
    PMID:42706321 makes the same caveat structurally: it is unclear whether the
    inflammation of sarcopenia resembles that of cancer or the other wasting
    conditions where anti-inflammatory agents have been tried, and the TNF decoy
    etanercept showed no effect on muscle mass in cancer trials.

- name: Apelin Receptor Agonism
  description: >-
    Replacement of an exerkine rather than blockade of a pathological signal.
    Apelin is a peptide released by contracting muscle whose production falls with
    age in both humans and rodents; mice lacking apelin or its receptor develop
    marked age-dependent muscle dysfunction, and restoring apelin signalling in
    aged mice improves muscle function through mitochondrial biogenesis,
    autophagy and anti-inflammatory pathways in myofibers while also acting on
    muscle stem cells. It is one of the mechanisms through which the review's
    vascular axis reaches muscle, since apelin acts on the endothelial APJ
    receptor.
  therapeutic_modality: PEPTIDE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  target_mechanisms:
  - target: Capillary Rarefaction and Impaired Muscle Perfusion
    description: Acts on the endothelial APJ receptor, the angiocrine arm of this treatment's effect.
  - target: Mitochondrial Dysfunction and Oxidative Stress
    description: Triggers mitochondrial biogenesis and autophagy in aged myofibers.
  - target: Muscle Satellite Cell Exhaustion
    description: Enhances regenerative capacity by acting on muscle stem cells.
  - target: Chronic Low-Grade Inflammation
    description: Engages anti-inflammatory pathways in myofibers.
  evidence:
  - reference: PMID:30061698
    reference_title: "The exerkine apelin reverses age-associated sarcopenia."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "production of the endogenous peptide apelin, induced by muscle contraction, is reduced in an age-dependent manner in humans and rodents and is positively associated with the beneficial effects of exercise in older persons"
    explanation: >-
      The human arm, which establishes the deficiency this treatment would
      correct. INDIRECT: an age-dependent decline and an association with
      exercise benefit, not a trial of apelin administration.
  - reference: PMID:30061698
    reference_title: "The exerkine apelin reverses age-associated sarcopenia."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "this peptide considerably enhanced muscle function by triggering mitochondriogenesis, autophagy and anti-inflammatory pathways in myofibers as well as enhancing the regenerative capacity by targeting muscle stem cells"
    explanation: The interventional rodent result, and the source of all four target mechanisms recorded above.
  notes: >-
    therapeutic_agent is omitted deliberately. The cited evidence is for the
    apelin peptide itself, which NCIT codes as a protein (NCIT:C104098) outside
    the pharmacologic-substance branch the schema's ChemicalEntityTerm enum
    draws from, so it cannot be bound in this slot. The clinical-stage agent of
    this class, azelaprag, does have a term (NCIT:C166746), but no evidence here
    is about azelaprag, so binding it would assert more than the citations
    support.
    The one apelin-pathway agent to reach a phase 2 trial, the apelin receptor
    agonist azelaprag combined with tirzepatide, was discontinued in the STRIDES
    trial for liver transaminitis, per PMID:42706321. That is a company
    announcement rather than an indexed paper, so it is described here and not
    cited as evidence. It matters for this entry because it is a safety signal
    against the most advanced clinical form of this strategy, not against the
    mechanism.

- name: VEGF Signalling Restoration
  description: >-
    Preclinical strategy addressing the vascular contribution to muscle ageing
    rather than muscle itself. Age raises production of the soluble VEGF decoy
    receptor sFlt-1, so VEGFA-driven capillary sprouting becomes insufficient; in
    mice, low-dose VEGFA overexpression counteracts this, prevents capillary
    loss, improves perfusion, and ameliorates sarcopenia among several other
    ageing pathologies while extending life span. No human muscle data.
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  target_mechanisms:
  - target: Capillary Rarefaction and Impaired Muscle Perfusion
    description: Restores the VEGFA signalling that age-related sFlt-1 production renders insufficient.
  evidence:
  - reference: PMID:34326210
    reference_title: "Counteracting age-related VEGF signaling insufficiency promotes healthy aging and extends life span."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Increasing VEGF signaling prevented age-associated capillary loss, improved organ perfusion and function, and extended life span."
    explanation: The mechanism this treatment asserts, measured in aged mice.
  - reference: PMID:34326210
    reference_title: "Counteracting age-related VEGF signaling insufficiency promotes healthy aging and extends life span."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "amelioration of aging-associated pathologies including hepatic steatosis, sarcopenia, osteoporosis"
    explanation: >-
      Names sarcopenia specifically among the conditions improved, which is what
      makes this a candidate treatment for this entry rather than a general
      longevity result.
  notes: >-
    The intervention was genetic overexpression in mice, not a deliverable drug,
    so therapeutic_modality is OTHER rather than GENE_THERAPY: no vector-based
    therapeutic was tested. No therapeutic_agent is bound, because the NCIT VEGF
    terms name the protein or the receptor complex rather than an agent, and
    binding one would assert a specific therapeutic that does not exist.

- name: Nicotinamide plus Pyridoxine (Muscle Stem Cell Nutrition)
  description: >-
    Combination of two vitamins identified in a high-content imaging screen of
    food-derived molecules against human myogenic progenitors, so the target here
    is the muscle stem cell rather than the myofiber. The two synergize through
    CK1-mediated cytoplasmic beta-catenin activation and AKT signalling. Both
    decline with age and their levels associate with muscle mass and walking speed
    in older people; oral treatment accelerated regeneration and overcame
    age-related regenerative failure in mice. Both have a long history of safe
    human use, which is the practical argument for this combination over a novel
    chemical entity.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Nutritional Supplementation
    term:
      id: NCIT:C15425
      label: Nutritional Supplementation
    therapeutic_agent:
    - preferred_term: nicotinamide
      term:
        id: CHEBI:17154
        label: nicotinamide
    - preferred_term: pyridoxine (vitamin B6)
      term:
        id: CHEBI:16709
        label: pyridoxine
  target_mechanisms:
  - target: Muscle Satellite Cell Exhaustion
    description: Stimulates muscle stem cell amplification and differentiation, overcoming the regenerative failure of ageing.
  evidence:
  - reference: PMID:39531334
    reference_title: "Nicotinamide and pyridoxine stimulate muscle stem cell expansion and enhance regenerative capacity during aging."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Oral treatment with a combination of NAM and PN accelerated muscle regeneration in vivo by stimulating MuSCs, increased muscle strength during recovery, and overcame MuSC dysfunction and regenerative failure during aging."
    explanation: The interventional result, including the ageing arm that makes it relevant to this disease rather than to injury repair generally.
  - reference: PMID:39531334
    reference_title: "Nicotinamide and pyridoxine stimulate muscle stem cell expansion and enhance regenerative capacity during aging."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "Levels of NAM and bioactive PN spontaneously declined during aging in model organisms and interindependently associated with muscle mass and walking speed in a cohort of 186 aged people."
    explanation: >-
      The human observational arm establishing the deficiency. INDIRECT: an
      association in a cohort of 186, not a supplementation trial.
  notes: >-
    PMID:42706321 reports a randomised trial of NAM/PN after eccentric
    contraction injury in young volunteers that increased muscle stem cell
    numbers and de novo myofiber formation. That report is a medRxiv preprint
    and was not fetched here, so the human interventional result is not claimed.

- name: BIO101 (20-Hydroxyecdysone)
  description: >-
    Pharmaceutical-grade plant ecdysteroid that activates the MAS receptor, the
    protective arm of the renin-angiotensin-aldosterone system, and thereby
    AKT/mTOR-driven protein synthesis. In 22-month-old mice a 14-week oral course
    produced anabolic effects with improved running capacity and velocity;
    in vitro it also drives myoblast differentiation, and both effects are
    abolished by the MAS antagonist A779, which is what pins the mechanism to
    that receptor.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: 20-hydroxyecdysone
      term:
        id: CHEBI:16587
        label: 20-hydroxyecdysone
  target_mechanisms:
  - target: Anabolic Resistance
    description: Raises AKT/mTOR-driven protein synthesis through MAS receptor activation.
  - target: Muscle Satellite Cell Exhaustion
    description: Promotes myoblast differentiation and fusion.
  evidence:
  - reference: PMID:38064183
    reference_title: "BIO101 stimulates myoblast differentiation and improves muscle function in adult and old mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Chronic BIO101 oral treatment induced AKT/mTOR activation and anabolic effects accompanied with improved physical performances in adult and old animals"
    explanation: The in vivo result in adult and 22-month-old mice, covering both the signalling and the performance claims.
  notes: >-
    The differentiation and MAS-dependence results come from C2C12 myoblasts and
    would be graded IN_VITRO; only the in vivo arm is cited here, so the entry
    does not rest a claim about animals on a cell-line result.

- name: Angiotensin II Type 1 Receptor Blockade (Losartan)
  description: >-
    Repurposing of a common antihypertensive, on the argument that AT1 receptor
    blockade lowers TGF-beta signalling and raises IGF1/AKT/mTOR signalling in
    muscle. In sarcopenic mice losartan reduced fibrosis after injury and
    protected against disuse atrophy during hindlimb immobilization - and
    notably, the protection against disuse ran through IGF1/AKT/mTOR rather than
    through the TGF-beta pathway the strategy was designed around. In older men
    the acute human study was essentially null: no effect on satellite cell
    number or myogenic pathways after a single bout of heavy resistance exercise,
    with greater suppression of myostatin mRNA as the one positive signal.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: losartan
      term:
        id: CHEBI:6541
        label: losartan
  target_mechanisms:
  - target: Myosteatosis and Intramuscular Fibro-Adipogenic Infiltration
    description: Reduces fibrotic remodelling after injury by blunting canonical and non-canonical TGF-beta signalling.
  - target: Anabolic Resistance
    description: Raises IGF1/AKT/mTOR signalling, the route by which it protected against disuse atrophy.
  evidence:
  - reference: PMID:21562229
    reference_title: "Losartan restores skeletal muscle remodeling and protects against disuse atrophy in sarcopenia."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "We showed that immobilized mice treated with losartan were protected against loss of muscle mass."
    explanation: The disuse-atrophy result in aged mice, which is the strongest preclinical claim for this repurposing.
  - reference: PMID:29040223
    reference_title: "Effect of Losartan on the Acute Response of Human Elderly Skeletal Muscle to Exercise."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "In general, there does not seem to be any effect of AT1R blocking on satellite cell number or myogenic pathways in elderly men in the days after one bout of heavy-resistance exercise."
    explanation: >-
      Refutes translation of the rodent myogenic effect to older men, in the
      acute setting the trial tested. Recorded as REFUTE rather than omitted
      because it is the only human evidence for this strategy in this entry.
  - reference: PMID:29040223
    reference_title: "Effect of Losartan on the Acute Response of Human Elderly Skeletal Muscle to Exercise."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "losartan intake resulted in a greater suppression of myostatin messenger RNA"
    explanation: >-
      The one positive human signal, and the authors' own basis for suggesting
      long-term hypertrophic potential. INDIRECT: a transcript-level change, not
      a mass or strength outcome.
  notes: >-
    PMID:42706321 records that early observational work linked ACE-inhibitor use
    to better physical function in older women, but that recent meta-analyses
    have not confirmed muscle benefit for this drug class. Those sources were not
    fetched here. On present evidence this is a repurposing hypothesis with a
    null acute human study against it, not a candidate therapy.

- name: Muscle-Sparing Co-therapy During GLP1 Receptor Agonist Weight Loss
  description: >-
    A preventative rather than a treatment for established sarcopenia. GLP1
    receptor agonists produce large weight loss of which a substantial fraction
    is lean mass, and after the drug is stopped fat returns and muscle does not -
    so widespread incretin use is creating a new, iatrogenic route into
    sarcopenia in older people. Two co-therapy strategies have preclinical
    support: blocking the activin type II receptors or their ligands GDF8 and
    activin A alongside the incretin, which preserves or increases lean mass in
    obese mice and non-human primates while improving fat loss; and inhibiting
    15-PGDH, which restores post-injury myofiber growth and force in
    semaglutide-treated obese mice without compromising weight loss.
  therapeutic_modality: MONOCLONAL_ANTIBODY
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: bimagrumab
      term:
        id: NCIT:C116852
        label: Bimagrumab
    - preferred_term: trevogrumab
      term:
        id: NCIT:C152733
        label: Trevogrumab
    - preferred_term: garetosmab
      term:
        id: NCIT:C170022
        label: Garetosmab
    - preferred_term: semaglutide
      term:
        id: NCIT:C152328
        label: Semaglutide
  target_mechanisms:
  - target: Myostatin and Activin Receptor Signalling
    description: ActRII or dual GDF8/activin A blockade removes the growth restraint that caloric deficit otherwise leaves unopposed.
  - target: Muscle Satellite Cell Exhaustion
    description: The 15-PGDH arm restores muscle stem cell function and myofiber growth during incretin-induced weight loss.
  - target: Loss of Skeletal Muscle Mass, Strength and Quality
    description: Preserves lean mass and contractile force during pharmacologically induced weight loss.
  evidence:
  - reference: PMID:38218536
    reference_title: "Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Combination treatment with bimagrumab and semaglutide led to superior fat mass loss while simultaneously preserving lean mass despite reduced food intake."
    explanation: The receptor-blockade arm, in diet-induced obese mice.
  - reference: PMID:40360507
    reference_title: "GDF8 and activin A blockade protects against GLP-1-induced muscle loss while enhancing fat loss in obese male mice and non-human primates."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "we report that dual blockade can also prevent muscle loss associated with glucagon-like peptide-1 receptor agonists - and even increase muscle mass - in both obese mice and non-human primates"
    explanation: >-
      The ligand-blockade arm, extended to non-human primates, which is the
      closest preclinical evidence to the human trials now running.
  - reference: PMID:42228536
    reference_title: "15-PGDH inhibition promotes muscle repair and strength recovery during GLP-1 receptor agonist-induced weight loss."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "In a high fat diet-induced mouse model of obesity, semaglutide alone caused significant loss of muscle mass, while preserving contractile function."
    explanation: >-
      Establishes the harm this co-therapy is meant to prevent, and states the
      nuance: the mass loss came without a contractile-function loss in this
      model, so the risk is to reserve rather than to immediate strength.
  - reference: PMID:42228536
    reference_title: "15-PGDH inhibition promotes muscle repair and strength recovery during GLP-1 receptor agonist-induced weight loss."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "PGDHi synergizes with semaglutide to boost postinjury muscle quality and muscle force without compromising weight loss."
    explanation: The 15-PGDH co-therapy arm, and the point that the muscle benefit does not come at the cost of the weight loss.
  notes: >-
    All the evidence here is preclinical. PMID:42706321 reports human phase II
    data - bimagrumab increasing weight loss while protecting lean mass in adults
    with obesity, and interim COURAGE results for trevogrumab plus garetosmab
    with semaglutide - but those are conference and company communications rather
    than indexed papers, so they are described and not cited. Whether preserved
    mass translates into preserved strength is explicitly open, which is the same
    question the myostatin-pathway entries in this file raise.
    therapeutic_modality is MONOCLONAL_ANTIBODY because the antibody arms
    dominate the entry; the 15-PGDH arm is a small molecule, and the slot is
    single-valued.

definitions:
- name: EWGSOP2 sarcopenia case definition
  definition_type: DIAGNOSTIC_CRITERIA
  derivation_basis: ESTABLISHED_CRITERIA
  description: >-
    The dominant European clinical algorithm. Case-find (SARC-F or clinical
    suspicion), then assess muscle strength — low strength alone establishes
    "probable sarcopenia" and is sufficient to start treatment. Confirm with low
    muscle quantity or quality (DXA, BIA, CT, or MRI). Grade severity by physical
    performance (gait speed, SPPB, TUG, 400 m walk); poor performance defines
    severe sarcopenia.
  evidence:
  - reference: PMID:30312372
    reference_title: "Sarcopenia: revised European consensus on definition and diagnosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "focuses on low muscle strength as a key characteristic of sarcopenia, uses detection of low muscle quantity and quality to confirm the sarcopenia diagnosis, and identifies poor physical performance as indicative of severe sarcopenia"
    explanation: The consensus statement of the three-tier algorithm described here.
- name: AWGS 2019 sarcopenia case definition
  definition_type: DIAGNOSTIC_CRITERIA
  derivation_basis: ESTABLISHED_CRITERIA
  description: >-
    The Asian consensus, with population-specific cut-offs and separate community
    and hospital algorithms. Notably introduces "possible sarcopenia" — low
    strength or low physical performance alone — explicitly to enable lifestyle
    intervention in primary care before a confirmatory mass measurement is
    available.
  evidence:
  - reference: PMID:32033882
    reference_title: "Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "AWGS 2019 also introduces \"possible sarcopenia,\" defined by either low muscle strength or low physical performance only, specifically for use in primary health care or community-based health promotion, to enable earlier lifestyle interventions."
    explanation: States the "possible sarcopenia" category and its intended use.

animal_models:
- name: Naturally aged C57BL/6 mouse (28 months)
  species: Mouse
  genotype: Wild-type C57BL/6, aged to 28 months
  publication: PMID:33580198
  description: >-
    Chronological-ageing model with a time course of phenotypic and
    transcriptomic measurements in gastrocnemius muscle, analysed alongside
    matched rat and human data. Its value is the cross-species comparison: it
    identifies which arms of human sarcopenia rodents actually reproduce.
  evidence:
  - reference: PMID:33580198
    reference_title: "Molecular and phenotypic analysis of rodent models reveals conserved and species-specific modulators of human sarcopenia."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Here we generated a time series of phenotypic measurements and RNA sequencing data in mouse gastrocnemius muscle and analyzed them alongside analogous data from rats and humans."
    explanation: Describes the model and the cross-species design that makes it informative for human sarcopenia.
  modeled_mechanisms:
  - target: Loss of Skeletal Muscle Mass, Strength and Quality
    relationship: RECAPITULATES
    fidelity: MODERATE
    description: >-
      Aged mice lose muscle mass and grip strength together, reproducing the
      defining human combination rather than mass loss alone.
    limitations: >-
      Chronological age is a poor proxy for sarcopenia status even within the
      model; the authors argue muscle mass is the better indicator. Mouse
      lifespan compresses decades of human exposure, and laboratory mice lack
      the comorbidity burden that drives most human secondary sarcopenia.
    readouts:
    - name: All-limb grip strength
      target: Loss of Skeletal Muscle Mass, Strength and Quality
      direction: DECREASED
      interpretation: Functional correlate of the strength domain of the human triad.
      evidence:
      - reference: PMID:33580198
        reference_title: "Molecular and phenotypic analysis of rodent models reveals conserved and species-specific modulators of human sarcopenia."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "All-limb grip strength decreased in parallel with muscle mass, reaching a 34.2 ± 3.4% loss in 28 months-old mice compared to 8–18 months-old mice"
        explanation: Reports the measured grip-strength decrement in this model.
    evidence:
    - reference: PMID:33580198
      reference_title: "Molecular and phenotypic analysis of rodent models reveals conserved and species-specific modulators of human sarcopenia."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Our study demonstrates that phenotypic measurements, such as muscle mass, are better indicators of muscle health than chronological age and should be considered when analyzing aging-related molecular data."
      explanation: >-
        Attests what makes this model informative for the mass/strength node
        specifically: its muscle-phenotype measurements, rather than the animals'
        chronological age, are what track muscle health.
  - target: Mitochondrial Dysfunction and Oxidative Stress
    relationship: RECAPITULATES
    fidelity: MODERATE
    description: >-
      Transcriptomic comparison shows the mitochondrial arm of human sarcopenia
      is reproduced in rodents.
    limitations: >-
      Inflammatory changes are conserved only at pathway level, not gene level,
      so this model is a poor vehicle for the inflammaging arm specifically.
    evidence:
    - reference: PMID:33580198
      reference_title: "Molecular and phenotypic analysis of rodent models reveals conserved and species-specific modulators of human sarcopenia."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "We found that rodents recapitulate mitochondrial changes observed in human sarcopenia, while inflammatory responses are conserved at pathway but not gene level."
      explanation: >-
        States directly that the mitochondrial changes of human sarcopenia are
        reproduced in rodents, which is the claim this link makes; the same
        sentence carries the inflammatory-arm limitation recorded above.
    readouts:
    - name: Muscle transcriptome mitochondrial gene signature
      target: Mitochondrial Dysfunction and Oxidative Stress
      direction: ALTERED
      interpretation: Cross-species conserved transcriptomic correlate of the mitochondrial node.
      evidence:
      - reference: PMID:33580198
        reference_title: "Molecular and phenotypic analysis of rodent models reveals conserved and species-specific modulators of human sarcopenia."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "We found that rodents recapitulate mitochondrial changes observed in human sarcopenia, while inflammatory responses are conserved at pathway but not gene level."
        explanation: Establishes both the conserved mitochondrial signature and the limitation noted above.

- name: Naturally occurring sarcopenia in aged companion dogs and cats
  species: Dog
  genotype: Outbred companion animals, no genetic modification
  publication: PMID:22111652
  description: >-
    Spontaneous, naturally occurring age-related loss of lean body mass in pet
    dogs and cats. Its value is that it is not an induced model: the animals age
    in a shared human environment, over a lifespan long enough for the process to
    develop, and the veterinary literature separates it from disease-driven
    cachexia in the same species. That separation is the useful part — it is the
    same primary-versus-secondary distinction this entry draws, made
    independently in another species.
  notes: >-
    Recorded under `species: Dog` because the slot is single-valued; the cited
    source covers dogs and cats together and the claim is not dog-specific.
  evidence:
  - reference: PMID:22111652
    reference_title: "Cachexia and sarcopenia: emerging syndromes of importance in dogs and cats."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "As many of the diseases associated with muscle loss are more common in aging, cachexia and sarcopenia often are concurrent problems."
    explanation: >-
      Establishes the model population and its principal confound: in aged
      companion animals the age-related and disease-driven forms co-occur, so
      individual animals are not cleanly one or the other. This is a different
      claim from the link-level evidence, which is about what the model is
      informative for.
  modeled_mechanisms:
  - target: Loss of Skeletal Muscle Mass, Strength and Quality
    relationship: PARTIALLY_RECAPITULATES
    fidelity: LOW
    description: >-
      Reproduces age-related lean body mass loss arising without an underlying
      disease, in a long-lived outbred species sharing the human environment.
    limitations: >-
      The cited source is a veterinary review reporting lean body mass, not the
      strength and physical-performance measures that define human sarcopenia
      under EWGSOP2, so only the mass component of the target node is supported.
      No fibre-type, motor-unit, or neuromuscular-junction data are cited, and
      the review's principal subject is cachexia rather than sarcopenia. Graded
      LOW fidelity and PARTIALLY_RECAPITULATES for those reasons.
    evidence:
    - reference: PMID:22111652
      reference_title: "Cachexia and sarcopenia: emerging syndromes of importance in dogs and cats."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Sarcopenia, the loss of LBM that occurs with aging, is a related syndrome, although sarcopenia occurs in the absence of disease."
      explanation: >-
        Supports the link claim directly: what this model carries is age-related,
        disease-independent lean-mass loss, which is what makes it informative for
        the primary form of the target node rather than for secondary sarcopenia.

- name: Aged rat neuromuscular transmission model
  species: Rat
  genotype: Wild-type, aged
  publication: PMID:42424105
  description: >-
    Aged rats used to localise the sarcopenic transmission defect and to test
    both a sufficiency manipulation (acute NaV1.4 blockade in young adults) and a
    rescue (ClC-1 inhibition in old animals).
  evidence:
  - reference: PMID:42424105
    reference_title: "Neuromuscular junction failure in sarcopenia is linked to NaV1.4 loss and reversed by ClC-1 inhibition."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Acute NaV1.4 inhibition with μ-conotoxin GIIIB in adult rats reproduced findings of NMJ transmission failure observed in aged rodents and humans."
    explanation: Establishes the rat preparation as reproducing the human transmission phenotype under a defined manipulation.
  modeled_mechanisms:
  - target: Neuromuscular Junction Transmission Failure
    relationship: RECAPITULATES
    fidelity: HIGH
    description: >-
      Reproduces the human finding of NMJ transmission failure and adds the
      electrophysiological localisation to post-synaptic fiber excitability that
      human studies could not provide.
    limitations: >-
      The human arm establishes correlation with weakness severity but not the
      rescue; the ClC-1 benefit is rodent-only, so translation of the therapeutic
      claim is untested.
    readouts:
    - name: Neuromuscular junction transmission safety factor
      target: Neuromuscular Junction Transmission Failure
      direction: RESTORED
      interpretation: >-
        ClC-1 inhibition reverses the transmission deficit, supporting the
        excitability mechanism rather than fiber loss as its cause.
      evidence:
      - reference: PMID:42424105
        reference_title: "Neuromuscular junction failure in sarcopenia is linked to NaV1.4 loss and reversed by ClC-1 inhibition."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "ClC-1 chloride ion channel inhibition enhanced muscle excitability and improved NMJ transmission and muscle function in old rodents."
        explanation: The rescue result this readout records.
    evidence:
    - reference: PMID:42424105
      reference_title: "Neuromuscular junction failure in sarcopenia is linked to NaV1.4 loss and reversed by ClC-1 inhibition."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Preclinical experiments showed similar NMJ transmission failure in aged rodents that was associated with localized loss of muscle fiber excitability at the NMJ."
      explanation: Supports treating the aged rodent as informative for the human transmission node.

computational_models:
- name: Multiscale kinetic model of leucine-stimulated muscle protein metabolism
  description: >-
    A mechanistic kinetic model linking leucine ingestion and absorption,
    insulin secretion, intracellular mTORC1-p70S6K signalling, and muscle
    protein synthesis and breakdown in human skeletal muscle. It was extended to
    represent anabolic resistance: the ageing-related impairments were
    parameterised individually and in combination, and a virtual population was
    classified as anabolic-sensitive or anabolic-resistant. The model was then
    used to simulate single-target and multi-target interventions.
  model_type: KINETIC
  model_software: MATLAB
  repository_url: https://doi.org/10.5281/zenodo.19413844
  publication: PMID:42464764
  notes: >-
    The stimulus represented is protein feeding. Resistance exercise and
    mechanical loading are not in the model, so it says nothing directly about
    the Blunted Load-Induced mTORC1 Signalling node; the authors note that
    exercise enhances muscle sensitivity to protein feeding, which is the
    interaction a loading extension would need to capture.
  modeled_mechanisms:
  - target: Anabolic Resistance
    relationship: RECAPITULATES
    fidelity: MODERATE
    model_scale: CELLULAR
    description: >-
      Reproduces the reduced protein-synthetic response to feeding in older
      adults, and only when several impairments are combined.
    limitations: >-
      Calibrated against two small human feeding studies, developed from male
      data only, feeding-only, and focused on protein turnover rather than
      strength or function.
    divergences:
    - divergence_type: BOUNDARY_OMISSION
      materiality: QUALIFYING
      description: >-
        Mechanical loading and the exercise arm of anabolic resistance are
        outside the model boundary; only the leucine-feeding stimulus is
        represented.
    - divergence_type: POPULATION_MISMATCH
      materiality: QUALIFYING
      description: >-
        Parameters come from studies in men. Sex differences in ageing-related
        protein metabolism are reported in some studies but not others, so the
        results may not transfer to older women, who are the majority of
        sarcopenia trial participants.
    - divergence_type: CALIBRATION_PROVENANCE
      materiality: QUALIFYING
      description: >-
        The anabolic-resistant phenotype was evaluated against two small cohort
        studies, so the size of each simulated impairment is weakly constrained
        given how variable anabolic resistance is between individuals.
    evidence:
    - reference: PMID:42464764
      reference_title: "Multifactorial nature of anabolic resistance in ageing skeletal muscle: A systems modelling study."
      supports: SUPPORT
      evidence_source: COMPUTATIONAL
      snippet: "Virtual population simulations of MPS responses to amino acid feeding were classified as anabolic sensitive or anabolic resistant."
      explanation: Establishes that the model represents the anabolic-resistant phenotype this node describes.
    - reference: PMID:42464764
      reference_title: "Multifactorial nature of anabolic resistance in ageing skeletal muscle: A systems modelling study."
      supports: SUPPORT
      evidence_source: COMPUTATIONAL
      snippet: "Second, the model was developed using data from males."
      explanation: Source for the population-mismatch divergence.
  findings:
  - statement: >-
      No single age-related impairment reproduced the reduced protein synthesis
      of older adults; the anabolic-resistant phenotype appeared only when
      several impairments acted together.
    evidence:
    - reference: PMID:42464764
      reference_title: "Multifactorial nature of anabolic resistance in ageing skeletal muscle: A systems modelling study."
      supports: SUPPORT
      evidence_source: COMPUTATIONAL
      snippet: "No single dysregulated mechanism reproduced age-related reductions in MPS."
      explanation: States the single-mechanism negative result.
  - statement: >-
      Restoring protein synthesis when all impairments were present required
      coordinated multi-target interventions; single targets proximal to
      mTORC1 were sufficient only against isolated impairments.
    evidence:
    - reference: PMID:42464764
      reference_title: "Multifactorial nature of anabolic resistance in ageing skeletal muscle: A systems modelling study."
      supports: SUPPORT
      evidence_source: COMPUTATIONAL
      snippet: "Restoring MPS from multifactorial dysregulation required co-ordinated, multitarget therapeutic strategies."
      explanation: States the intervention-simulation result.
  evidence:
  - reference: PMID:42464764
    reference_title: "Multifactorial nature of anabolic resistance in ageing skeletal muscle: A systems modelling study."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "Here, we applied a mechanistic, multiscale kinetic model of leucine-mediated signalling and protein metabolism in human skeletal muscle to study anabolic resistance mechanisms."
    explanation: Identifies the model type and scope.

datasets:
- accession: geo:GSE303899
  title: "Unraveling the Epigenetic Landscape of Sarcopenic Obesity: Insights into DNA Methylation Mechanisms from a Pilot Study in Older Women"
  description: >-
    DNA methylation profiling in sarcopenic obesity, the only human dataset among
    the candidates surfaced for this entry. Relevant to has_subtypes#Sarcopenic
    obesity and to the epigenetic component of the ageing muscle phenotype.
  data_type: METHYLATION
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  sample_count: 32
  publication: PMID:41578880
  notes: >-
    Selected by manual relevance triage from `just discover-datasets Sarcopenia`
    and accession-verified with `just verify-datasets`. No evidence block: an
    evidence item needs an exact quote from the cited abstract supporting a
    specific claim, and this record asserts only that the dataset exists and is
    on topic.
- accession: geo:GSE316316
  title: Association between elevated expression of GDF15/GFRAL and sarcopenia risk
  description: >-
    Single-cell RNA-seq addressing GDF-15/GFRAL signalling, one of the leading
    candidate circulating biomarkers of sarcopenia and a readout of the
    mitochondrial-stress arm modelled in pathophysiology#Mitochondrial
    Dysfunction and Oxidative Stress.
  data_type: SINGLE_CELL_RNA_SEQ
  organism:
    preferred_term: mouse
    term:
      id: NCBITaxon:10090
      label: Mus musculus
  sample_count: 5
  publication: PMID:41797911
  notes: >-
    Mouse data; small n. Selected by manual relevance triage and
    accession-verified. No evidence block, as above.
- accession: geo:GSE281658
  title: IGF2 deficiency induces sarcopenia and muscle functional decline
  description: >-
    Single-cell RNA-seq of an IGF2-deficiency model producing sarcopenia and
    functional decline, bearing on pathophysiology#Declining Anabolic Hormone
    Signalling.
  data_type: SINGLE_CELL_RNA_SEQ
  organism:
    preferred_term: mouse
    term:
      id: NCBITaxon:10090
      label: Mus musculus
  sample_count: 6
  notes: >-
    Mouse data, no linked publication in the GEO record. Selected by manual
    relevance triage and accession-verified. No evidence block, as above.
- accession: geo:GSE318551
  title: >-
    TRalpha Deficiency Drives Sarcopenia by Disrupting Perimitochondrial
    Targeting of Pink1 mRNA and Mitophagy
  description: >-
    Spatial transcriptomics linking thyroid hormone receptor alpha deficiency to
    sarcopenia through PINK1-dependent mitophagy, bearing directly on the
    defective-mitophagy component of pathophysiology#Mitochondrial Dysfunction
    and Oxidative Stress.
  data_type: SPATIAL_TRANSCRIPTOMICS
  organism:
    preferred_term: mouse
    term:
      id: NCBITaxon:10090
      label: Mus musculus
  sample_count: 6
  notes: >-
    Mouse data, no linked publication in the GEO record. Selected by manual
    relevance triage and accession-verified. No evidence block, as above.
- accession: geo:GSE296198
  title: Chronic circadian misalignment accelerates sarcopenia progression in mice
  description: >-
    Bulk RNA-seq testing circadian misalignment as an accelerant of sarcopenia
    progression; the largest of the candidate mouse datasets.
  data_type: BULK_RNA_SEQ
  organism:
    preferred_term: mouse
    term:
      id: NCBITaxon:10090
      label: Mus musculus
  sample_count: 30
  publication: PMID:41321491
  notes: >-
    Mouse data. Selected by manual relevance triage and accession-verified.
    Candidates rejected in triage: geo:GSE279051 (cortical bone metabolism, not
    muscle), geo:GSE276208 (sarcopenia as the exposure driving tumorigenesis,
    not the subject), and geo:GSE304351 / geo:GSE304464 / geo:GSE315575, which
    name sarcopenia only in the summary and study muscle atrophy or lifespan
    more broadly. No evidence block, as above.

biochemical:
- name: Interleukin-6
  notes: >-
    Circulating IL-6 is a core inflammaging mediator and one of the most
    consistently nominated candidate biomarkers of sarcopenia. It reports on
    pathophysiology#Chronic Low-Grade Inflammation rather than on muscle mass
    directly.
  biomarker_term:
    preferred_term: interleukin-6
    term:
      id: NCIT:C20451
      label: Interleukin-6
  evidence:
  - reference: PMID:42511674
    reference_title: "Biomarkers and Early Mechanisms of Sarcopenia: Central Roles of Mitochondrial Dysfunction, Inflammaging, Cellular Senescence, and Neuromuscular Degeneration."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Chronic inflammation, mediated primarily through IL-6 and TNF-α, further accelerates muscle catabolism and regenerative failure, whereas senescence-associated pathways impair satellite cell function and muscle repair."
    explanation: Identifies IL-6 as a principal mediator of the inflammatory arm.
  readouts:
  - target: Chronic Low-Grade Inflammation
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: MONITORING
    interpretation: >-
      Circulating IL-6 is the one marker of the three in this section with
      evidence that it discriminates in older adults: a meta-analysis of 8,154
      patients against 33,967 controls found it elevated with a significant
      odds-ratio signal, and concluded it is usable as a peripheral inflammation
      marker where TNF and IL-1-beta are not. MONITORING rather than DIAGNOSTIC
      because that evidence is across age-related comorbidities generally, not a
      sarcopenia case-finding study; it tracks the inflammatory state this node
      represents, and no sarcopenia decision threshold exists for it.
    evidence:
    - reference: PMID:42511674
      reference_title: "Biomarkers and Early Mechanisms of Sarcopenia: Central Roles of Mitochondrial Dysfunction, Inflammaging, Cellular Senescence, and Neuromuscular Degeneration."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Chronic inflammation, mediated primarily through IL-6 and TNF-α, further accelerates muscle catabolism and regenerative failure"
      explanation: Supports the mapping this link encodes - IL-6 measures the inflammatory mechanism, rather than muscle mass directly.
    - reference: PMID:38495887
      reference_title: "Level of IL-6, TNF, and IL-1β and age-related diseases: a systematic review and meta-analysis."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The potential diagnostic usefulness of IL-6 was confirmed by odds ratio (OR) analysis (OR: 1.03, 95% CI (1.01; 1.05), p=0.0029)."
      explanation: >-
        The quantitative basis for recording an endpoint context at all. Note how
        small the odds ratio is: the signal is real and the effect is marginal,
        which is consistent with the field's position that no single biomarker is
        yet usable alone.
- name: Tumor necrosis factor alpha
  notes: >-
    TNF-alpha, the second principal inflammaging cytokine implicated in muscle
    catabolism, nominated alongside IL-6 as a candidate circulating marker. The
    nomination does not survive contact with the measurement literature: see the
    readout link below, where a meta-analysis of over 42,000 subjects found
    circulating TNF did not separate older patients with comorbidities from
    controls. The mechanism claim and the biomarker claim come apart here, and
    the entry keeps both rather than dropping either.
  biomarker_term:
    preferred_term: tumor necrosis factor
    term:
      id: NCIT:C20535
      label: Tumor Necrosis Factor
  evidence:
  - reference: PMID:42511674
    reference_title: "Biomarkers and Early Mechanisms of Sarcopenia: Central Roles of Mitochondrial Dysfunction, Inflammaging, Cellular Senescence, and Neuromuscular Degeneration."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Among the candidate biomarkers, GDF-15, FGF-21, IL-6, TNF-α, CAF22, p16INK4a, p21/CDKN1A, IGF-1, and myostatin appear particularly promising for characterizing the biological heterogeneity of sarcopenia."
    explanation: Lists TNF-alpha among the leading candidate biomarkers for sarcopenia.
  readouts:
  - target: Chronic Low-Grade Inflammation
    relationship: READOUT_OF
    direction: POSITIVE
    interpretation: >-
      TNF-alpha mediates the inflammatory mechanism, so the mechanistic link is
      sound, but its performance as a circulating marker is not. The same
      meta-analysis that validated IL-6 found no significant difference in TNF
      between older patients with comorbidities and controls. endpoint_context is
      therefore deliberately omitted: there is no established use context to
      record, and tagging this MONITORING alongside IL-6 would assert a
      measurability the evidence contradicts.
    evidence:
    - reference: PMID:42511674
      reference_title: "Biomarkers and Early Mechanisms of Sarcopenia: Central Roles of Mitochondrial Dysfunction, Inflammaging, Cellular Senescence, and Neuromuscular Degeneration."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Chronic inflammation, mediated primarily through IL-6 and TNF-α, further accelerates muscle catabolism and regenerative failure"
      explanation: Supports the mechanistic half of this link - TNF-alpha is a mediator of the node it is mapped to.
    - reference: PMID:38495887
      reference_title: "Level of IL-6, TNF, and IL-1β and age-related diseases: a systematic review and meta-analysis."
      supports: REFUTE
      evidence_source: HUMAN_CLINICAL
      snippet: "For TNF, however, the difference was statistically insignificant."
      explanation: >-
        Refutes the measurement half: circulating TNF did not separate older
        patients from controls in a meta-analysis of over 42,000 subjects.
        Recorded as REFUTE on the readout link rather than on the biomarker
        entry, because what fails is the claim that this analyte reports the
        node, not the claim that TNF-alpha participates in it.
    - reference: PMID:38495887
      reference_title: "Level of IL-6, TNF, and IL-1β and age-related diseases: a systematic review and meta-analysis."
      supports: REFUTE
      evidence_source: HUMAN_CLINICAL
      snippet: "IL-6, unlike TNF and IL-1β, could be a useful and convenient marker of peripheral inflammation in older adults with various comorbidities."
      explanation: >-
        The authors' own conclusion, stated as a contrast that singles TNF out.
        Kept as a second REFUTE item because it generalizes the null above from
        one comparison to a usability verdict.
- name: Insulin-like growth factor 1
  notes: >-
    Reduced circulating IGF-1 reports on pathophysiology#Declining Anabolic
    Hormone Signalling. Like the other candidates it is not diagnostic on its
    own.
    No reference_ranges are recorded for any of the three markers in this
    section. None has an established sarcopenia decision threshold, and the
    cited review states outright that no single biomarker has sufficient
    diagnostic accuracy for routine use, so recording cut-offs would overstate
    the field.
  biomarker_term:
    preferred_term: insulin-like growth factor I
    term:
      id: NCIT:C16743
      label: Insulin-Like Growth Factor I
  evidence:
  - reference: PMID:42511674
    reference_title: "Biomarkers and Early Mechanisms of Sarcopenia: Central Roles of Mitochondrial Dysfunction, Inflammaging, Cellular Senescence, and Neuromuscular Degeneration."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Among the candidate biomarkers, GDF-15, FGF-21, IL-6, TNF-α, CAF22, p16INK4a, p21/CDKN1A, IGF-1, and myostatin appear particularly promising for characterizing the biological heterogeneity of sarcopenia."
    explanation: Lists IGF-1 among the leading candidate biomarkers for sarcopenia.
  readouts:
  - target: Declining Anabolic Hormone Signalling
    relationship: READOUT_OF
    direction: NEGATIVE
    interpretation: >-
      Direction is NEGATIVE because the linked node is a decline: higher
      circulating IGF-1 tracks with less of it, not more. endpoint_context is
      omitted - the human evidence here is a genetic association in UK Biobank
      rather than a study of IGF-1 measurement in a clinical pathway, so no use
      context has been established.
    evidence:
    - reference: PMID:38046952
      reference_title: "Ubiquitin-proteasome pathway in skeletal muscle atrophy."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "The IGF-1/PI3K/AKT pathway, by inhibiting FOXO, prevents the upregulation of Atrogin-1 and suppresses muscle atrophy"
      explanation: >-
        Establishes that IGF-1 is the ligand of the signalling axis this node
        names, which is what makes measuring it a readout of the node rather
        than a correlate of it.
    - reference: PMID:36771461
      reference_title: "Identification and Characterization of Genomic Predictors of Sarcopenia and Sarcopenic Obesity Using UK Biobank Data."
      supports: SUPPORT
      directness: INDIRECT
      evidence_source: HUMAN_CLINICAL
      snippet: "whereas protective alleles were positively associated with bone mineral density, serum testosterone, IGF1, and 25-hydroxyvitamin D levels"
      explanation: >-
        Supports the NEGATIVE direction from the human side: alleles protective
        against sarcopenia track higher serum IGF-1. INDIRECT because this is a
        genetic association, not a measurement of IGF-1 against the mechanism.

diagnosis:
- name: Dual-energy X-ray absorptiometry for appendicular lean mass
  description: >-
    DXA-derived appendicular skeletal muscle mass indexed to height is the
    reference method for the muscle-quantity criterion. Office-based
    bioimpedance is the practical substitute; in a pilot comparison one
    consumer BIA scale captured every low-mass participant DXA identified.
  diagnosis_term:
    preferred_term: dual-energy X-ray absorptiometry
    term:
      id: NCIT:C48789
      label: Dual X-ray Absorptiometry
  evidence:
  - reference: PMID:38045877
    reference_title: "Addressing the Main Barrier to Sarcopenia Identification: Utility of Practical Office-Based Bioimpedance Tools Vs. Dual Energy X-ray Absorptiometry (DXA) Body Composition for Identification of Low Muscle Mass in Older Adults."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "OMRON captured all low MM participants identified by DXA plus all on DXA diagnostic borderline."
    explanation: >-
      Supports office bioimpedance as a usable substitute for DXA in identifying
      low muscle mass, with DXA as the stated gold standard.
  - reference: PMID:38045877
    reference_title: "Addressing the Main Barrier to Sarcopenia Identification: Utility of Practical Office-Based Bioimpedance Tools Vs. Dual Energy X-ray Absorptiometry (DXA) Body Composition for Identification of Low Muscle Mass in Older Adults."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Sarcopenia diagnostic criteria include muscle mass (MM) and function assessments. ... However,
      MM requires dual-energy X-ray absorptiometry (DXA) Body Composition (BC) or other costly
      tools, not readily available. ... This study’s objective was, therefore, to look at two types
      of practical, affordable, readily available, direct-to-consumer BIA BC scales, and compare
      their diagnostic ability for both muscle and fat mass to the current gold-standard of DXA BC.
      ... Appendicular skeletal muscle mass (ASM) and percentage fat are the only DXA parameters
      reported in this study. ... Because muscle mass is correlated with body size, once ASM has
      been calculated it is then adjusted for the height of the individual and reported as
      ASM/height2, which is the parameter used by EWGSOP to assess muscle mass. ... However, using
      the manufacturers pre-set algorithms, the OMRON scale (utilising additional hand sensors) was
      a low-cost, readily available, easy-to-use means to identify all participants found to have
      low muscle mass by DXA, as well as those with borderline low muscle mass.
    explanation: >-
      Links sarcopenia muscle-quantity assessment to height-indexed appendicular muscle mass, DXA as
      the reference method and practical bioimpedance assessment. Ellipses mark omitted text in
      source order. The excerpt quotes the authors' all-participants conclusion; their discussion
      separately reports OMRON sensitivity of 93.3%, so that conclusion should not be read as a
      general sensitivity estimate.
- name: SARC-F screening questionnaire
  description: >-
    Five-item self-report screen recommended by EWGSOP2 for case-finding. The
    conventional cut-off of 4 or more is specific but insensitive; a
    cross-sectional primary-care study argues for lowering it to 2 or more.
  evidence:
  - reference: PMID:40711821
    reference_title: "Assessment of SARC-F Sensitivity for Probable Sarcopenia Among Community-Dwelling Older Adults: Cross-Sectional Questionnaire Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The recommended threshold of ≥4 has low sensitivity and high specificity in identifying probable sarcopenia."
    explanation: Records the sensitivity limitation of the conventional SARC-F threshold.
  - reference: PMID:40711821
    reference_title: "Assessment of SARC-F Sensitivity for Probable Sarcopenia Among Community-Dwelling Older Adults: Cross-Sectional Questionnaire Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A SARC-F cut point of ≥2 yielded an area under the curve of 0.77 (95% CI 0.67-0.88), with sensitivity of 0.78, specificity of 0.75, accuracy of 0.77, positive predictive value of 0.31, and negative predictive value of 0.96."
    explanation: >-
      Gives the operating characteristics of the proposed lower threshold. Note
      the positive predictive value of 0.31, which is why SARC-F screens rather
      than diagnoses.

clinical_trials:
- name: NCT06643780
  status: UNKNOWN
  description: >-
    Randomized, double-blind, double-dummy, active-controlled trial of denosumab
    (RANKL inhibition) for sarcopenia in patients with underlying osteoporosis.
  evidence:
  - reference: PMID:40760465
    reference_title: "RANK-ligand inhibition to combat sarcopenia with underlying osteoporosis: a study protocol for a randomized, double-blind, double-dummy, active-controlled trial."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "This study aims to investigate the effects of denosumab to treat sarcopenia in patients with underlying osteoporosis."
    explanation: States the trial's objective, from the published protocol.
  - reference: clinicaltrials:NCT06643780
    reference_title: "RANK-ligand Inhibition to Combat Sarcopenia with Underlying Osteoporosis: a Randomized, Double-blind, Double-dummy, Active-Controlled Trial"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The objective of this study was to conduct a randomized, double-blind, double-dummy active controlled trial to determine the efficacy of denosumab in treating sarcopenia with underlying osteoporosis."
    explanation: The ClinicalTrials.gov registration record establishing the trial's identity and design.
  notes: >-
    `phase` is deliberately omitted rather than set to NOT_APPLICABLE. That value
    is a positive claim that the study does not follow FDA phase classification,
    which is almost certainly false for a randomised double-blind drug trial; the
    ClinicalTrials.gov record fetched here is a summary and carries no phase
    field, and ClinicalTrialPhaseEnum has no UNKNOWN value. An omitted slot is
    the honest encoding. `status: UNKNOWN` is an explicit enum value and is kept.
- name: NCT02582138
  phase: NOT_APPLICABLE
  status: UNKNOWN
  description: >-
    SPRINTT. Randomised multicomponent intervention (moderate-intensity
    physical activity with technology support plus nutritional counselling)
    against healthy-ageing education in 1,519 adults aged 70 or older with
    physical frailty and sarcopenia across 11 European countries. Primary
    outcome: mobility disability.
  notes: >-
    The registry status has not been updated since the trial finished; results
    were published in 2022 (PMID:35545258), with the subgroup findings by sex and
    baseline SPPB recorded under the resistance-training treatment.
  evidence:
  - reference: clinicaltrials:NCT02582138
    reference_title: "Sarcopenia and Physical fRailty IN Older People: Multi-componenT Treatment Strategies (SPRINTT)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The SPRINTT study will evaluate the efficacy of a multicomponent intervention programme (physical activity, nutritional counselling/dietary intervention, and information and communications technology intervention) compared with a healthy aging lifestyle education programme on mobility disability, in non-disabled older people with physical frailty and sarcopenia."
    explanation: ClinicalTrials.gov registration record establishing the trial's identity and design.
  - reference: PMID:35545258
    reference_title: "Multicomponent intervention to prevent mobility disability in frail older adults: randomised controlled trial (SPRINTT project)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Among participants with SPPB scores of 3-7, mobility disability occurred in 283/605 (46.8%) assigned to the multicomponent intervention and 316/600 (52.7%) controls (hazard ratio 0.78, 95% confidence interval 0.67 to 0.92; P=0.005)."
    explanation: Primary result of the trial.
- name: NCT04355299
  phase: NOT_APPLICABLE
  status: COMPLETED
  description: >-
    Short-term mixed exercise programme for sarcopenia in hospitalised patients
    aged 80 and over. It targets the oldest and frailest stratum, which most
    exercise trials, run in relatively healthy community-dwelling adults,
    exclude.
  evidence:
  - reference: clinicaltrials:NCT04355299
    reference_title: "Effectiveness of a Short-term Mixed Exercise Program for Treating Sarcopenia in Hospitalized Patients Aged 80 Years and Older"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Therefore, the investigators aimed to assess the effectiveness of short-term exercise for treating sarcopenia in hospitalized older patients aged 80 years and over."
    explanation: ClinicalTrials.gov registration record establishing the trial's objective and population.
- name: NCT03752359
  phase: NOT_APPLICABLE
  status: COMPLETED
  description: >-
    Whey protein versus placebo, each combined with 12 weeks of supervised
    resistance training, in older women with sarcopenic obesity.
  evidence:
  - reference: clinicaltrials:NCT03752359
    reference_title: "Effect of Whey Protein Supplementation Combined With Resistance Training on Body Composition, Muscular Strength, Functional Capacity, and Plasma-metabolism Biomarkers in Older Women With Sarcopenic Obesity"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The main purpose of the present study was to investigate the effects of whey protein following resistance training on body composition, muscular strength, functional capacity, and plasma-metabolism biomarkers in older women with sarcopenic obesity."
    explanation: ClinicalTrials.gov registration record establishing the trial's identity.
  - reference: PMID:31221297
    reference_title: "Effect of whey protein supplementation combined with resistance training on body composition, muscular strength, functional capacity, and plasma-metabolism biomarkers in older women with sarcopenic obesity: A randomized, double-blind, placebo-controlled trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Both groups demonstrated improved (P < 0.05) scores for muscular strength, waist-hip ratio, functional capacity, and other plasma-metabolism biomarkers without significant differences between conditions."
    explanation: Resistance training improved strength and function in both arms; protein added lean tissue but not strength.
- name: NCT01489930
  phase: NOT_APPLICABLE
  status: COMPLETED
  description: >-
    Randomised comparison of 8 weeks of endurance, resistance, or combined
    training in young (18-30) and older (65 and over) adults, with muscle-protein
    synthesis and mitochondrial physiology as outcomes. It tests directly
    whether training adaptations depend on age.
  evidence:
  - reference: clinicaltrials:NCT01489930
    reference_title: "Effects of Resistance and Endurance Training on Synthesis of Individual Muscle Proteins in Young and Older Adults"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "to determine whether changes in protein synthesis in response to resistance exercise programs are dependent on age"
    explanation: ClinicalTrials.gov registration record stating the age-dependence hypothesis.
  - reference: PMID:25599385
    reference_title: "Combined training enhances skeletal muscle mitochondrial oxidative capacity independent of age."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Importantly, most of the adaptations to training occurred independent of age."
    explanation: Published result of the trial.
- name: NCT07513025
  phase: NOT_APPLICABLE
  status: RECRUITING
  description: >-
    Twelve weeks of twice-weekly progressive elastic-band resistance training
    for older adults in rural long-term care facilities in Taiwan. It tests a
    low-equipment, low-staff delivery format.
  evidence:
  - reference: clinicaltrials:NCT07513025
    reference_title: "The Clinical Effectiveness of Progressive Resistance Training With Elastic Band in Postponing and Preventing Sarcopenia Among Older Adults in Rural Long-Term Care Facilities"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The goal of this clinical trial is to evaluate the effectiveness of progressive resistance training using elastic bands in treating and delaying the progression of sarcopenia among older adults in long-term care facilities."
    explanation: ClinicalTrials.gov registration record establishing the trial's objective.
- name: NCT07821164
  phase: NOT_APPLICABLE
  status: COMPLETED
  description: >-
    Exercise snacks (short bouts spread through the day) versus home-based
    resistance training versus no exercise for 8 weeks in older adults with
    possible sarcopenia.
  evidence:
  - reference: clinicaltrials:NCT07821164
    reference_title: "Effects of Exercise Snacks Versus Home-Based Resistance Training on Muscle Strength in Older Adults With Possible Sarcopenia: A Randomized Controlled Trial"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Participants will be randomly assigned to an exercise snacks group, a home-based resistance training group, or a non-exercise control group."
    explanation: ClinicalTrials.gov registration record establishing the trial's design.

progression:
- phase: Peak muscle mass and gradual decline
  age_range: 20-60 years
  notes: >-
    Muscle mass and strength peak in the third to fourth decade, plateau, then
    decline gradually from roughly age 40. Recorded from the deep-research
    report's synthesis; no single primary source for the trajectory was
    snippet-verified in this session, so no evidence item is attached.
- phase: Accelerated decline and clinical sarcopenia
  age_range: 60+ years
  notes: >-
    Decline accelerates after 60-70, when prevalence rises steeply and the
    diagnostic thresholds are crossed. Falls are the outcome most consistently
    attributable to sarcopenia in this phase.
  evidence:
  - reference: PMID:40898141
    reference_title: "Association between sarcopenia and falls, fractures, hospital readmission, and all-cause mortality in older adults with endocrine disorders: a longitudinal study of aging in China."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Sarcopenia significantly increased the risk of falls (adjusted HR: 2.38, 95% CI: 1.06-5.35, P = 0.036) but was not associated with hospital readmissions (adjusted HR: 0.87, 95% CI: 0.49-1.53, P = 0.630), fractures (adjusted HR: 1.01, 95% CI: 0.20-3.92, P = 0.992), or all-cause mortality (adjusted HR: 1.81, 95% CI: 0.49-6.67, P = 0.374)."
    explanation: >-
      Quantifies the fall risk and, importantly, records the null results for
      fracture, readmission, and mortality in this cohort. Quoted in full rather
      than trimmed to the positive finding, because the consensus literature
      attributes all four outcomes to sarcopenia and this study supports only
      one of them.
  - reference: PMID:40898141
    reference_title: "Association between sarcopenia and falls, fractures, hospital readmission, and all-cause mortality in older adults with endocrine disorders: a longitudinal study of aging in China."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Impaired gait speed was a strong predictor of increased fall risk (adjusted HR: 5.00, 95%CI: 1.27 ~ 19.90, P = 0.022)"
    explanation: >-
      Supports the physical-performance domain as the component carrying the
      fall risk, consistent with EWGSOP2 using it to grade severity.

differential_diagnoses:
- name: Cachexia
  description: >-
    Distinguished by weight loss: cachexia requires at least 5% weight loss in
    12 months or less plus additional criteria, and is typically a late-stage
    manifestation of chronic disease. Sarcopenia can occur at stable or even
    increased body weight (sarcopenic obesity).
  evidence:
  - reference: PMID:38225199
    reference_title: "Unraveling the causes of sarcopenia: Roles of neuromuscular junction impairment and mitochondrial dysfunction."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Cachexia, a systemic wasting condition, is typically considered a late‐stage manifestation of chronic diseases, such as cancer, organ failure, or infections"
    explanation: States the distinction between cachexia and sarcopenia used here.
- name: Frailty
  description: >-
    A broader multisystem syndrome of reduced physiological reserve; sarcopenia is
    its principal muscular component but frailty additionally spans cognition,
    nutrition, and comorbidity.
  evidence:
  - reference: PMID:27891296
    reference_title: "Welcome to the ICD-10 code for sarcopenia."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Sarcopenia is the most important cause of frailty in older persons."
    explanation: Establishes the part-whole relationship that distinguishes the two constructs.
- name: Primary myopathy or muscular dystrophy
  description: >-
    Inherited or inflammatory muscle disease presenting with weakness and
    atrophy, but typically with a distinctive distribution, earlier onset, raised
    creatine kinase, or a causal genotype — none of which characterise sarcopenia.
    Note that some acquired neuromuscular conditions are formally included within
    secondary sarcopenia rather than excluded by it.
  evidence:
  - reference: PMID:38225199
    reference_title: "Unraveling the causes of sarcopenia: Roles of neuromuscular junction impairment and mitochondrial dysfunction."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "In contrast, secondary sarcopenia is associated with various diseases (Figure 1) (Bauer et al., 2019; Chen et al., 2020; Nishikawa et al., 2016), such as intensive care unit‐acquired weakness (ICU‐AW), amyotrophic lateral sclerosis (ALS), and muscular atrophy due to inadequate exercise and nutrition, and often results in prolonged hospital stays and higher mortality rates"
    explanation: >-
      Supports the caveat that neuromuscular disease can fall inside the
      secondary-sarcopenia category rather than being a clean exclusion.

discussions:
- discussion_id: sarcopenia_resistance_training_sex_difference
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    Do older women and older men with sarcopenia differ in how much strength,
    muscle mass, and function they gain from resistance training, and if so,
    in which direction and through which mechanism?
  attaches_to:
  - treatments#Progressive Resistance Exercise Training
  - pathophysiology#Blunted Load-Induced mTORC1 Signalling
  rationale: >-
    The evidence points both ways. A supervised 18-week trial in adults over 65
    found larger torque and muscle-quality gains in men. SPRINTT, a larger
    multicomponent trial in physical frailty and sarcopenia, reported lean-mass
    and grip benefits in women. The meta-analysis that finds similar relative
    hypertrophy across sexes was limited to adults aged 18-45. The only
    mechanistic model of anabolic resistance was built from male data. Sex is
    therefore an unresolved effect modifier for the cornerstone treatment, and
    the mechanistic layer cannot yet say whether the load-sensing deficit
    differs by sex.
  proposed_experiments:
  - experiment_id: sex_stratified_rt_sarcopenia_ipd
    name: Sex-stratified individual-participant meta-analysis of resistance training in sarcopenia
    description: >-
      Pool individual-participant data from resistance-training RCTs in
      sarcopenic older adults and test a sex-by-treatment interaction on grip
      strength, appendicular lean mass, and gait speed. Adjust for baseline
      strength, training intensity, and protein intake. Where acute biopsy
      substudies exist, add mTORC1 effector phosphorylation after a standard
      loading bout.
    would_support:
    - pathophysiology#Blunted Load-Induced mTORC1 Signalling
    supporting_outcome:
    - >-
      A sex-by-treatment interaction persists after adjustment, and the sex with
      the smaller clinical gain also shows the smaller acute mTORC1 response to
      loading.
    refuting_outcome:
    - >-
      No sex-by-treatment interaction remains once baseline strength and
      training dose are adjusted for, indicating that the published differences
      reflect cohort and dosing differences rather than biology.

- discussion_id: sarcopenia_nmj_reversibility_in_humans
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    Does reversing neuromuscular junction transmission failure improve strength in
    humans with sarcopenia, and how much of age-related weakness is attributable
    to this reversible excitability defect rather than to lost contractile tissue?
  attaches_to:
  - pathophysiology#Neuromuscular Junction Transmission Failure
  - treatments#ClC-1 Chloride Channel Inhibition
  rationale: >-
    The human evidence establishes that transmission failure tracks weakness
    severity; the rescue is rodent-only. The attributable fraction matters
    practically, because it sets the ceiling on what an excitability-targeting
    drug could achieve, and it is the one prediction that separates this model
    from the mass-centred account. It is also the question that would explain why
    myostatin-pathway drugs add mass without adding strength.
  proposed_experiments:
  - experiment_id: clc1_inhibition_rct_sarcopenia
    name: Randomised trial of ClC-1 inhibition in older adults with sarcopenia
    description: >-
      Placebo-controlled trial in older adults with confirmed sarcopenia,
      powered on maximal voluntary contraction, with single-fiber EMG measurement
      of transmission failure and DXA muscle mass as co-primary mechanistic
      readouts.
    would_support:
    - pathophysiology#Neuromuscular Junction Transmission Failure
    supporting_outcome:
    - >-
      Strength improves relative to placebo with no corresponding increase in
      appendicular lean mass, and the improvement tracks the reduction in
      measured transmission failure.
    refuting_outcome:
    - >-
      Transmission failure is reduced pharmacologically without any accompanying
      improvement in maximal voluntary contraction, indicating the deficit is not
      rate-limiting for force in humans.

- discussion_id: sarcopenia_rodent_inflammaging_fidelity
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  prompt: >-
    Do rodent ageing models represent the inflammatory arm of human sarcopenia
    well enough to support translational inference about anti-inflammatory
    interventions?
  attaches_to:
  - pathophysiology#Chronic Low-Grade Inflammation
  - animal_models#Naturally aged C57BL/6 mouse (28 months)
  rationale: >-
    The cross-species transcriptomic comparison found that rodents reproduce the
    mitochondrial changes of human sarcopenia at gene level but the inflammatory
    response only at pathway level. Evidence therefore exists in the model, but
    its fidelity to human inflammaging is the open question — the
    HUMAN_MODEL_MISMATCH case rather than a plain absence of evidence. This
    matters because inflammaging is one of the arms most often nominated as a
    drug target.
  proposed_experiments:
  - experiment_id: cross_species_muscle_inflammatory_profiling
    name: Species-matched inflammatory profiling of sarcopenic human and rodent muscle
    description: >-
      Profile the inflammatory transcriptome and cytokine content of skeletal
      muscle from aged humans and aged rodents stratified by measured sarcopenia
      status rather than by chronological age, and test whether the gene-level
      divergence reported across species is a true biological difference or an
      artefact of comparing animals and people matched on age instead of on
      muscle phenotype. The stratification is the point: the source study's own
      conclusion is that muscle mass, not age, indicates muscle health.
    would_support:
    - pathophysiology#Chronic Low-Grade Inflammation
    supporting_outcome:
    - >-
      Phenotype-matched aged rodents and humans show concordant muscle
      inflammatory gene expression, indicating the previously reported gene-level
      divergence came from age-matching rather than from species biology, and
      that rodent inflammaging findings can be carried across.
    refuting_outcome:
    - >-
      The divergence persists after phenotype matching, establishing that rodent
      muscle inflammaging is not a faithful model of the human arm and that
      anti-inflammatory targets validated only in rodents should not be assumed
      to translate.

- discussion_id: sarcopenia_genetic_susceptibility_unverified
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    Which common genetic variants actually modify sarcopenia risk, and what is
    the effect size of the widely cited ACTN3 R577X association in older adults?
  attaches_to:
  - genetic#ACTN3
  rationale: >-
    The genetic section rests on leads carried forward from a deep-research
    report without primary-source verification in this session. The ACTN3 and
    GWAS claims are plausible and widely repeated, which is exactly the condition
    under which an unverified claim propagates. Recorded as an explicit gap so
    that a later curation pass verifies or removes them rather than inheriting
    them as established.

- discussion_id: sarcopenia_mass_versus_strength_endpoints
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    Why do interventions that reliably add muscle mass in older adults so often
    fail to add strength or physical function, and which mechanism should a
    sarcopenia trial's primary endpoint therefore measure?
  attaches_to:
  - pathophysiology#Loss of Skeletal Muscle Mass, Strength and Quality
  - pathophysiology#Neuromuscular Junction Transmission Failure
  - treatments#Bimagrumab (Anti-Activin Type II Receptor Antibody)
  - treatments#Myostatin Ligand Neutralization (Landogrozumab, Trevogrumab)
  - treatments#Selective Androgen Receptor Modulation (Enobosarm, MK-0773)
  rationale: >-
    The dissociation is now the single most consistent finding across this
    entry's pharmacological treatments, and it recurs across drug classes that
    share no mechanism. Bimagrumab raised lean body mass by 7% in older adults
    with sarcopenia and produced no functional difference from placebo; MK-0773
    raised lean mass in sarcopenic women with no strength or function gain;
    landogrozumab met its lean-mass endpoint while moving only some performance
    measures. Reading these as three separate disappointments misses that they
    are one result repeated. The pattern is not absolute: the earlier 40-person
    bimagrumab study did find gait-speed and walking-distance gains in its
    slowest-walking participants, which is itself a lead - it suggests the
    dissociation may be a question of who is treated rather than of what the
    drug does. Two explanations are on the table and they imply
    different drug-development programmes: either added mass is added
    low-quality tissue, or force production in aged muscle is limited by
    something other than contractile mass - excitability and neuromuscular
    transmission being the candidate this entry already models. Which is right
    determines whether strength, specific force, or mass belongs in the primary
    endpoint, and PMID:42706321 argues the field should shift away from mass.
  proposed_experiments:
  - experiment_id: mass_gain_quality_partition
    name: Partitioning drug-induced lean-mass gain into contractile quality and excitability
    description: >-
      In a trial of an agent with an established lean-mass effect, measure
      appendicular lean mass, single-fiber specific force from biopsy, and
      neuromuscular transmission by single-fiber EMG in the same participants
      before and after treatment, and test which of the two intermediate
      measures accounts for the gap between the mass change and the
      maximal-voluntary-contraction change.
    would_support:
    - pathophysiology#Neuromuscular Junction Transmission Failure
    supporting_outcome:
    - >-
      Mass rises without a corresponding rise in single-fiber specific force, and
      the residual weakness tracks unchanged transmission failure - indicating
      that force is limited by excitability and that mass-adding drugs cannot
      close the gap on their own.
    refuting_outcome:
    - >-
      Single-fiber specific force falls as mass rises, with transmission
      unchanged, indicating the added tissue is of lower contractile quality and
      that the problem is the anabolic drug's tissue product rather than the
      neuromuscular arm.

tracked_issues:
- url: https://github.com/monarch-initiative/mondo/issues/6008
  title: "review \"muscle tissue disorder\" branch"
  tracked_issue_role: ontology_coverage_gap
  tracked_issue_status: CLOSED
  notes: >-
    The term-tracker item (IAO:0000233) recorded on the obsoleted
    MONDO:0006516. It is a bulk branch review opened 2023-03-03 and closed
    2023-06-28, labelled Branch Review / obsolete / on list, arising from a
    2023-03-02 expert meeting on the muscle tissue disorder branch. Sarcopenia
    is not discussed individually in the thread: the per-term decisions were
    recorded in monarch-initiative/mondo#5984 and an external spreadsheet, so
    there is no citable recorded rationale for this particular obsoletion beyond
    the term's own comment. Searching the MONDO tracker for "sarcopenia" and for
    the CURIE returns only this issue, so as of 2026-08-31 nobody appears to have
    disputed or revisited the decision. That absence, rather than any recorded
    counter-argument, is what an upstream ticket would address.
- url: https://github.com/monarch-initiative/dismech/issues/6056
  title: "[kgap-scan] Sarcopenia: Neuromuscular junction transmission failure as reversible driver"
  notes: >-
    The knowledge-gap scan that prompted this entry. Its handoff — capture NMJ
    transmission failure as a pathophysiology node, NaV1.4 loss as the mechanism,
    and ClC-1 as a therapeutic target — is implemented by
    pathophysiology#Neuromuscular Junction Transmission Failure,
    pathophysiology#Postsynaptic NaV1.4 Depletion, and
    treatments#ClC-1 Chloride Channel Inhibition.

review_notes: >-
  Curated with a claude_code deep-research report (research/Sarcopenia-deep-research-claude_code.md;
  falcon was requested but its account was out of credits, so the run fell back
  and recorded the substitution in its own frontmatter). Every snippet in this
  entry was taken from a locally cached reference, not from the report body: the
  report attributes to EWGSOP2 a definition of sarcopenia as "a condition
  characterized by loss of muscle mass and function occurring as a natural part
  of aging process", which does not appear in that paper and inverts its actual
  position that sarcopenia is a muscle disease rather than a normal ageing
  correlate. The report's own reference validation was otherwise clean (37/37
  resolved, 0 off topic) and its term validation flagged MONDO:0006516 as
  obsolete, which is consistent with the finding recorded in notes.
  This entry was revised after an adversarial pre-PR review. That pass corrected
  three evidence_source misgradings (a review and an editorial graded
  HUMAN_CLINICAL, and a C2C12 cell-line result graded MODEL_ORGANISM rather than
  IN_VITRO), replaced two model-link evidence items whose exact quotes did not
  support the claims their explanations made, removed a conforms_to that pointed
  at a module node asserting the opposite of this entry's Anabolic Resistance
  node, rebound alpha motor neuron to the precise CL:0008038, corrected three
  genetic relationship_type values that asserted variant-level claims their own
  notes disclaimed, and sourced a previously uncited NF-kappaB claim.
  Consensus-statement citations (PMID:30312372, PMID:32033882) are left as
  HUMAN_CLINICAL. That is a deliberate, arguable call rather than an oversight:
  CLAUDE.md routes "expert consensus without data" to OTHER, but these papers
  synthesize human cohort data and the quoted passages are diagnostic criteria
  derived from it. A reviewer who prefers OTHER has a reasonable case.
  Gaps a future pass should close: the genetic section remains lead-quality
  rather than verified (see discussions) -- the ACTN3 entry is deliberately
  UNKNOWN with a NO_EVIDENCE citation rather than an asserted association, and
  the GWAS record is keyed on a single representative locus because the schema's
  genetic[] entries are gene-keyed. Vitamin D is recorded on association grounds
  with no interventional trial cited. The denosumab trial's registry record has
  been fetched, but it caches as a summary carrying no phase field, so `phase`
  is omitted rather than asserted and `status` remains UNKNOWN; a source that
  states the phase would close that. There are no comorbidity
  entries, despite sarcopenia being a well-documented convergence point for CKD,
  heart failure, COPD, cirrhosis, and cancer, and no computational_models record
  although PMID:42464764 is a published multiscale kinetic model of anabolic
  resistance in this disease. Sarcopenia is also a strong future
  candidate for a kb/modules/ mechanism module in the "disease-like phenotypes"
  family, since several existing entries (Werner_Syndrome, Cushings_Syndrome,
  Ovarian_High-Grade_Serous_Carcinoma) already reference it as a downstream
  convergence; that was left out of scope here because the module family
  convention expects both an HP and a MONDO identifier and sarcopenia has neither.
  A later pass curated the therapeutic pipeline of PMID:42706321 (Nat Rev Drug
  Discov 2026) into the treatments section, adding 15 treatments, one
  pathophysiology node (Capillary Rarefaction and Impaired Muscle Perfusion,
  which the entry previously lacked entirely and which the VEGF and apelin
  treatments needed as a target), and a discussion of the mass-versus-strength
  endpoint problem. Two rules governed that pass. First, the review is cited
  only where it is itself the source of a landscape statement; every
  experimental and trial claim is cited to the primary paper, all 28 of which
  were fetched into references_cache in this session. Second, results that
  exist only as conference abstracts or company press releases are described in
  a treatment's notes and never asserted as evidence -- this covers the MF-300
  phase 1 result and the aged-mouse dosing study, the COURAGE interim readout,
  the STRIDES discontinuation, the low-dose RAD001 trials in older adults, and
  the NAM/PN human RCT, which is a medRxiv preprint. The review's own cache
  entry is abstract-only, so nothing from its body text is quotable.
  Deliberately not curated from that review: elamipretide and MOTS-c (the
  elamipretide trial is in primary mitochondrial myopathy, not sarcopenia, and
  MOTS-c is preclinical with no muscle-ageing intervention study), GH/IGF1 and
  testosterone (the review's own summary is that the evidence is mixed and
  testosterone has not been tested in sarcopenia patients), and the muscle stem
  cell rejuvenation targets FGF2-Sprouty1, p38 MAPK, Oncostatin M and CD47,
  which are preclinical mechanism work rather than treatments. The
  clinical_trials section was not extended; several treatments added here name
  registered trials in their notes and a future pass could key them properly.
  A follow-up round in the same session structured the three biochemical
  entries' readout links, which previously existed only as prose inside their
  notes. Two of the three carry no endpoint_context on purpose. TNF-alpha has a
  sound mechanistic link and a failed measurement claim, and IGF-1's only human
  evidence here is a genetic association rather than a study of the analyte in a
  clinical pathway; in neither case is there a use context to record. Only IL-6
  is tagged, as MONITORING. No regulatory_endpoint_refs are recorded because
  sarcopenia has no row in kb/surrogate_endpoints/fda_surrogate_endpoints.yaml,
  and it cannot have one: that table lists endpoints that supported an approval,
  and this disease has no approved therapy.

📚

References & Deep Research

References

2

PMID:30312372

Sarcopenia: revised European consensus on definition and diagnosis.

No top-level findings curated for this source.

PMID:32033882

Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment.

No top-level findings curated for this source.

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Evaluations and curation notes (2)

Record review notes

Curated with a claude_code deep-research report (research/Sarcopenia-deep-research-claude_code.md; falcon was requested but its account was out of credits, so the run fell back and recorded the substitution in its own frontmatter). Every snippet in this entry was taken from a locally cached reference, not from the report body: the report attributes to EWGSOP2 a definition of sarcopenia as "a condition characterized by loss of muscle mass and function occurring as a natural part of aging process", which does not appear in that paper and inverts its actual position that sarcopenia is a muscle disease rather than a normal ageing correlate. The report's own reference validation was otherwise clean (37/37 resolved, 0 off topic) and its term validation flagged MONDO:0006516 as obsolete, which is consistent with the finding recorded in notes. This entry was revised after an adversarial pre-PR review. That pass corrected three evidence_source misgradings (a review and an editorial graded HUMAN_CLINICAL, and a C2C12 cell-line result graded MODEL_ORGANISM rather than IN_VITRO), replaced two model-link evidence items whose exact quotes did not support the claims their explanations made, removed a conforms_to that pointed at a module node asserting the opposite of this entry's Anabolic Resistance node, rebound alpha motor neuron to the precise CL:0008038, corrected three genetic relationship_type values that asserted variant-level claims their own notes disclaimed, and sourced a previously uncited NF-kappaB claim. Consensus-statement citations (PMID:30312372, PMID:32033882) are left as HUMAN_CLINICAL. That is a deliberate, arguable call rather than an oversight: CLAUDE.md routes "expert consensus without data" to OTHER, but these papers synthesize human cohort data and the quoted passages are diagnostic criteria derived from it. A reviewer who prefers OTHER has a reasonable case. Gaps a future pass should close: the genetic section remains lead-quality rather than verified (see discussions) -- the ACTN3 entry is deliberately UNKNOWN with a NO_EVIDENCE citation rather than an asserted association, and the GWAS record is keyed on a single representative locus because the schema's genetic[] entries are gene-keyed. Vitamin D is recorded on association grounds with no interventional trial cited. The denosumab trial's registry record has been fetched, but it caches as a summary carrying no phase field, so `phase` is omitted rather than asserted and `status` remains UNKNOWN; a source that states the phase would close that. There are no comorbidity entries, despite sarcopenia being a well-documented convergence point for CKD, heart failure, COPD, cirrhosis, and cancer, and no computational_models record although PMID:42464764 is a published multiscale kinetic model of anabolic resistance in this disease. Sarcopenia is also a strong future candidate for a kb/modules/ mechanism module in the "disease-like phenotypes" family, since several existing entries (Werner_Syndrome, Cushings_Syndrome, Ovarian_High-Grade_Serous_Carcinoma) already reference it as a downstream convergence; that was left out of scope here because the module family convention expects both an HP and a MONDO identifier and sarcopenia has neither. A later pass curated the therapeutic pipeline of PMID:42706321 (Nat Rev Drug Discov 2026) into the treatments section, adding 15 treatments, one pathophysiology node (Capillary Rarefaction and Impaired Muscle Perfusion, which the entry previously lacked entirely and which the VEGF and apelin treatments needed as a target), and a discussion of the mass-versus-strength endpoint problem. Two rules governed that pass. First, the review is cited only where it is itself the source of a landscape statement; every experimental and trial claim is cited to the primary paper, all 28 of which were fetched into references_cache in this session. Second, results that exist only as conference abstracts or company press releases are described in a treatment's notes and never asserted as evidence -- this covers the MF-300 phase 1 result and the aged-mouse dosing study, the COURAGE interim readout, the STRIDES discontinuation, the low-dose RAD001 trials in older adults, and the NAM/PN human RCT, which is a medRxiv preprint. The review's own cache entry is abstract-only, so nothing from its body text is quotable. Deliberately not curated from that review: elamipretide and MOTS-c (the elamipretide trial is in primary mitochondrial myopathy, not sarcopenia, and MOTS-c is preclinical with no muscle-ageing intervention study), GH/IGF1 and testosterone (the review's own summary is that the evidence is mixed and testosterone has not been tested in sarcopenia patients), and the muscle stem cell rejuvenation targets FGF2-Sprouty1, p38 MAPK, Oncostatin M and CD47, which are preclinical mechanism work rather than treatments. The clinical_trials section was not extended; several treatments added here name registered trials in their notes and a future pass could key them properly. A follow-up round in the same session structured the three biochemical entries' readout links, which previously existed only as prose inside their notes. Two of the three carry no endpoint_context on purpose. TNF-alpha has a sound mechanistic link and a failed measurement claim, and IGF-1's only human evidence here is a genetic association rather than a study of the analyte in a clinical pathway; in neither case is there a use context to record. Only IL-6 is tagged, as MONITORING. No regulatory_endpoint_refs are recorded because sarcopenia has no row in kb/surrogate_endpoints/fda_surrogate_endpoints.yaml, and it cannot have one: that table lists endpoints that supported an approval, and this disease has no approved therapy.

Create: Sarcopenia · 2026-08-31T15:21:20Z · View source

New Disease entry for sarcopenia, created in response to the knowledge-gap handoff in issue #6056 (Arnold et al., J Clin Invest 2026, PMID:42424105), which asked for an entry capturing NMJ transmission failure as a pathophysiology node, postsynaptic NaV1.4 loss as its mechanism, and ClC-1 inhibition as a therapeutic target. All three are implemented. ONTOLOGY BINDING - deliberate omission of disease_term. MONDO:0006516 (sarcopenia) is obsolete, retired with the reason "out of scope - MONDO:excludeBiologicalProcess. This term represent a natural aging process, and not a disease." There is no replacement term. NCIT does code Sarcopenia (NCIT:C186726) and Acute Sarcopenia (NCIT:C189016), but OAK ancestor traversal puts both under NCIT:C3367 (Finding), not NCIT:C2991 (Disease or Disorder), so they are unreachable from the NCITDiseaseOrFindingTerm dynamic enum and could not be used in mappings.ncit_mappings; they are recorded in prose instead. HPO likewise has no sarcopenia term, so the diagnostic triad is represented by component HP terms. The entry therefore omits disease_term and records ICD10CM:M62.84 under mappings.icd10cm_mappings, following the precedent set by Volumetric_Muscle_Loss. This is a substantive disagreement with MONDO's scope call rather than an oversight, is surfaced in the entry notes, and is worth an upstream MONDO ticket that this session did not file. DEEP RESEARCH. falcon was the requested provider but its account returned HTTP 402 (out of credits). Rather than substituting a provider by hand, the run was re-issued with --fallback, so the report records fell_back: true, requested_provider: falcon, and the provider_attempts trail itself. The report produced is research/Sarcopenia-deep-research-claude_code.md (48 citations, 30 web searches). The recipe did not emit validation sections despite the flags, so they were retro-fitted with `just validate-research-reference` and `just validate-research-terms`. Reference validation came back clean (37/37 resolved, 0 unresolved, 0 off topic). Term validation flagged MONDO:0006516 as obsolete, independently confirming the binding finding above, and flagged CL:0000188 as mislabelled in the report ("skeletal muscle fiber" where CL calls it "cell of skeletal muscle") - the entry uses CL:0008002 for skeletal muscle fiber instead. REPORT DEFECT FOUND. The report attributes to EWGSOP2 a definition of sarcopenia as "a condition characterized by loss of muscle mass and function occurring as a natural part of aging process". That sentence is not in PMID:30312372 and inverts the paper's actual position, which is that sarcopenia is a muscle disease rather than a normal ageing correlate. It was not used. Every snippet in this entry was taken from a locally cached reference rather than from the report body, and the report was treated as a lead throughout. CONTENT. 15 pathophysiology nodes wired as a causal chain rather than a category list, running from alpha motor neuron loss and NMJ transmission failure through mitochondrial dysfunction, inflammaging, satellite-cell exhaustion, anabolic hormone decline, anabolic resistance, myostatin/activin signalling, and ubiquitin-proteasome proteolysis to negative net protein balance, type II fiber atrophy, myosteatosis, and the clinical convergence node. Five causal edges carry their own evidence where a source makes the causal claim specifically; the rest are left uncited rather than papered over with a node's citation. Conformance is declared against the mitochondrial_dysfunction, inflammaging, stem_cell_exhaustion, and deregulated_nutrient_sensing modules. Two mechanistic_hypotheses: an EMERGING NMJ-excitability model and the CANONICAL multifactorial-convergence model. Also three subtypes, two prevalence records, seven phenotypes, three genetic entries, three environmental exposures each with influences_mechanisms and their own edge evidence, four treatments, two diagnostic definitions (EWGSOP2 and AWGS 2019), two animal models with modeled_mechanisms and readouts, five datasets, three differential diagnoses, and three discussions. The bimagrumab treatment records the mass-versus-function dissociation as a paired SUPPORT and REFUTE from the same trial rather than as one hedged item, since the study supports the mass claim and contradicts the strength claim. DATASETS. Five GEO accessions selected by manual relevance triage from `just discover-datasets` and all five verified with `just verify-datasets`. Rejections are recorded in the last dataset's notes: GSE279051 (cortical bone, not muscle), GSE276208 (sarcopenia as exposure driving tumorigenesis rather than as subject), and GSE304351/GSE304464/GSE315575 (sarcopenia named only in the summary). Per the dataset SOP these records carry publication and provenance notes but no evidence block. VALIDATION. `just validate` passes (schema, terms, references) with 78/78 snippets verified. `just validate-disorders` passes. check-entity-refs, check-duplicate-keys, check-folded-hyphens, check-snippet-length, check-title-snippets, check-snippet-grading, check-environmental-evidence, check-reference-titles, check-term-cache-integrity and check-not4curation all pass; check-source-defect-claims reports nothing for this file. `just test-kb` passes in full (39,065 tests). check-snippet-grading initially failed on a real defect introduced here - one PMID:40678078 quote graded HUMAN_CLINICAL in one place and OTHER in two others - which was corrected to OTHER, the right grading for a review. Compliance is 83.8%. KNOWN GAPS, recorded in review_notes and in discussions. The genetic section is lead-quality: the ACTN3 R577X association is carried from the report without a verified primary source and deliberately carries no evidence item, tracked by an explicit knowledge-gap discussion. No biochemical/biomarker records despite GDF-15, IL-6, TNF-alpha, IGF-1 and myostatin being established candidates. No clinical_trials records. No comorbidity entries, despite sarcopenia being a documented convergence point for CKD, heart failure, COPD, cirrhosis and cancer. Sarcopenia is also a strong candidate for a kb/modules/ mechanism module in the disease-like-phenotypes family - Werner_Syndrome, Cushings_Syndrome and Ovarian_High-Grade_Serous_Carcinoma already reference it as a downstream convergence - but that family's convention expects both an HP and a MONDO identifier and sarcopenia has neither, so it was left out of scope.

Claude Code ▸

Sarcopenia: Comprehensive Research Report

claude-haiku-4-5-20251001, claude-sonnet-5 48 citations 2026-08-31T14:46:04.596890

I'll research this now using web search, covering the disease characteristics systematically. Let me start by loading the search tools and running parallel queries across the major topic areas.

I now have sufficient identifier and mechanism data, plus solid coverage of etiology, epidemiology, treatment pipeline, diagnostics, and animal models. I have enough to write the comprehensive report now.

Sarcopenia: Comprehensive Research Report

1. Disease Information

Overview. Sarcopenia is a progressive, generalized skeletal muscle disorder characterized by accelerated loss of muscle mass and function, most classically associated with aging but increasingly recognized as also arising secondary to disuse, malnutrition, and chronic disease. It sits at the intersection of geriatric medicine, endocrinology, and musculoskeletal biology and is now recognized internationally as a distinct disease entity rather than merely a normal correlate of aging. The 2019 revised consensus (EWGSOP2) defines it operationally: "sarcopenia is a condition characterized by loss of muscle mass and function occurring as a natural part of aging process," with diagnosis requiring the presence of low muscle strength as the primary criterion, confirmed by low muscle quantity/quality, with severity graded by poor physical performance (PMC6322506).

Key identifiers: - ICD-10-CM: M62.84 (Sarcopenia) — assigned in 2016, formally recognizing sarcopenia as a billable disease state rather than a normal aging finding (icd10data.com; PubMed 27891296, "Welcome to the ICD-10 code for sarcopenia"). - MONDO: MONDO:0006516 exists but is flagged obsolete in the current ontology release, described there as "Progressive decline in muscle mass due to aging which results in decreased functional capacity of muscles" — curators should verify current mapping status/replacement term directly against the live Mondo release before binding. - NCIT: NCIT:C186726 (Sarcopenia); NCIT:C189016 (Acute Sarcopenia) — NCIT distinguishes acute (≤6 months, typically post-illness/surgery) from chronic (>6 months) forms. - MeSH: D055948. - EFO: EFO:1000653. - SNOMED CT: 772791006. - UMLS/MedGen: C0872084. - No dedicated OMIM or Orphanet entry was found — sarcopenia in its primary (age-related) form is not a monogenic/rare disease in the classic Orphanet/OMIM sense, though secondary/genetic myopathic sarcopenias may map to related entries (e.g., myostatin-related muscle hypertrophy, OMIM #614457, is the inverse phenotype). - No dedicated HPO term was identified in this search; OLS returned zero HP hits for "sarcopenia," suggesting the concept may need representation via composed terms (e.g., HP:0003324 Generalized muscle weakness, HP:0003202 Skeletal muscle atrophy) rather than a single canonical HP identifier — this should be confirmed against a live HPO browser query before curation.

Synonyms: age-related muscle loss, sarcopenic muscle wasting, myopenia (less common), primary/secondary sarcopenia, sarcopenic obesity (comorbid variant).

Data provenance: Most disease-level knowledge (prevalence, mechanism, treatment efficacy) derives from aggregated cohort studies, meta-analyses, and consensus panels (EWGSOP2, AWGS, IWGS, FNIH) rather than individual EHR case reports, though EHR-based sarcopenia/frailty/cachexia phenotyping is an active research area (PMC7395344).

Sources: - Sarcopenia: revised European consensus on definition and diagnosis - ICD-10-CM M62.84 - Welcome to the ICD-10 code for sarcopenia - PubMed

2. Etiology

Primary vs. secondary classification. The field distinguishes primary (age-related) sarcopenia, diagnosed when aging is the only apparent cause, from secondary sarcopenia, driven by identifiable extrinsic factors. Secondary sarcopenia is categorized into three main mechanistic buckets: (1) activity-related (disuse, bed rest, sedentary lifestyle, zero-gravity/immobilization), (2) disease-related (organ failure — heart, kidney, lung, liver, brain; inflammatory disease; malignancy; endocrine disease), and (3) nutrition-related (insufficient energy/protein intake, malabsorption, GI disease, anorexia of aging, drug-induced anorexia) (PMC8773430).

Disease Causal Factors — primary/age-related mechanism: Reduction in alpha-motor neuron number and motor unit remodeling, mitochondrial dysfunction, hormonal shifts (declining IGF-1, testosterone, estrogen; rising cortisol and pro-inflammatory cytokines TNF-α/IL-6), and insulin resistance.

Genetic risk factors. - Heritability: Twin and family studies estimate heritability of muscle strength at 30–85% and of muscle mass at 45–90%, with handgrip strength specifically at 30–65% (ScienceDirect S0026049523003153, "Pathophysiology of sarcopenia: Genetic factors and their interplay with environmental factors"). - GWAS loci: A multivariate GWAS identified 215 loci and >30,000 SNPs contributing to the polygenic architecture of sarcopenia-related traits; 78 independent SNPs across 73 loci were associated with handgrip strength, lean mass, and walking pace with consistent effect direction. A large European-ancestry meta-analysis (20 cohorts) identified five loci for total lean body mass: HSD17B11, VCAN, ADAMTSL3, IRS1, and FTO. Earlier work also implicated ESR1, NOS3, KLF5, and HLA-DQA1 in low handgrip strength/lean mass (Nature Scientific Reports 41598-022-07567-9; PMC9920138, UK Biobank). - Candidate genes: ACTN3 R577X null polymorphism (α-actinin-3 deficiency, present in >1.5 billion people worldwide) is associated with reduced skeletal muscle mass persisting into old age and increased risk of sarcopenia, frailty, and functional loss (PMC/biorxiv on ACTN3). MSTN (myostatin) K153R polymorphism (rs1805086) associates with muscle power phenotypes, though a meta-analysis found inconsistent overall effects on strength/mass across studies, and MSTN/ACTN3 variants were not associated with exceptional longevity in Japanese centenarians (PMC5115755).

Environmental/lifestyle risk factors: Physical inactivity/sedentary behavior, inadequate dietary protein intake, vitamin D deficiency, smoking, excess alcohol, obesity (via sarcopenic obesity), and chronic disease exposure. Age itself and, per EWGSOP2 data, male sex are risk factors under some diagnostic criteria (though IWGS criteria show higher prevalence in women) (PMC/Wiley global prevalence meta-analysis, jcsm.12783).

Protective factors: Regular resistance/aerobic exercise, adequate high-quality (leucine-rich) protein intake (1.0–1.2 g/kg/day, up to 1.2–1.5 g/kg/day with inflammatory disease), vitamin D sufficiency, and possibly favorable genetic variants (e.g., ACTN3 R577 "wild-type" allele).

Gene-environment interaction: The interplay is bidirectional — genetic susceptibility (e.g., ACTN3 XX genotype) may amplify vulnerability to disuse-induced atrophy, while chronic environmental stressors (inflammation, malnutrition) can epigenetically or transcriptionally suppress anabolic gene programs regardless of baseline genotype (ScienceDirect S0026049523003153).

Sources: - Pathophysiology of sarcopenia: Genetic factors and their interplay with environmental factors - Unveiling genetic variants for age-related sarcopenia — Korean cohorts - Genomic Predictors of Sarcopenia — UK Biobank - Effect of Exercise on Secondary Sarcopenia: A Comprehensive Literature Review - Muscle-Related Polymorphisms (MSTN, ACTN3) Not Associated with Longevity

3. Phenotypes

Sarcopenia is defined by a triad of measurable phenotypic domains rather than a single symptom:

Phenotype	Type	Suggested term	Notes
Low muscle strength (grip strength, chair-stand)	Sign/functional	HP:0003324 (Generalized muscle weakness)	Primary EWGSOP2 diagnostic criterion
Low muscle mass/quantity (appendicular skeletal muscle index)	Sign (imaging/anthropometric)	HP:0003202 (Skeletal muscle atrophy)	Confirms diagnosis (DXA/BIA/CT/MRI)
Low physical performance (gait speed, SPPB, TUG, 400m walk)	Functional/behavioral	HP:0002015 (dysphagia, if severe) not applicable; consider HP:0001288 (Gait disturbance)	Determines severity grading
Falls	Clinical sign	HP:0002527 (Falls)	Downstream consequence
Frailty	Syndromic	—	Overlapping but distinct construct
Reduced muscle quality (fatty infiltration, fibrosis)	Imaging/histological	—	CT/MRI attenuation-based

Onset: Muscle mass and strength typically peak in the 3rd–4th decade of life, plateau, then decline progressively from approximately age 40–50 onward, accelerating markedly after age 60–70 ("late-onset," though disuse/critical-illness sarcopenia can develop acutely within days-to-weeks in ICU settings — reflected in the NCIT "Acute Sarcopenia," NCIT:C189016, ≤6 months, vs. chronic, >6 months).

Severity/progression: EWGSOP2 grades severity in three tiers: (1) probable sarcopenia (low strength only), (2) confirmed sarcopenia (low strength + low muscle mass/quality), (3) severe sarcopenia (low strength + low mass/quality + poor physical performance) (PMC6322506). Course is typically chronic and progressive in primary sarcopenia; secondary/disuse forms can progress rapidly (muscle loss of up to several percent per week during bed rest or critical illness) and are partially reversible with rehabilitation.

Frequency: By definition all sarcopenia patients have the diagnostic triad; downstream phenotypes occur at variable frequency — falls, frailty, disability, and reduced quality of life are common consequences, with an estimated prevalence gradient depending on diagnostic criteria used (see Epidemiology, §9).

QoL impact: Reduced physical function correlates with diminished independence in activities of daily living, increased fall/fracture risk, loss of mobility, and downstream depression; validated via SF-36/EQ-5D-type instruments in several of the reviewed cohort studies, though disease-specific quantification (e.g., utility decrements) was not directly retrieved in this search pass.

Sources: - Sarcopenia: revised European consensus on definition and diagnosis - Diagnostic Criteria and Measurement Techniques of Sarcopenia

4. Genetic/Molecular Information

Sarcopenia is fundamentally a complex/polygenic trait, not a single-gene Mendelian disorder, so this section summarizes contributing loci/pathways rather than causal Mendelian variants.

Candidate/contributing genes (with GO/functional relevance): - MSTN (myostatin, GDF8) — hgnc:7204 (approx.) — negative regulator of muscle mass; K153R (rs1805086) polymorphism associated with muscle power phenotypes; myostatin pathway is the leading pharmacological target class (see §12) (PMC3024427; PMC9690375). - ACTN3 — R577X null polymorphism; loss of α-actinin-3 (compensated by α-actinin-2) associated with reduced sprint/power performance and increased sarcopenia/frailty risk in old age. - IRS1, FTO, HSD17B11, VCAN, ADAMTSL3 — lean-mass GWAS loci (European ancestry meta-analysis, 20 cohorts). - ESR1 (estrogen receptor), NOS3 (endothelial NOS), KLF5, HLA-DQA1 — implicated in earlier handgrip-strength/lean-mass association studies.

Functional consequences: Myostatin overexpression/gain-of-function drives muscle atrophy via TGF-β superfamily/activin receptor signaling → SMAD2/3 activation → suppression of Akt/mTOR anabolic signaling and upregulation of the ubiquitin-proteasome atrogenes. This is essentially the inverse of the loss-of-function MSTN phenotype (myostatin-related muscle hypertrophy).

Epigenetics: Not extensively covered in this search pass, but the multi-omics literature (e.g., PMC EP092853, "multi-omics investigation of sarcopenia and frailty: genomic, epigenomic and telomere length data") indicates epigenetic and telomere-length changes are being actively integrated into sarcopenia risk models alongside genomics.

Chromosomal abnormalities: Not a recognized feature of primary sarcopenia; not applicable in the way it is for classic Mendelian disorders.

Somatic vs. germline: Sarcopenia genetics is entirely germline/constitutional (polygenic susceptibility); no somatic mutation component is described.

Sources: - A multi-omics investigation of sarcopenia and frailty - Association of Myostatin Gene Polymorphisms with Strength and Muscle Mass in Athletes - K153R Polymorphism in the Myostatin Gene

5. Environmental Information

Environmental/lifestyle factors: Sedentary behavior and physical inactivity are the dominant modifiable drivers; prolonged bed rest, immobilization, and hindlimb/limb unloading are used experimentally (and occur clinically in hospitalization) to model rapid disuse atrophy. Malnutrition (inadequate protein/caloric intake), smoking, and excessive alcohol use contribute. Obesity independently and synergistically worsens sarcopenia via ectopic intramuscular fat deposition and anabolic resistance (sarcopenic obesity) (PMC4326920, "Muscle ectopic fat deposition contributes to anabolic resistance in obese sarcopenic old rats").

Infectious agents: No primary infectious etiology; however, acute/critical illness (including sepsis and severe infections) is a major precipitant of secondary/ICU-acquired sarcopenia via a combination of immobilization, systemic inflammation, and catabolic stress.

Occupational/toxin exposure: Not a well-characterized primary driver in the literature retrieved; disuse (occupational sedentarism) and chronic corticosteroid/medication exposure (iatrogenic) are more relevant secondary contributors than classic toxicological exposures.

Sources: - Muscle ectopic fat deposition contributes to anabolic resistance in obese sarcopenic old rats - Sarcopenic obesity: epidemiology, pathophysiology, cardiovascular disease, mortality, and management

6. Mechanism / Pathophysiology

Ordered causal chain (age-related/primary sarcopenia):

Aging (and/or disuse/inflammatory disease) → motor neuron loss and neuromuscular junction (NMJ) instability (denervation, acetylcholine receptor fragmentation) — this is now considered an early, possibly initiating, event (PMC10789655, "Unraveling the causes of sarcopenia: Roles of neuromuscular junction impairment and mitochondrial dysfunction").
NMJ denervation → loss of type II (fast-twitch) fiber innervation, with denervated fibers either reinnervated by adjacent type I motor units (fiber-type grouping/shift toward slow-twitch) or undergoing atrophy and replacement by fat/fibrous tissue (myosteatosis/fibrosis) → net preferential type II fiber atrophy and reduced peak power output.
In parallel, aging drives mitochondrial dysfunction (reduced biogenesis, impaired oxidative phosphorylation, elevated ROS) within myofibers, which both correlates with and reinforces NMJ degeneration, creating a feed-forward loop → reduced ATP availability and increased oxidative damage to contractile and structural proteins.
Chronic low-grade "inflammaging" — elevated circulating TNF-α and IL-6 — activates NF-κB signaling in myofibers, which (a) upregulates E3 ubiquitin ligases Atrogin-1 (FBXO32) and MuRF1 (TRIM63), accelerating ubiquitin-proteasome-mediated myofibrillar protein degradation, and (b) represses MyoD, impairing myogenic differentiation; IL-6/STAT3 signaling separately inhibits satellite cell-mediated regeneration.
Concurrently, declining anabolic hormonal drive (falling IGF-1 and testosterone, rising myostatin/activin signaling through activin type II receptors → SMAD2/3) suppresses Akt/mTORC1 signaling, producing "anabolic resistance" — a blunted muscle protein synthesis response to dietary protein/leucine and resistance exercise stimuli, worsened further by obesity/insulin resistance via eIF2α phosphorylation and ectopic intramuscular lipid (ceramide) accumulation.
Satellite cells (muscle stem cells), whose niche is degraded by the same mitochondrial dysfunction, chronic inflammation, and NMJ decline above, lose quiescence/proliferation/differentiation capacity; senescent cells accumulating in the regenerative niche secrete a senescence-associated secretory phenotype (SASP) that further suppresses regeneration (2023 finding on CD36+ secretome/SASP as negative muscle-regeneration regulators).
The net result of steps 2–6 — degradation exceeding synthesis, impaired regeneration, fiber-type shift, and myosteatosis — is progressive loss of skeletal muscle mass, strength, and quality, converging on the clinical phenotype: low strength (step 1° criterion) → low muscle mass/quality (confirmatory) → impaired physical performance (severity marker) → falls, disability, frailty, hospitalization, and increased mortality.

Branch — sarcopenic obesity: steps 3 and 5 are amplified by adipose-tissue-derived inflammatory cytokines and ectopic intramuscular/intermuscular fat, producing a distinct oxidative-stress-driven mechanistic branch with disproportionate anabolic resistance (PMC/Frontiers fendo.2023.1185221).

Branch — disease-associated secondary sarcopenia (e.g., CKD, heart failure, cancer, T2DM): organ-specific catabolic signals (uremic toxins, natriuretic peptide/cytokine excess in heart failure, tumor-derived cachectic factors, hyperglycemia/insulin resistance in diabetes) feed into the same NF-κB/ubiquitin-proteasome and anabolic-resistance nodes described above, producing disease-flavored but mechanistically convergent muscle wasting (T2DM-related sarcopenia is now considered mechanistically distinct from both classic age-related sarcopenia and pure disuse atrophy — PMC11157032).

Additional hallmark framework: A 2023 review proposed nine core aging hallmarks plus five sarcopenia-specific additions: perturbed inflammation, compromised vascular perfusion, neural dysfunction, extracellular matrix (ECM) dysregulation, and ionic imbalance (PMC12295260).

Suggested ontology terms: - GO biological processes: GO:0006511 (ubiquitin-dependent protein catabolic process), GO:0006914 (autophagy), GO:0008283 (cell population proliferation, satellite cells), GO:0007520 (myoblast fusion), GO:0043123 (positive regulation of NF-κB signaling), GO:0032496 (response to lipopolysaccharide/inflammation) - GO molecular function: GO:0005160 (TGF-beta receptor binding, for myostatin/activin signaling) - CL cell types: CL:0000188 (skeletal muscle myoblast/satellite cell — more precisely CL:0000594 skeletal muscle satellite cell), CL:0000188 (skeletal muscle fiber), CL:0000738 (leukocyte, for inflammatory infiltrate) - Molecular targets: myostatin/GDF8, activin type II receptor (ACVR2B), IGF-1/Akt/mTORC1, NF-κB, Atrogin-1/FBXO32, MuRF1/TRIM63

Sources: - Unraveling the causes of sarcopenia: NMJ impairment and mitochondrial dysfunction - Sarcopenia: Current Insights into Molecular Mechanisms, Diagnostics, and Emerging Interventional Approaches - Molecular constraints of sarcopenia in the ageing muscle - Type 2 diabetes mellitus related sarcopenia - Sarcopenic obesity: epidemiology, pathophysiology - Ubiquitin-proteasome pathway in skeletal muscle atrophy

7. Anatomical Structures Affected

Organ/system level: Primary target is skeletal muscle (musculoskeletal system), generalized across the body but with particular clinical emphasis on appendicular musculature (limbs — the basis of the appendicular skeletal muscle index, ASMI, used diagnostically). Secondary/complication involvement includes the skeletal system (falls → fractures; disuse → osteosarcopenia overlap with osteoporosis), cardiovascular system (sarcopenia-heart failure interplay), and metabolic/endocrine systems (insulin resistance).

Tissue/cell level: Skeletal muscle tissue — specifically type II (fast-twitch, glycolytic) muscle fibers, which undergo preferential atrophy and denervation, with relative sparing/compensatory reinnervation of type I (slow-twitch) fibers. Cell populations: skeletal myofibers, satellite cells (muscle stem cells, CL:0000594), motor neurons and their NMJ synaptic terminals, and infiltrating fibro-adipogenic progenitors/adipocytes (myosteatosis) and fibroblasts (fibrosis).

Subcellular level: Mitochondria (biogenesis/OXPHOS dysfunction, GO:0005739), sarcomeric contractile apparatus (myofibrillar protein degradation via the ubiquitin-proteasome system), and the neuromuscular junction as a specialized subcellular structure (postsynaptic acetylcholine receptor clusters).

Localization: Generalized/bilateral and symmetric — sarcopenia is by definition a systemic process, distinguishing it from focal/localized muscle atrophy (e.g., from a single peripheral nerve injury). UBERON terms of relevance: UBERON:0001134 (skeletal muscle tissue), UBERON:0000383 (musculature of limb/appendicular musculature — commonly the diagnostic focus site, e.g., mid-thigh CT/MRI, calf circumference).

Sources: derived from the pathophysiology sources cited in §6 (PMC10789655, PMC12267276, PMC10690626).

8. Temporal Development

Onset: Muscle mass and strength peak around the third decade, then decline gradually from ~40 years, accelerating after 60–70. Primary sarcopenia is thus adult/late-onset and insidious. Secondary/disuse or critical-illness sarcopenia has an acute-to-subacute onset (days to weeks), formally distinguished by NCIT as "Acute Sarcopenia" (≤6 months) vs. chronic (>6 months).

Progression: Chronic primary sarcopenia is typically slowly progressive over years to decades; disease-associated secondary sarcopenia (cancer cachexia, heart failure, CKD) can progress much faster. EWGSOP2's staged framework (probable → confirmed → severe) functions as an implicit staging system based on accumulating deficits across strength, mass, and performance domains (PMC6322506).

Course pattern: Generally progressive rather than relapsing-remitting, though partial reversal is achievable with resistance exercise and nutritional intervention, particularly in secondary/disuse-related cases and earlier disease stages — this reversibility is a key rationale for early detection.

Critical periods/intervention windows: Midlife (40s–60s) is increasingly emphasized as a window for preventive intervention before muscle loss accelerates; post-acute-illness/post-hospitalization periods are critical windows for rehabilitative intervention to prevent conversion of transient disuse atrophy into persistent sarcopenia.

Sources: - Sarcopenia: revised European consensus on definition and diagnosis - Prognostic Features of Sarcopenia in Older Hospitalized Patients: A 6-Month Follow-Up Study

9. Inheritance and Population

Epidemiology: - Global prevalence estimates vary substantially by diagnostic criteria: ~5% (EWGSOP2) to ~17% (IWGS) among elderly populations in one meta-analysis; another large meta-analysis (58,404 community-dwelling participants ≥60 years) estimated overall global prevalence at ~10% (PubMed 34816624, jcsm.12783). - Prevalence ranges from 8–36% in adults <60 years to 10–27% in adults ≥60 years, reflecting major criteria-dependent heterogeneity. - Severe sarcopenia prevalence: 2–9%. - Sex differences differ by criteria set: EWGSOP2 shows higher prevalence in men (11% vs. 2% in women), while IWGS criteria show higher prevalence in women (17% vs. 12% in men) — a striking illustration of definitional sensitivity (PubMed 36907247, Metabolism 2023 epidemiology review).

Inheritance pattern: Sarcopenia is multifactorial/polygenic, not Mendelian. No single inheritance pattern (AD/AR/X-linked) applies; risk is distributed across many common variants of small effect (see §4 GWAS loci) interacting with environmental exposures.

Penetrance/expressivity: Not applicable in the classical monogenic sense; "penetrance" of the polygenic risk score is modulated heavily by lifestyle, nutrition, and comorbidity burden.

Founder effects/consanguinity/carrier frequency: Not applicable — sarcopenia is a complex age-related trait, not a rare monogenic disorder.

Population demographics: Prevalence rises steeply with age and is influenced by geography, diagnostic criteria applied (EWGSOP vs. AWGS [Asian Working Group for Sarcopenia] vs. IWGS vs. FNIH), and setting (community-dwelling vs. hospitalized vs. long-term care, with hospitalized/institutionalized populations showing substantially higher rates). Regional/ethnic variation in cutoff values is a recognized methodological issue (Frontiers fmed.2024.1405438, "Diagnosing sarcopenia in clinical practice: international guidelines vs. population-specific cutoff criteria").

Sources: - Global prevalence of sarcopenia and severe sarcopenia: a systematic review and meta-analysis - Epidemiology of sarcopenia: Prevalence, risk factors, and consequences - Diagnosing sarcopenia in clinical practice: international guidelines vs. population-specific cutoff criteria

10. Diagnostics

EWGSOP2 four-step algorithm (the dominant clinical framework): 1. Find — case-finding via clinical suspicion or the SARC-F questionnaire (self-report screening tool). 2. Assess — measure muscle strength: grip strength (dynamometry) and/or chair-stand test; low strength → "probable sarcopenia," sufficient to initiate treatment in practice. 3. Confirm — quantify muscle mass/quality: bioimpedance analysis (BIA) or DXA in routine clinical care; DXA, CT, or MRI in research/specialty high-risk settings. 4. Severity — assess physical performance: gait speed, Short Physical Performance Battery (SPPB), Timed-Up-and-Go (TUG), or 400-meter walk test (PMC10684299; PMC6322506).

Laboratory/biomarkers: No single validated diagnostic blood biomarker yet, but candidates under active investigation include: - Myostatin (GDF8) — elevated, inhibitory myokine. - GDF-15 — higher circulating levels independently associated with greater sarcopenia risk (PMC7740254). - Follistatin — antagonizes myostatin/activin A; differs between sarcopenic and non-sarcopenic populations. - IGF-1 — reduced levels correlate with decreased muscle anabolism (though one study found IGF-1/TGF-β family/follistatin levels did not reliably reflect different dynapenia/sarcopenia stages in elderly women — PubMed 25681638 — underscoring current lack of a validated single biomarker). - Activin A, irisin, vitamin D, myoglobin, cortisol.

Imaging: DXA (appendicular lean mass), CT/MRI (cross-sectional muscle area and intramuscular fat/attenuation — used in specialty/research settings), ultrasound (emerging, portable, used to measure muscle thickness/cross-sectional area, e.g., quadriceps).

Genetic testing: Not part of routine clinical diagnosis (sarcopenia is not diagnosed via genetic testing); genetic risk scores remain a research tool.

Differential diagnosis: Cachexia (distinct — requires ≥5% weight loss in ≤12 months plus ≥3 of: decreased strength, fatigue, anorexia, low fat-free mass index, abnormal biochemistry), frailty (overlapping but broader multisystem syndrome), primary myopathies/muscular dystrophies, disuse atrophy without the aging/chronic-disease substrate, malnutrition alone, and inflammatory myopathies (which can be assessed similarly via DXA/grip strength — PubMed 38544289).

Screening: SARC-F is the standard community screening instrument; sensitivity for detecting probable sarcopenia has been specifically evaluated in recent cross-sectional studies (PMC12292031, 2025).

Sources: - Sarcopenia: revised European consensus on definition and diagnosis - Addressing the Main Barrier to Sarcopenia Identification: BIA vs. DXA - Elevated GDF-15 Is a Biomarker of Sarcopenia in Older Adults - Assessment of SARC-F Sensitivity for Probable Sarcopenia

11. Outcome/Prognosis

Mortality/morbidity: Sarcopenia is independently associated with increased all-cause mortality, particularly in hospitalized and critically ill older adults; a routine sarcopenia assessment at ICU admission is proposed as a prognostic tool (PMC8616666). It is linked to increased rehospitalization, falls, fractures, and loss of independence — one 2025 longitudinal China-based aging study specifically linked sarcopenia to falls, fractures, hospital readmission, and all-cause mortality in older adults with endocrine disorders (PMC12403857).

Functional/QoL outcomes: Progressive disability, worsening ADL/IADL function, increased risk of institutionalization (long-term care admission), and depression are recognized downstream consequences (PMC/Springer chapters on frailty-sarcopenia-falls).

Prognostic factors: Severity grade (EWGSOP2 "severe sarcopenia" carries worse prognosis than "probable"), presence of comorbid frailty, and comorbid chronic disease burden (heart failure, CKD, cancer) all modify prognosis; the Multidimensional Prognostic Index has been used to track longitudinal changes predicting rehospitalization/mortality up to 6 months post-discharge (PMC11172762).

Reversibility/recovery potential: Unlike many chronic degenerative conditions, sarcopenia — especially secondary/disuse forms — has meaningful reversibility potential with early resistance exercise and nutritional rehabilitation, making early identification prognostically important.

Sources: - Prognostic Features of Sarcopenia in Older Hospitalized Patients - Correlation of Sarcopenia With Modified Frailty Index in Critically Ill Elderly Patients - Association between sarcopenia and falls, fractures, hospital readmission, and all-cause mortality in older adults with endocrine disorders

12. Treatment

Pharmacotherapy — established/guideline-recommended: No drug is yet FDA-approved specifically for sarcopenia; current guideline-based management centers on non-pharmacological intervention (below). Vitamin D repletion is recommended where deficient (NCIT:C1621, Cholecalciferol / relevant vitamin D agents), though a 2024 RCT (DPVD ancillary study, Lancet Healthy Longevity) found active vitamin D (eldecalcitol) reduced sarcopenia onset risk in adults with prediabetes by increasing skeletal muscle volume/strength.

Advanced/investigational therapeutics — myostatin/activin pathway (the leading pharmacological target class): - Bimagrumab — anti-activin type II receptor monoclonal antibody blocking myostatin/activin signaling. Phase 2 proof-of-concept: thigh muscle volume +4.80% vs. −1.01% placebo at 24 weeks; lean body mass gains of 1.9–2.8 kg across dose groups; however, no significant improvement in physical performance (gait speed, SPPB, 6-minute walk test) despite mass gains — a critical mass-vs-function dissociation. 2025 data extend this to post-hip-fracture recovery, again showing muscle-mass but only minimal mobility/strength benefit (PubMed 41248895; JAMA Network Open 2771858; PMC12141158; PMC12146653). - Apitegromab (SRK-015) — targets latent (pro-)myostatin specifically, reducing TGF-β superfamily cross-reactivity; validated in spinal muscular atrophy; FDA issued a 2025 Complete Response Letter citing third-party manufacturing concerns (not efficacy/safety). - Trevogrumab (REGN1033) — myostatin monoclonal antibody; in the Phase 2 COURAGE trial, adding trevogrumab to semaglutide preserved roughly half the lean mass otherwise lost to semaglutide-induced weight loss — relevant to the emerging "GLP-1-associated sarcopenia" concern. - Taldefgrobep alfa — myostatin-targeting adnectin; awaiting Phase 2 obesity-context data. - KER-065 — selective activin receptor ligand trap, initially targeting Duchenne muscular dystrophy, mechanistically relevant to sarcopenia. - RANK-ligand inhibition (denosumab-class) is being trialed for combined sarcopenia-with-osteoporosis indications (PMC12323245).

Suggested NCIT terms: NCIT:C15986 (Pharmacotherapy) as the generic action term paired with therapeutic_agent bindings for specific compounds (myostatin/activin inhibitors generally lack individual NCIT drug codes yet given investigational status; use CHEBI/NCIT where available per compound), NCIT:C15302 (Physical Therapy), NCIT:C15447 (Dietary Intervention), NCIT:C15747 (Supportive Care).

Exercise (cornerstone, highest-grade recommendation): Progressive resistance exercise training (RET), moderate-to-high intensity, is the single most consistently effective intervention for both muscle mass and strength, with benefit demonstrated even in frail/multimorbid populations. NCIT:C15302 (Physical Therapy).

Nutrition: Increased daily protein intake (1.0–1.2 g/kg/day; 1.2–1.5 g/kg/day with inflammatory disease), high-quality/whey protein rich in leucine/essential amino acids; combined resistance-training + protein supplementation produces the largest gains in handgrip strength and gait speed; adding vitamin D further improves appendicular skeletal muscle index (network meta-analysis, Frontiers fnut.2025.1685014). Creatine supplementation is also recommended as an adjunct to structured exercise programs.

Treatment response/limitations: A recurring theme across trials (bimagrumab, others) is dissociation between muscle mass gain and functional/performance improvement — mass-focused pharmacotherapy alone appears insufficient without concurrent exercise, an important consideration for future combination-therapy trial design (PMC12146653, "Sarcopenia in Ageing and Chronic Illness: Trial Endpoints and Regulatory Issues").

Sources: - Bimagrumab: Novel Medical Therapy for IBM, Sarcopenia, and Medication-Induced Lean Body Mass Loss - Bimagrumab vs Optimized Standard of Care — JAMA Network Open — actually JAMA Network Open - Current and investigational medications for the treatment of sarcopenia - Sarcopenia in Ageing and Chronic Illness: Trial Endpoints and Regulatory Issues - Active vitamin D treatment in the prevention of sarcopenia (DPVD ancillary study) - Exercise and nutrition strategies for sarcopenia in older adults: network meta-analysis - 5 Sarcopenia Drugs Poised to Make an Impact - Trevogrumab (REGN1033): Myostatin Blocker, COURAGE Data

13. Prevention

Primary prevention: Regular structured resistance/multicomponent exercise throughout mid-to-late life is the strongest evidence-based primary prevention strategy; adequate dietary protein and vitamin D sufficiency across the lifespan support this. USPSTF recommends exercise interventions to prevent falls in community-dwelling adults ≥65 at increased fall risk.

Secondary prevention (early detection): Population screening using SARC-F in primary-care and geriatric settings, with reflex grip-strength/chair-stand testing, enables earlier identification before functional decline is severe; targeted screening in high-risk disease populations (CKD, heart failure, cancer, post-hospitalization) is increasingly recommended.

Tertiary prevention: Structured rehabilitation (physical/occupational therapy) post-hospitalization or post-acute-illness to prevent conversion of transient disuse atrophy into persistent sarcopenia; nutritional support during and after catabolic illness.

Behavioral interventions: Smoking cessation, alcohol moderation, sustained physical activity, weight management (particularly relevant to sarcopenic obesity).

Immunization/infectious prevention: Not directly applicable as a primary sarcopenia-prevention strategy, though preventing severe infections/hospitalizations indirectly reduces acute-catabolic sarcopenia risk.

Genetic counseling/screening: Not applicable given the polygenic, non-Mendelian nature of the condition; polygenic risk scoring remains investigational.

Public health: Nutritional support programs for older adults, fall-prevention public health initiatives, and geriatric assessment integration into primary care are the relevant population-level interventions (PMC11119320, "The nutritional support to prevent sarcopenia in the elderly").

Sources: - Vitamin D and Sarcopenia in the Elderly: Mechanisms and Consequences - The nutritional support to prevent sarcopenia in the elderly - Draft Recommendation: Vitamin D, Calcium, or Combined Supplementation — USPSTF

14. Other Species / Natural Disease

Taxonomy: Naturally occurring, age-related sarcopenia is well documented in companion animals, particularly dogs (Canis lupus familiaris, NCBITaxon:9615) and cats (Felis catus, NCBITaxon:9685), making them recognized comparative/natural models rather than purely induced laboratory models (PMC/Wiley, "Cachexia and Sarcopenia in Companion Animals: An Under-Utilized Natural Animal Model of Human Disease").

Natural disease/veterinary relevance: Aging Labrador retriever colonies show significant loss of lean body mass with age; epaxial muscle cross-sectional area (measured by ultrasound/CT) is significantly lower in healthy geriatric vs. young dogs. Cats show a significant negative correlation between muscle condition score (MCS, assessed by DEXA) and age. Clinically, muscle loss in companion animals impairs strength/balance, depresses immune function, and reduces recovery capacity from illness, surgery, or injury — directly paralleling the human syndrome.

Sarcopenic obesity in animals: Approximately 40% of aged pet cats and dogs are obese, with 12–15% of these specifically showing extremely low lean mass (i.e., comorbid sarcopenic obesity), closely mirroring the human sarcopenic-obesity phenotype.

Comparative biology/One Health angle: Tufts University and collaborators have explicitly framed companion-animal sarcopenia as a "One Health" comparative model, leveraging the shared home environment, similar aging trajectory, and non-invasive longitudinal measurement opportunities that companion animals offer versus purely laboratory rodent models.

Cross-species conservation: Core molecular pathways (myostatin/activin signaling, ubiquitin-proteasome atrogenes, mitochondrial dysfunction) are broadly evolutionarily conserved across mammals, supporting translational relevance of both natural (companion animal) and induced (rodent) models — though species-specific modulators exist (see PMC7881157, "Molecular and phenotypic analysis of rodent models reveals conserved and species-specific modulators of human sarcopenia").

Sources: - Cachexia and Sarcopenia in Companion Animals: An Under-Utilized Natural Animal Model - Taking a One Health Approach to Muscle Loss Research — Tufts - Cachexia and sarcopenia: emerging syndromes of importance in dogs and cats - Molecular and phenotypic analysis of rodent models reveals conserved and species-specific modulators of human sarcopenia

15. Model Organisms

Model types and induction strategies: - Natural aging models — considered the most representative/suitable model, as it most closely resembles the human aging process compared to genetic or accelerated-senescence models (though slow and resource-intensive). Aged Fischer-344/Brown Norway F1 hybrid rats are a widely used strain, showing progressive skeletal muscle atrophy with age while remaining relatively disease-free until advanced age — a valuable feature for isolating pure aging effects from comorbid pathology. - Senescence-accelerated models — SAMP8 (senescence-accelerated mouse-prone 8) mice are commonly used for accelerated-timeline aging studies, including metabolic changes in specific muscles (e.g., extensor digitorum longus). - Genetic modification models — e.g., muscle-specific OPA1 knockout mice (mitochondrial dynamics disruption) recapitulate sarcopenia-relevant pathophysiology; a 2024 JCI paper describes a mouse sarcopenia model revealing sex- and age-specific differences in phenotypic/molecular characteristics. - Induced-atrophy models — hindlimb unloading/suspension, surgical or chemical denervation, and immobilization are used to model the disuse-related mechanistic arm specifically (complementary to, but mechanistically distinct from, natural aging models).

Evaluation methods: Grip strength testing, treadmill/rotarod functional performance, muscle mass and fiber cross-sectional area quantification, fiber-type distribution analysis, and (in genetic models) targeted molecular pathway readouts (mitochondrial function, UPS activity, satellite cell markers).

Model limitations: Genetically modified and senescence-accelerated models can decouple specific pathway perturbations from the full multifactorial aging process, so findings may not fully generalize to naturally aging (and especially human) sarcopenia; natural aging models, while more representative, are slow, costly and confounded by comorbid age-related pathology in longer-lived strains.

Applications: Rodent models are used to dissect individual mechanistic contributions (mitochondrial, NMJ, satellite cell, inflammatory) that are difficult to isolate in human cohort studies, and to test candidate pharmacological interventions (myostatin/activin pathway antagonists in particular) prior to human trials.

Sources: - Mouse models of accelerated aging in musculoskeletal research - Animal models of sarcopenia — Aging Cell - Two Types of Mouse Models for Sarcopenia Research - JCI - Mouse sarcopenia model reveals sex- and age-specific differences - The recent development, application, and future prospects of muscle atrophy animal models

Curation Notes for dismech KB Entry

MONDO binding needs live verification. MONDO:0006516 returned as obsolete in this search — before binding disease_term, run the standard OAK/OLS lookup workflow (per the dismech-terms skill) to find the current, non-obsolete replacement term, if one exists, rather than trusting this report's identifier.
No canonical single HP term surfaced for "sarcopenia" itself in this search pass — the phenotype triad (low strength/low mass/low performance) likely needs to be represented via component HP terms rather than one umbrella term; verify directly against a live HPO instance during curation.
This is a polygenic/complex-disease entry, not a Mendelian one — the genetic: section should likely use relationship_type: SUSCEPTIBILITY for the GWAS loci listed (IRS1, FTO, HSD17B11, VCAN, ADAMTSL3, ESR1, NOS3, KLF5, HLA-DQA1) and for ACTN3/MSTN polymorphisms, not causal variant framing.
The bimagrumab mass-vs-function dissociation is a mechanistically important, citable nuance worth capturing explicitly in a treatments[].evidence or notes field — several independent trials (2017 phase 2, JAMA Network Open, 2025 post-hip-fracture) converge on the same finding.
NCIT already codes "Acute Sarcopenia" (NCIT:C189016) distinctly from chronic — this could inform a temporality qualifier (ACUTE/CHRONIC) on phenotype/pathophysiology descriptors per the Descriptor Qualifier Slots convention.
All PMIDs/URLs above should be run through the standard just fetch-reference and snippet-verification workflow before being embedded as evidence: blocks in any KB YAML — this report is a research lead, not pre-verified curation content.

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome	Count
References checked	37
Resolved	37
Unresolved (possible confabulation)	0
Unverifiable	0
References weighed for topical relevance	37
On topic	22
Off topic	0

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Outcome	Count
Terms checked	29
Resolved	28
Unresolved (possible confabulation)	0
Obsolete	1
Unverifiable	0
Terms whose name was checked	19
Terms named correctly	12
Terms named as a different term	1
Terms whose name is worth a second look	6

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

CL:0000738 (1 mention) - the report calls it "leukocyte, for inflammatory infiltrate"; CL calls it leukocyte

Obsolete terms

These terms are real but deprecated. Citing one is not a fabrication; it does mean the report is naming something the ontology has retired:

MONDO:0006516 (obsolete sarcopenia) (2 mentions)

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

NCIT:C189016 (3 mentions) - the report calls it "Acute Sarcopenia", "NCIT already codes "Acute Sarcopenia"; NCIT calls it Acute Sarcopenia
GO:0008283 (1 mention) - the report calls it "cell population proliferation, satellite cells"; GO calls it cell population proliferation
GO:0043123 (1 mention) - the report calls it "positive regulation of NF-κB signaling"; GO calls it positive regulation of canonical NF-kappaB signal transduction, and lists "positive regulation of I-kappaB kinase/NF-kappaB signaling" among its other names
GO:0032496 (1 mention) - the report calls it "response to lipopolysaccharide/inflammation"; GO calls it response to lipopolysaccharide
GO:0005160 (1 mention) - the report calls it "TGF-beta receptor binding, for myostatin/activin signaling"; GO calls it transforming growth factor beta receptor binding, and lists "TGF-beta receptor binding" among its other names
CL:0000188 (2 mentions) - the report calls it "skeletal muscle fiber"; CL calls it cell of skeletal muscle, and lists "skeletal muscle cell" among its other names

Terms named inconsistently

The report gives these identifiers more than one name of its own:

NCIT:C189016 - called "Acute Sarcopenia", "NCIT already codes "Acute Sarcopenia"

Ask OpenScientist

OpenScientist Report

Mappings

Definitions

Inheritance

Subtypes

Mechanistic Hypotheses

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Environmental Factors

Biochemical Markers

Diagnosis

Progression

Prevalence

Differential Diagnoses

Related Datasets

Clinical Trials

Animal Models

Computational Models

Source YAML

References & Deep Research

References

Deep Research

Sarcopenia: Comprehensive Research Report

1. Disease Information

2. Etiology

3. Phenotypes

4. Genetic/Molecular Information

5. Environmental Information

6. Mechanism / Pathophysiology

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome/Prognosis

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Curation Notes for dismech KB Entry

Reference Validation

Term Validation

Terms the report names something else

Obsolete terms

Terms whose name is worth a second look

Terms named inconsistently